Generation of antibody-derived peptides by polypeptide chain exchange

Through the polypeptide chain exchange technology of heterodimer precursor polypeptides, multispecific antigen binding is generated using the CH3 domains of pestle mutation and mortar mutation, which solves the problem of antigen binding screening and isolation in the prior art, and achieves efficient Antibody combination screening and isolation are suitable for the generation and application of multispecific antibodies.

CN113728002BActive Publication Date: 2024-11-12F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080031092.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-04-25
Filing Date
2020-04-24
Publication Date
2024-11-12
Estimated Expiration
2040-04-24

AI Technical Summary

Technical Problem

The prior art is difficult to efficiently generate multispecific antigen binding through polypeptide chain exchange, especially in the isolation and analysis of product molecules, and the asymmetric domain arrangement of precursor molecules and product molecules in existing methods makes it difficult to screen the most Good antigen binding combination.

Method used

Heterodimer precursor polypeptides are employed, which contain at least two polypeptide chains associated with each other through the CH3 domain, one CH3 domain contains a pestle mutation and the other contains a mortar mutation, and a specific amino acid substitution is introduced therein, such as hydrophobic or charged amino acid substitution to form a stable or unstable CH3/CH3 interface for polypeptide chain exchange to generate multispecific antigen binding.

Benefits of technology

The generation of multispecific antigen binding by polypeptide chain exchange allows easy separation of product polypeptides with unreacted precursor polypeptides, reduce off-target effects, and facilitate screening of favorable combinations of antigen-binding moieties, suitable for therapeutic and diagnostic purposes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113728002B_ABST
    Figure CN113728002B_ABST
Patent Text Reader

Abstract

The present invention relates to a group of heterodimeric polypeptides and their uses, for example, for generating multispecific antigen binders by polypeptide chain exchange.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a group of heterodimeric polypeptides and their uses, for example, for generating multispecific antigen binders by polypeptide chain exchange. Background Art

[0002] Providing the best combination of antigen binders in a multispecific antibody from a variety of possible antigen binders is a challenge when each generated multispecific antibody needs to be provided individually by recombinant methods. Alternative methods are needed to screen multiple multispecific antibodies.

[0003] Labrijn, AF et al. disclose the efficient generation of stable bispecific IgG1 by controlled Fab arm exchange (Proc. Natl. Acad. Sci. USA 110 (2013) 5145-5150). In short, two monospecific precursor molecules with IgG-like domains arranged with point mutations in the CH3 domain are contacted for polypeptide chain exchange to form a bispecific product molecule, which is also an IgG-like domain arrangement. Therefore, the size of the precursor molecule and the product molecule is the same, making it challenging to separate the product molecule from the unreacted precursor molecule and analyze the product molecule.

[0004] Unpublished prior art PCT / EP2018 / 078675 and PCT / EP2018 / 079523 disclose methods for producing multispecific antigen binders from two different precursor molecules by polypeptide chain exchange. Both precursor molecules are heterodimeric polypeptides with asymmetric domain arrangements. Both precursor molecules contain a CH3 domain modified according to the "knob into hole" technique (WO 96 / 027011, Ridgway, JB, et al., Protein Eng. 9 (1996) 617-621; and Merchant, AM, et al., Nat. Biotechnol. 16 (1998) 677-681) and containing further destabilizing mutations arranged in an asymmetric pattern. In each precursor molecule, only one CH3 domain contains this destabilizing mutation. After polypeptide chain exchange, two product molecules are formed, each of which contains a polypeptide from each precursor molecule. Precursor molecules and product molecules have different domain arrangements. PCT / EP2018 / 078675 and PCT / EP2018 / 079523 disclose the amino acid positions in the CH3 / CH3 interface of the precursor molecule to be substituted.

[0005] However, there remains a need for alternative methods of generating multispecific antigen binders by polypeptide chain exchange. Summary of the invention

[0006] The present invention relates to a set of heterodimeric precursor polypeptides comprising:

[0007] - a first heterodimeric precursor polypeptide comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising a CH3 domain associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation,

[0008] wherein the first heterodimeric precursor polypeptide comprises a first antigen binding portion, wherein at least a portion of the first antigen binding portion is disposed on one of the two polypeptide chains comprising a CH3 domain, and

[0009] - a second heterodimeric precursor polypeptide comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising a CH3 domain associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation,

[0010] wherein the second heterodimeric precursor polypeptide comprises a second antigen binding portion, wherein at least a portion of the second antigen binding portion is disposed on one of the two polypeptide chains comprising a CH3 domain;

[0011] in

[0012] A) either i) within the first heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain comprising the knob mutation comprises at least a portion of the first antigen binding portion, and within the second heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain having the hole mutation comprises at least a portion of the second antigen binding portion, or ii) within the first heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain comprising the hole mutation comprises at least a portion of the first antigen binding portion, and within the second heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain having the knob mutation comprises at least a portion of the second antigen binding portion; and wherein

[0013] B) or

[0014] i) a CH3 domain of a first heterodimeric precursor polypeptide comprising a knob mutation and a CH3 domain of a second heterodimeric precursor polypeptide comprising a hole mutation, or

[0015] ii) a CH3 domain of a first heterodimeric precursor polypeptide comprising a hole mutation and a CH3 domain of a second heterodimeric precursor polypeptide comprising a knob mutation

[0016] The following amino acid substitutions are included, where numbering is according to the Kabat numbering system:

[0017] - the CH3 domain with hole mutation comprises at least one amino acid substitution selected from the group consisting of:

[0018] o Replacement of S354 with a hydrophobic amino acid;

[0019] o Replacement of D356 with a positively charged amino acid;

[0020] o replacing E357 with a positively charged amino acid or with a hydrophobic amino acid;

[0021] o replacement of D356 with a positively charged amino acid and replacement of E357 with a positively charged amino acid or with a hydrophobic amino acid;

[0022] o replacing S364 with a hydrophobic amino acid;

[0023] o replacing A368 with a hydrophobic amino acid;

[0024] ο Replacement of E392 with a negatively charged amino acid;

[0025] o Replacement of T394 with a hydrophobic amino acid;

[0026] o Replacement of D399 with a hydrophobic amino acid and replacement of S400 with a positively charged amino acid;

[0027] o replacement of D399 with a hydrophobic amino acid and replacement of F405 with a positively charged amino acid;

[0028] o replacing V407 with a hydrophobic amino acid; and

[0029] o replacing K409 with a negatively charged amino acid; and

[0030] ο Replacement of K439 with a negatively charged amino acid;

[0031] - the CH3 domain with the knob mutation comprises at least one amino acid substitution selected from the group consisting of:

[0032] o replacement of Q347 with a positively charged amino acid and replacement of K360 with a negatively charged amino acid;

[0033] o Replacement of Y349 with a negatively charged amino acid;

[0034] o replacing L351 with a hydrophobic amino acid and replacing E357 with a hydrophobic amino acid;

[0035] o replacing S364 with a hydrophobic amino acid;

[0036] o replacement of W366 with a hydrophobic amino acid and replacement of K409 with a negatively charged amino acid;

[0037] o replacing L368 with a hydrophobic amino acid;

[0038] ο Replacement of K370 with a negatively charged amino acid;

[0039] o replacement of K370 with a negatively charged amino acid and replacement of K439 with a negatively charged amino acid;

[0040] ο Replacement of K392 with a negatively charged amino acid;

[0041] o Replacement of T394 with a hydrophobic amino acid;

[0042] o Replacement of V397 with a hydrophobic amino acid;

[0043] o replacing D399 with a positively charged amino acid and replacing K409 with a negatively charged amino acid;

[0044] ο Replacement of S400 with a positively charged amino acid;

[0045] οF405W;

[0046] οY407W; and

[0047] o Replacement of K439 with a negatively charged amino acid.

[0048] One embodiment of the present invention relates to the set of heterodimeric polypeptides of the present invention, wherein either i) the CH3 domain comprising the knob mutation of the first heterodimeric precursor polypeptide comprises a cysteine ​​mutation, and the CH3 domain comprising the hole mutation of the second heterodimeric precursor polypeptide comprises a cysteine ​​mutation, or ii) the CH3 domain comprising the hole mutation of the first heterodimeric precursor polypeptide comprises a cysteine ​​mutation, and the CH3 domain comprising the knob mutation of the second heterodimeric precursor polypeptide comprises a cysteine ​​mutation.

[0049] One embodiment of the present invention relates to the set of heterodimeric polypeptides of the present invention, wherein the first antigen binding moiety and / or the second antigen binding moiety is an antibody fragment.

[0050] Another aspect of the invention is a method for producing a heterodimeric polypeptide comprising the steps of:

[0051] a) contacting a first heterodimeric precursor polypeptide and a second heterodimeric precursor polypeptide of the present invention to form a third heterodimeric polypeptide comprising at least one polypeptide chain derived from the first heterodimeric precursor polypeptide and at least one polypeptide chain derived from the second heterodimeric polypeptide, and

[0052] b) recovering the third heterodimeric polypeptide.

[0053] One embodiment of the present invention relates to a method for producing a heterodimeric polypeptide of the present invention, wherein the second heterodimeric precursor polypeptide comprises an antigen binding portion that specifically binds to a second antigen, and wherein the third heterodimeric polypeptide comprises an antigen binding portion that specifically binds to a first antigen, and an antigen binding portion that specifically binds to a second antigen.

[0054] Another aspect of the invention is a heterodimeric polypeptide obtainable by the method according to the invention.

[0055] Another aspect of the invention is a method for identifying a multispecific heterodimeric polypeptide comprising the steps of:

[0056] a) producing a plurality of multispecific heterodimeric polypeptides by performing the method of producing a heterodimeric polypeptide of the present invention on each of the following combinations:

[0057] - a first heterodimeric precursor polypeptide from the plurality of first heterodimeric precursor polypeptides, comprising an antigen binding portion that specifically binds to a first antigen, and

[0058] - a second heterodimeric precursor polypeptide from the plurality of second heterodimeric precursor polypeptides, comprising an antigen binding portion that specifically binds to a second antigen;

[0059] as well as

[0060] b) individually testing each multispecific heterodimeric polypeptide from the plurality of multispecific heterodimeric polypeptides produced in step a) for a desired characteristic, and

[0061] c) Selecting a multispecific heterodimeric polypeptide.

[0062] Another aspect of the invention is the set of heterodimeric precursor polypeptides according to the invention for use as a medicament.

[0063] By the invention disclosed herein, a precursor polypeptide capable of polypeptide chain exchange to form a product polypeptide is provided. Thus, a multispecific antigen-binding polypeptide can be produced. The production of a multispecific antigen-binding polypeptide may occur due to the combination of two precursor polypeptides comprising antigen-binding moieties that specifically bind to different antigens, or by activating the antigen-binding site due to polypeptide chain exchange, resulting in association with an antibody variable domain that specifically binds to the antigen, or by both.

[0064] The present invention provides methods for producing product polypeptides of different sizes from precursor polypeptides, thereby allowing the desired product polypeptide to be easily separated from the unreacted precursor polypeptide. The method and polypeptide group according to the present invention are suitable for providing product polypeptides, such as bispecific or multispecific antibodies, by exchanging polypeptide chains in vitro and avoiding the recombinant expression of product polypeptides. Thus, the method and polypeptide group of the present invention are suitable for screening product polypeptides formed by a variety of precursor polypeptides, such as, allowing the identification of favorable combinations of antigen binding moieties. The method and polypeptide group of the present invention can be advantageously used to provide antigen-binding polypeptides for treatment or diagnosis purposes.

[0065] The therapeutic application of the precursor polypeptide groups of the present invention allows the production of the desired product polypeptide at the target site, thereby reducing the off-target effects of the product polypeptide. BRIEF DESCRIPTION OF THE DRAWINGS

[0066] Figure 1:Exemplary structures of heterodimeric precursor polypeptides and corresponding product polypeptides formed after polypeptide chain exchange. The first heterodimeric precursor polypeptide comprises three polypeptide chains: 1. A first heavy chain polypeptide, which comprises antibody domains VH, CH1, hinge, CH2 and CH3 from the N-terminus to the C-terminus. The CH3 domain comprises a knob mutation and a cysteine ​​mutation, and does not comprise a destabilizing mutation. 2. A second heavy chain polypeptide, which comprises antibody domain hinge, CH2 and CH3 from the N-terminus to the C-terminus. The tag portion is fused to the C-terminus of the CH3 domain. The CH3 domain comprises a hole mutation and a destabilizing mutation. 3. A light chain polypeptide, which comprises antibody domains VL and CL from the N-terminus to the C-terminus. The VH domain and the VL domain form an antigen binding site that specifically binds to the first antigen. The heavy chain polypeptides of the first heterodimeric precursor polypeptide associate with each other through their CH3 domains. The hinge region comprises an interchain disulfide bond. The second heterodimer precursor polypeptide comprises three polypeptide chains: 1. A first heavy chain polypeptide, which comprises antibody domains VH, CH1, hinge, CH2 and CH3 from the N-terminus to the C-terminus. The CH3 domain comprises a hole mutation and a cysteine ​​mutation, and does not comprise a destabilizing mutation. 2. A second heavy chain polypeptide, which comprises antibody domain hinge, CH2 and CH3 from the N-terminus to the C-terminus. The tag portion is fused to the C-terminus of the CH3 domain. The CH3 domain comprises a knob mutation and a destabilizing mutation. 3. A light chain polypeptide, which comprises antibody domains VL and CL from the N-terminus to the C-terminus. The VH domain and the VL domain form an antigen binding site that specifically binds to the second antigen. The heavy chain polypeptides of the second heterodimer precursor polypeptide associate with each other through their CH3 domains. The hinge region comprises an interchain disulfide bond. In the presence of a reducing agent, the interchain disulfide bonds in the hinge region are reduced, thereby destabilizing the heterodimer formed by the first heavy chain polypeptide and the second heavy chain polypeptide and supporting polypeptide chain exchange. As a result, a heterodimer product polypeptide is formed. The first product polypeptide comprises two antigen binding sites, namely the antigen binding site from the first heterodimer precursor polypeptide and the antigen binding site from the second heterodimer precursor polypeptide. The first product polypeptide comprises the first heavy chain polypeptide from the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide, which are associated through their CH3 domains. Both heavy chain polypeptides contained in the first product polypeptide comprise a CH3 domain that does not comprise a destabilizing mutation. Both CH3 domains comprise cysteine ​​mutations, which interact and support the formation of heterodimer product polypeptides. The second product polypeptide, which does not comprise an antigen binding site in this example, comprises a second heavy chain polypeptide from the first heterodimer precursor polypeptide and a second heavy chain polypeptide from the second heterodimer precursor polypeptide. Both heavy chain polypeptides are associated through their CH3 domains. Both CH3 domains comprise destabilizing mutations, which interact and support the formation of heterodimer product polypeptides. The product polypeptide comprises a tag portion that allows purification by tag-specific chromatography.

[0067] Figure 2: Exemplary structures of heterodimeric precursor polypeptides and corresponding product polypeptides formed after polypeptide chain exchange, wherein polypeptide chain exchange results in activation of an antigen binding site. The first heterodimeric precursor polypeptide comprises three polypeptide chains: 1. A first heavy chain polypeptide, which comprises antibody domains VH, CH1, a peptide connector, a VH domain derived from a first antibody, and CH3 from the N-terminal to the C-terminal direction. The CH3 domain comprises a knob mutation and does not comprise a destabilizing mutation. 2. A second heavy chain polypeptide, which comprises the following antibody domains from the N-terminal to the C-terminal direction: a VL domain derived from a second antibody and CH3. The CH3 domain comprises a hole mutation and a destabilizing mutation. 3. A light chain polypeptide, which comprises antibody domains VL and CL from the N-terminal to the C-terminal direction. The N-terminal VH domain from the first heavy chain polypeptide and the VL domain from the light chain polypeptide form an antigen binding site that specifically binds to a target antigen. The heavy chain polypeptides of the first heterodimeric precursor polypeptide associate with each other through their CH3 domains. No interchain disulfide bond is formed between the first heavy chain polypeptide and the second heavy chain polypeptide. A pair of VH domains and VL domains are formed between the VH domain derived from the first antibody and the VL domain derived from the second heavy chain polypeptide. The two variable domains associate with each other, but do not form a binding site that specifically binds to the antigen. The second heterodimeric precursor polypeptide comprises three polypeptide chains: 1. A first heavy chain polypeptide, which comprises antibody domains VH, CH1, a peptide connector, a VL domain derived from the first antibody, and CH3 from the N-terminal to the C-terminal direction. The CH3 domain comprises a hole mutation and does not comprise a destabilizing mutation. 2. A second heavy chain polypeptide, which comprises the following antibody domains from the N-terminal to the C-terminal direction: a VH domain and CH3 derived from a third antibody. The CH3 domain comprises a knob mutation and a destabilizing mutation. 3. A light chain polypeptide, which comprises antibody domains VL and CL from the N-terminal to the C-terminal direction. The N-terminal VH domain of the first heavy chain polypeptide and the VL domain from the light chain polypeptide form an antigen binding site that specifically binds to the target antigen. The heavy chain polypeptides of the second heterodimer precursor polypeptide are associated with each other through their CH3 domains. No interchain disulfide bond is formed between the first heavy chain polypeptide and the second heavy chain polypeptide. A pair of VH domains and VL domains are formed between the VL domain derived from the first antibody and the VH domain derived from the second heavy chain polypeptide. The two variable domains are associated with each other, but do not form a binding site that specifically binds to the antigen. After the polypeptide chain is exchanged, a heterodimer product polypeptide is formed. The first product polypeptide comprises two antigen binding sites from the precursor polypeptide, i.e., an antigen binding site from the first heterodimer precursor polypeptide and an antigen binding site from the second heterodimer precursor polypeptide. The first product polypeptide comprises a first heavy chain polypeptide from the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide, which are associated through their CH3 domains. Both heavy chain polypeptides contained in the first product polypeptide comprise a CH3 domain that does not comprise a destabilizing mutation.By the association of the first heavy chain polypeptide from the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide, a pair of VH domains derived from the first antibody and the VL domains derived from the first antibody are formed, which form an antigen binding site specifically bound to the first antigen. The antigen binding site is not present in any precursor polypeptide and is only formed (activated) after polypeptide chain exchange. The second product polypeptide comprises the second heavy chain polypeptide from the first heterodimer precursor polypeptide and the second heavy chain polypeptide from the second heterodimer precursor polypeptide. Both heavy chain polypeptides are associated through their CH3 domains. Both CH3 domains include destabilizing mutations, which interact and support the formation of heterodimer product polypeptides. By the association of the second heavy chain polypeptide from the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide, a pair of new VH domains and VL domains are formed. Both variable domains are associated in the second product polypeptide.

[0068] Figure 3: Exemplary structures of heterodimeric precursor polypeptides and corresponding product polypeptides formed after polypeptide chain exchange, wherein polypeptide chain exchange results in activation of an antigen binding site. The first heterodimeric precursor polypeptide comprises three polypeptide chains: 1. A first heavy chain polypeptide, which comprises antibody domains VH, CH1, a peptide connector, a VH domain derived from a first antibody, CH2, and CH3 from the N-terminal to the C-terminal direction. The CH3 domain comprises a knob mutation and does not comprise a destabilizing mutation. 2. A second heavy chain polypeptide, which comprises the following antibody domains from the N-terminal to the C-terminal direction: a VL domain derived from a second antibody, CH2, and CH3. The CH3 domain comprises a hole mutation and a destabilizing mutation. 3. A light chain polypeptide, which comprises antibody domains VL and CL from the N-terminal to the C-terminal direction. The N-terminal VH domain from the first heavy chain polypeptide and the VL domain from the light chain polypeptide form an antigen binding site that specifically binds to a target antigen. The heavy chain polypeptides of the first heterodimeric precursor polypeptide associate with each other through their CH3 domains. No interchain disulfide bond is formed between the first heavy chain polypeptide and the second heavy chain polypeptide. A pair of VH domains and VL domains are formed between the VH domain derived from the first antibody and the VL domain derived from the second heavy chain polypeptide. The two variable domains associate with each other, but do not form a binding site that specifically binds to the antigen. The second heterodimeric precursor polypeptide comprises three polypeptide chains: 1. A first heavy chain polypeptide, which comprises antibody domains VH, CH1, a peptide connector, a VL domain derived from the first antibody, CH2, and CH3 from the N-terminus to the C-terminus. The CH3 domain comprises a hole mutation and does not comprise a destabilizing mutation. 2. A second heavy chain polypeptide, which comprises the following antibody domains from the N-terminus to the C-terminus: a VH domain, CH2, and CH3 derived from a third antibody. The CH3 domain comprises a knob mutation and a destabilizing mutation. 3. A light chain polypeptide, which comprises antibody domains VL and CL from the N-terminus to the C-terminus. The N-terminal VH domain of the first heavy chain polypeptide and the VL domain from the light chain polypeptide form an antigen binding site that specifically binds to the target antigen. The heavy chain polypeptides of the second heterodimeric precursor polypeptide associate with each other through their CH3 domains. No interchain disulfide bond is formed between the first heavy chain polypeptide and the second heavy chain polypeptide. A pair of VH domains and VL domains are formed between the VL domain derived from the first antibody and the VH domain derived from the second heavy chain polypeptide. The two variable domains associate with each other, but do not form a binding site that specifically binds to the antigen. After the polypeptide chain is exchanged, a heterodimeric product polypeptide is formed. The first product polypeptide contains two antigen binding sites from the precursor polypeptide, namely, an antigen binding site from the first heterodimeric precursor polypeptide and an antigen binding site from the second heterodimeric precursor polypeptide. The first product polypeptide contains a first heavy chain polypeptide from the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide, which associate through their CH3 domains. Both heavy chain polypeptides contained in the first product polypeptide contain a CH3 domain that does not contain a destabilizing mutation.By the association of the first heavy chain polypeptide from the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide, a pair of VH domains derived from the first antibody and the VL domains derived from the first antibody are formed, which form an antigen binding site specifically bound to the first antigen. The antigen binding site is not present in any precursor polypeptide and is only formed (activated) after polypeptide chain exchange. The second product polypeptide comprises the second heavy chain polypeptide from the first heterodimer precursor polypeptide and the second heavy chain polypeptide from the second heterodimer precursor polypeptide. Both heavy chain polypeptides are associated through their CH3 domains. Both CH3 domains include destabilizing mutations, which interact and support the formation of heterodimer product polypeptides. By the association of the second heavy chain polypeptide from the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide, a pair of new VH domains and VL domains are formed. Both variable domains are associated in the second product polypeptide.

[0069] Figure 4 : Exemplary domain arrangement of the first heterodimeric precursor polypeptide. Description of knob-in-hole mutations, destabilizing mutations and cysteine ​​mutations and Figures 1 to 3 The same as in. The precursor polypeptide may contain one or more antigen binding sites, which may be arranged at the C-terminus or the N-terminus. Although the image indicates a precursor polypeptide containing a Fab fragment, it should be understood that the precursor polypeptide may contain other suitable antigen binding parts. The description of the hinge region disulfide bond is exemplary, and the hinge region disulfide bond may or may not be present depending on the desired application. The description of the cysteine ​​mutation is exemplary, but it is not mandatory in the precursor polypeptide of the present invention. A) A precursor polypeptide containing an N-terminal Fab fragment and a CH2 domain. B) A precursor polypeptide containing a C-terminal and N-terminal Fab fragment and a CH2 domain. C) A precursor polypeptide containing a C-terminal Fab fragment and a CH2 domain. D) A precursor polypeptide having an activatable binding site, comprising an N-terminal Fab fragment and a VH domain. E) A precursor polypeptide having an activatable binding site, comprising a C-terminal and N-terminal Fab fragment and a VH domain. F) A precursor polypeptide having an activatable binding site, comprising a C-terminal Fab fragment and a VH domain. G) A precursor polypeptide having an activatable binding site, comprising a CH2 domain containing an N-terminal Fab fragment and a VH domain. H) A precursor polypeptide having an activatable binding site, comprising a CH2 domain containing an N-terminal and C-terminal Fab fragment and a VH domain. I) A precursor polypeptide having an activatable binding site, comprising a CH2 domain containing a C-terminal Fab fragment and a VH domain. J) A precursor polypeptide having a C-terminal activatable binding site, comprising a CH2 domain containing an N-terminal Fab fragment and a VH domain. K) A precursor polypeptide having an activatable binding site, comprising an N-terminal Fab fragment and a VL domain.

[0070] Figure 5: Exemplary domain arrangement of the second heterodimeric precursor polypeptide. Description of knob-in-hole mutations, destabilizing mutations and cysteine ​​mutations and Figures 1 to 3 The same as in. The precursor polypeptide may contain one or more antigen binding sites, which may be arranged at the C-terminus or the N-terminus. Although the image indicates a precursor polypeptide containing a Fab fragment, it should be understood that the precursor polypeptide may contain other suitable antigen binding parts. The description of the hinge region disulfide bond is exemplary, and the hinge region disulfide bond may or may not be present depending on the desired application. The description of the cysteine ​​mutation is exemplary, but it is not mandatory in the precursor polypeptide of the present invention. A) A precursor polypeptide containing an N-terminal Fab fragment and a CH2 domain. B) A precursor polypeptide containing a C-terminal and N-terminal Fab fragment and a CH2 domain. C) A precursor polypeptide containing a C-terminal Fab fragment and a CH2 domain. D) A precursor polypeptide having an activatable binding site, comprising an N-terminal Fab fragment and a VL domain. E) A precursor polypeptide having an activatable binding site, comprising a C-terminal and N-terminal Fab fragment and a VL domain. F) A precursor polypeptide having an activatable binding site, comprising a C-terminal Fab fragment and a VL domain. G) A precursor polypeptide having an activatable binding site, comprising a CH2 domain containing an N-terminal Fab fragment and a VL domain. H) A precursor polypeptide having an activatable binding site, comprising a CH2 domain containing an N-terminal and C-terminal Fab fragment and a VL domain. I) A precursor polypeptide having an activatable binding site, comprising a CH2 domain containing a C-terminal Fab fragment and a VL domain. J) A precursor polypeptide having a C-terminal activatable binding site, comprising a CH2 domain containing an N-terminal Fab fragment and a VL domain. K) A precursor polypeptide having an activatable binding site, comprising an N-terminal Fab fragment and a VH domain. DETAILED DESCRIPTION

[0071] 1. definition

[0072] Unless otherwise defined herein, scientific and technical terms related to the present invention shall have the meanings commonly understood by those of ordinary skill in the art. In addition, unless the context otherwise requires, singular terms shall include plural terms, and plural terms shall include singular terms. The methods and techniques disclosed herein are generally carried out according to conventional methods well known in the art. Generally, the terms and techniques related to biochemistry, enzymology, molecular and cell biology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization as described herein are well known and commonly used in the art.

[0073] The terms "a", "an" and "the" generally include plural referents unless the context clearly dictates otherwise.

[0074] Unless otherwise defined herein, the term "comprising" shall include the term "consisting of."

[0075] Unless the context clearly indicates otherwise, use of the term "or" or "either" to provide two alternatives means that the alternatives are mutually exclusive.

[0076] As used herein, the term "antigen binding portion" refers to a portion that specifically binds to a target antigen. The term includes antibodies and other natural (eg, receptors, ligands) or synthetic (eg, DARPin) molecules that are capable of specifically binding to a target antigen.

[0077] The term "antibody" is used in the broadest sense and includes various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (eg, bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity.

[0078] As used herein, the term "binding site" or "antigen binding site" refers to one or more regions of an antigen binding moiety to which an antigen actually binds. In the case where the antigen binding moiety is an antibody, the antigen binding site includes an antibody heavy chain variable domain (VH) and / or an antibody light chain variable domain (VL), or a VH / VL pair. An antigen binding site derived from an antibody that specifically binds to a target antigen may be derived from a) a known antibody that specifically binds to an antigen or b) a new antibody or antibody fragment obtained by a de novo immunization method using an antigenic protein or nucleic acid or a fragment thereof, or by a phage display method.

[0079] When derived from an antibody, the antigen binding site of an antibody according to the invention may comprise six complementary determining regions (CDRs), which contribute to the affinity of the antigen binding site to varying degrees. There are three heavy chain variable domain CDRs (CDRH1, CDRH2, and CDRH3) and three light chain variable domain CDRs (CDRL1, CDRL2, and CDRL3). The extent of the CDRs and framework regions (FRs) is determined by comparison with a compiled database of amino acid sequences, in which those regions have been defined based on the variability between sequences. Also included within the scope of the invention are functional antigen binding sites consisting of fewer CDRs (i.e., wherein the binding specificity is determined by three, four, or five CDRs). For example, less than a complete set of 6 CDRs may be sufficient for binding.

[0080] As used herein, the term "valency" refers to the presence of a specified number of antigen binding sites in an antibody molecule. For example, a natural antibody has two binding sites and is divalent. Thus, the term "trivalent" refers to the presence of three binding sites in an antibody molecule.

[0081] "Antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody and binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv, scFab); and multispecific antibodies formed from antibody fragments.

[0082] "Specificity" refers to the selective recognition of a specific epitope of an antigen by an antigen-binding portion (e.g., an antibody). For example, a natural antibody is monospecific. As used herein, the term "monospecific antibody" refers to an antibody having one or more binding sites, each binding site binding to the same epitope of the same antigen. A "multispecific antibody" binds to two or more different epitopes (e.g., two, three, four or more different epitopes). The epitopes may be on the same or different antigens. An example of a multispecific antibody is a "bispecific antibody" that binds to two different epitopes. When an antibody has more than one specificity, the recognized epitopes may be associated with a single antigen or more than one antigen.

[0083] An epitope is a region of an antigen that binds to an antigen binding moiety (e.g., an antibody). The term "epitope" includes any polypeptide determinant that can specifically bind to an antibody or antigen binding moiety. In certain embodiments, an epitope determinant includes chemically active surface groups of molecules such as amino acids, polysaccharide side chains, phosphoryl or sulfonyl groups, and in certain embodiments, may have specific three-dimensional structural features and / or specific charge characteristics.

[0084] As used herein, the terms "bind" and "specific binding" refer to the determination of specific binding in an in vitro assay, preferably a plasmon resonance assay using purified wild-type antigen. In GE-Healthcare Uppsala, Sweden), the combination of an antibody or antigen binding portion with an antigenic epitope. In certain embodiments, when an antibody or antigen binding portion preferentially recognizes a target antigen in a complex mixture of proteins and / or macromolecules, the antibody or antigen binding portion is referred to as specifically binding to an antigen.

[0085] The affinity of antibody binding to antigen is measured by the term k a (association rate constant of the antibody from the antibody / antigen complex), k D (dissociation constant) and K D (k D In one embodiment, binding or specifically binding refers to 10 -8 mol / l or less binding affinity (K D ), in one embodiment 10 -8 M to 10 -13Therefore, the antigen binding part, especially the antibody binding site, is 10 -8 mol / l or less binding affinity (K D ) specifically binds to each antigen for which it is specific, e.g., binding affinity (K D ) is 10 -8 Up to 10 -13 In one embodiment, the binding affinity (K D ) is 10 -9 mol / l to 10 -13 mol / l.

[0086] The term "variable region" or "variable domain" refers to the domain of an antibody heavy chain or light chain that participates in binding of an antibody to an antigen. The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have similar structures, wherein each domain comprises four conserved framework regions (FRs) and three complementary determining regions (CDRs). (See, e.g., Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., p. 91 (2007)). A single VH or VL domain may be sufficient to confer antigen binding specificity. In addition, antibodies that bind to a specific antigen can be isolated using the VH or VL domains from antibodies that bind to the antigen, respectively, to screen for libraries of complementary VL or VH domains. See, e.g., Portolano et al., J. Immunol. 150: 880-887 (1993); Clarkson et al., Nature 352: 624-628 (1991).

[0087] The term "constant domain" or "constant region" used within the present application refers to the sum of antibody domains excluding the variable region. The constant region is not directly involved in antigen binding, but exhibits various effector functions.

[0088] Depending on the amino acid sequence of the constant region of their heavy chains, antibodies are divided into the following "classes": IgA, IgD, IgE, IgG and IgM, and some of them can be further divided into subclasses, such as IgG1, IgG2, IgG3 and IgG4, IgA1 and IgA2. The heavy chain constant regions corresponding to the different classes of antibodies are called α, δ, ε, γ and μ, respectively. The light chain constant regions (CL) that can be found in all five antibody classes are called κ (kappa) and λ (lambda).

[0089] As used herein, "constant domains" are preferably from human sources, which are constant heavy chain regions and / or constant light chain kappa or lambda regions of human antibodies of subclass IgG1, IgG2, IgG3 or IgG4. Such constant domains and regions are well known in the prior art, such as Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991).

[0090] In wild-type antibodies, the "hinge region" is a flexible stretch of amino acids in the central portion of the heavy chains of the IgG and IgA immunoglobulin classes that connects the two heavy chains via disulfide bonds (i.e., "interchain disulfide bonds" because they form between the two heavy chains). The hinge region of human IgG1 is generally defined as extending from about Glu216 or about Cys226 of human IgG1 to about Pro230 (Burton, Molec. Immunol. 22: 161-206 (1985)). The formation of disulfide bonds in the hinge region is avoided by deleting cysteine ​​residues in the hinge region or replacing cysteine ​​residues in the hinge region with other amino acids, such as serine.

[0091] The "light chain" of an antibody from any vertebrate species can be assigned to one of two different types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain. A wild-type light chain typically contains two immunoglobulin domains, usually a variable domain (VL) that is important for binding to the antigen and a constant domain (CL).

[0092] There are several different types of "heavy chains," which define the class, or isotype, of antibodies. A wild-type heavy chain contains a series of immunoglobulin domains, typically one variable domain (VH) that is important for binding to the antigen and several constant domains (CH1, CH2, CH3, etc.).

[0093] The term "Fc region" herein is used to define the C-terminal region of an immunoglobulin heavy chain, which comprises at least a portion of a constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, the human IgG heavy chain Fc region extends from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, which is also referred to as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0094] The "CH2 domain" of a human IgG Fc region generally extends from about amino acid residue 231 to about amino acid residue 340. Multispecific antibodies do not have a CH2 domain. "Without a CH2 domain" means that the antibody according to the present invention does not comprise a CH2 domain.

[0095] A "CH3 domain" comprises a stretch of residues at the C-terminus of a CH2 domain in an Fc region (i.e., from amino acid residue about 341 to amino acid residue about 447 of IgG). The "CH3 domain" herein is a variant CH3 domain in which the amino acid sequence of a native CH3 domain has undergone at least one different amino acid substitution (i.e., modification of the amino acid sequence of the CH3 domain) to promote heterodimerization of two CH3 domains facing each other in a multispecific antibody.

[0096] Typically, in heterodimerization methods known in the art, the CH3 domain of one heavy chain and the CH3 domain of another heavy chain are engineered in a complementary manner so that a heavy chain comprising an engineered CH3 domain no longer homodimerizes with another heavy chain of the same structure. Thus, a heavy chain comprising an engineered CH3 domain is forced to heterodimerize with another heavy chain comprising a CH3 domain engineered in a complementary manner.

[0097] One heterodimerization method known in the art is the so-called "knobs into holes" technology, which provides several examples described in detail in, for example, WO 96 / 027011, Ridgway, JB, et al., Protein Eng. 9 (1996) 617-621; Merchant, AM, et al., Nat. Biotechnol. 16 (1998) 677-681; and WO 98 / 050431, which are included herein by reference. In the "knobs into holes" technology, specific amino acids on each CH3 domain are engineered to produce a protrusion ("knob") in one CH3 structure and a cavity ("hole") in the other CH3 domain within the interface formed between the two CH3 domains in the tertiary structure of the antibody. In the tertiary structure of a multispecific antibody, a protrusion introduced in one CH3 domain can be positioned in a cavity introduced in another CH3 domain.

[0098] In combination with substitutions according to the knob-in-hole technique, additional interchain disulfide bonds can be introduced into the CH3 domain to further stabilize the heterodimeric polypeptide (Merchant, AM, et al., Nature Biotech. 16 (1998) 677-681). For example, such interchain disulfide bonds can be formed by introducing the following amino acid substitutions into the CH3 domain: D399C in one CH3 domain and K392C in the other CH3 domain; Y349C in one CH3 domain and S354C in the other CH3 domain; Y349C in one CH3 domain and E356C in the other CH3 domain; Y349C in one CH3 domain and E357C in the other CH3 domain; L351C in one CH3 domain and S354C in the other CH3 domain; T394C in one CH3 domain and V397C in the other CH3 domain. As used herein, "cysteine ​​mutation" refers to an amino acid in a CH3 domain substituted with cysteine, which is capable of forming an interchain disulfide bond with another matching amino acid in a second CH3 domain substituted with cysteine.

[0099] In addition to the previously mentioned "knobs-in-hole" technology, other techniques for modifying CH3 domains to perform heterodimerization are known in the art. These techniques, especially those described in WO 96 / 27011, WO 98 / 050431, EP 1870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO 2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012 / 058768, WO 2013 / 157954 and WO 2013 / 096291, are considered herein as alternatives to the "knobs-in-hole technology" for polypeptides provided by the present invention. All of these techniques involve engineering CH3 domains in a complementary manner by introducing amino acids of opposite charge or different side chain volumes, thereby supporting heterodimerization.

[0100] The precursor polypeptide of the present invention contains an amino acid substitution "destabilizing the CH3 / CH3 interface" in only one of its CH3 domains, also referred to herein as a "destabilizing mutation". For these ends, the amino acid substitution refers to being arranged only in one CH3 domain associated within the heterodimeric precursor polypeptide. In the CH3 domain, one or more amino acid positions known to interact within the CH3 / CH3 interface, such as disclosed in the prior art related to the above-mentioned CH3-heterodimerization strategy, are replaced by an amino acid having another site chain characteristic. In contrast to the heterodimerization strategy, in which a pair of interacting amino acids in the relevant CH3 domains (i.e., one or more amino acid residues in one CH3 domain involved in the heterodimer; and one or more amino acid residues in another CH3 domain involved in the heterodimer) are usually replaced, the destabilizing mutation is arranged only in one of the CH3 domains involved in the heterodimeric precursor polypeptide of the present invention. Exemplary amino acid substitutions that destabilize the CH3 / CH3 interface are listed in the "Destabilizing Mutations" section below. All exemplary amino acid substitutions specifically disclosed herein are arranged such that the substituted amino acids interact in the CH3 / CH3 interface within a pair of said CH3 domains.

[0101] As used herein, the term "polypeptide chain" refers to a linear organic polymer comprising a large number of amino acids linked together by peptide bonds. One or more polypeptide chains form a "polypeptide" or "protein", wherein these two terms are used interchangeably herein. A heterodimeric precursor polypeptide provided in one group according to the present invention comprises at least two polypeptide chains comprising a CH3 domain. Thus, a first polypeptide chain comprising a first CH3 domain "associates" with a second polypeptide chain comprising a second CH3 domain to form a dimeric polypeptide. Since the first CH3 domain and the second CH3 domain comprise amino acid substitutions according to the knob-in-hole technique, the two polypeptide chains form a "heterodimer", i.e. a dimer formed by two different polypeptides.

[0102] The polypeptide chains contained in the heterodimeric polypeptide, i.e. the heterodimeric precursor polypeptide and the heterodimeric product polypeptide, contain one or two polypeptide domains. When the order of the polypeptide domains is indicated in this article, it is indicated in the direction of N-terminus to C-terminus.

[0103] Each heterodimeric precursor polypeptide comprises at least two polypeptide chains comprising a CH3 domain.

[0104] In the case where the antigen binding moieties present in the two heterodimeric precursor polypeptides are antibody-derived antigen binding sites, such as antibody fragments, the polypeptide chains comprising the CH3 domains are also referred to herein as "heavy chain polypeptides". In this case, the heterodimeric precursor polypeptides may also comprise "light chain polypeptides", which typically comprise antibody variable domains and antibody constant domains, such as VL and CL.

[0105] The present invention provides a group comprising at least two polypeptides. The group comprises at least two heterodimeric "precursor" polypeptides. When the precursor polypeptides are reacted to exchange polypeptide chains with each other, a "product" polypeptide is formed. The present invention also provides a method for producing heterodimeric polypeptides, i.e., heterodimeric product polypeptides, by contacting at least two heterodimeric precursor polypeptides. The contacting step can be carried out under any suitable conditions that allow polypeptide chain exchange, preferably in a suitable buffer solution. When referred to in this article in connection with the present invention, "polypeptide chain exchange" refers to the exchange of polypeptide chains comprising a CH3 domain between two heterodimeric (precursor) polypeptides. Polypeptide chain exchange occurs when two initially associated polypeptide chains comprising a CH3 domain from a precursor polypeptide dissociate, and at least one of the dissociated polypeptide chains forms a new heterodimer by associating with a similarly dissociated CH3 domain from another precursor polypeptide. The mechanism of polypeptide chain exchange is also described. Figure 1 , Figure 2 and Figure 3 shown.

[0106] An "isolated" heterodimeric polypeptide, such as an antibody, is an antibody that has been separated from components of its natural environment. In some embodiments, the antibody is purified to a purity greater than 95% or 99% as determined, for example, by electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed phase HPLC). For a review of methods for assessing antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007).

[0107] As used herein, the amino acid positions of all constant regions and domains of heavy and light chains are numbered according to the Kabat numbering system described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991). In particular, for the variable domains and light chain constant domains CL of the kappa and lambda isotypes, the Kabat numbering system of Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) is used (see pages 647-660), and for the constant heavy chain domains (CH1, hinge, CH2 and CH3), the Kabat EU index numbering system is used (see pages 661-723). The amino acid positions provided herein are generally indicated by

[0108] Amino acid "substitutions" or "replacements" or "mutations" (all terms are used interchangeably herein) within a polypeptide chain are prepared by introducing appropriate nucleotide changes into the antibody DNA or by nucleotide synthesis. However, such modifications can only be performed to a very limited extent. For example, the modifications will not change the above-mentioned antibody characteristics, such as IgG isotype and antigen binding, but may further improve the yield of recombinant production, protein stability, or promote purification. In certain embodiments, antibody variants having one or more conservative amino acid substitutions are provided. As referred to herein, "double mutations" refer to the presence of two specified amino acid substitutions in the respective polypeptide chains.

[0109] As used herein, the term "amino acid" refers to an organic molecule having an amino moiety located at the alpha-position of a carboxyl group. Examples of amino acids include arginine, glycine, ornithine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine, tryptophan, methionine, serine, proline. The amino acid employed in each case is optionally an L-amino acid. The term "positively charged" or "negatively charged" amino acid refers to the charge of the amino acid side chain at pH 7.4. Amino acids can be grouped according to common side chain properties:

[0110] (1) Hydrophobicity: norleucine, Met, Ala, Val, Leu, Ile, Trp, Tyr, Phe;

[0111] (2) Neutral hydrophilicity: Cys, Ser, Thr, Asn, Gln;

[0112] (3) Acidic or negatively charged: Asp, Glu;

[0113] (4) Basic or positively charged: His, Lys, Arg;

[0114] (5) Residues that affect chain orientation: Gly, Pro;

[0115] Table – Amino acids with specific properties

[0116]

[0117]

[0118] As used herein, a "tag moiety" is a peptide sequence that is genetically grafted onto a polypeptide chain for various purposes (e.g., to support purification). In one embodiment, the tag moiety is an affinity tag. Therefore, a polypeptide comprising the affinity tag can be purified by appropriate affinity techniques (e.g., by affinity chromatography). Typically, the tag moiety is fused to the C-terminus of the CH3 domain via a peptide connector. Typically, the peptide connector is composed of flexible amino acid residues (e.g., glycine and serine). Therefore, a typical peptide connector for fusing the tag moiety to a polypeptide is a glycine-serine connector, i.e., a peptide connector composed of a pattern of glycine and serine residues.

[0119] As used herein, the term "purified" refers to a polypeptide that is removed or otherwise separated from its natural environment or from a recombinant production source, and that is at least 60%, such as at least 80%, free of other components (such as membranes and microsomes) naturally associated with it. Antibody purification (recovering antibodies from host cell cultures) is performed to eliminate cellular components or other contaminants (such as other cellular nucleic acids or proteins) by standard techniques, including alkali / SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis, and other techniques well known in the art. See Ausubel, Current Protocols in Molecular Biology (Greene Publishing and Wiley Interscience, New York, 1987), edited by F. et al. Different methods have been established and widely used for protein purification, such as microprotein affinity chromatography (e.g., using affinity media for purification of kappa or lambda isotype constant light chain domains, such as KappaSelect or LambdaSelect), ion exchange chromatography (e.g., cation exchange (carboxymethyl resin), anion exchange (aminoethyl resin) and mixed mode exchange), thiophilic adsorption (e.g., with β-mercaptoethanol and other SH ligands), hydrophobic interaction or aromatic adsorption chromatography (e.g., using phenyl-agarose, aza-arenophilic resin or m-aminophenylboronic acid), metal chelate affinity chromatography (e.g., using Ni(II)-affinity materials and Cu(II)-affinity materials), size exclusion chromatography and electrophoretic methods (such as gel electrophoresis, capillary electrophoresis) (Vijayalakshmi, MA, Appl. Biochem. Biotech. 75 (1998) 93-102).

[0120] Polypeptides comprising a tag portion can be purified by "tag-specific affinity chromatography". Suitable purification methods for tags are known in the art. Thus, polypeptides comprising a poly (his) tag can be purified, for example, by metal chelate affinity chromatography, in particular nickel chelate affinity chromatography.

[0121] As used herein, the term "peptide connector" refers to a peptide having an amino acid sequence that is preferably of synthetic origin. Within the heterodimeric polypeptides used in the present invention, the peptide connector can be used to fuse additional polypeptide domains, such as antibody fragments, to the C-terminus or N-terminus of a single polypeptide chain. In one embodiment, the peptide connector is a peptide having an amino acid sequence of at least 5 amino acids in length, in another embodiment, 5 to 100 amino acids in length, and in yet another embodiment, 10 to 50 amino acids in length. In one embodiment, the peptide connector is a glycine-serine linker. In one embodiment, the peptide connector is a peptide consisting of glycine and serine amino acid residues. In one embodiment, the peptide connector is

[0122] (G x S) n or (G x S) n G m

[0123] Where G = glycine, S = serine, and

[0124] x=3, n=3, 4, 5 or 6, m=0, 1, 2 or 3; or

[0125] x=4, n=2, 3, 4 or 5, m=0, 1, 2 or 3.

[0126] In one embodiment, x = 4 and n = 2 or 3, in another embodiment, x = 4, n = 2. In one embodiment, the peptide linker is (G4S)2.

[0127] As used herein, the term "valence" means that there are a specified number of binding sites in an antigen binding molecule. For example, a natural antibody has two binding sites and is divalent. Thus, the term "trivalent" means that there are three binding sites in an antigen binding molecule.

[0128] The polypeptide according to the present invention is produced by recombinant means. Recombinant production methods of polypeptides (e.g., antibodies) are well known in the prior art and include expressing proteins in prokaryotic and eukaryotic host cells, subsequently isolating the antibodies, and generally purifying them to pharmaceutical purity. In order to express the above-mentioned polypeptides in host cells, nucleic acids encoding the corresponding polypeptide chains are inserted into expression vectors by standard methods. Expression is performed in appropriate prokaryotic or eukaryotic host cells such as CHO cells, NSO cells, SP2 / 0 cells, HEK293 cells, COS cells, PER.C6 cells, yeast or Escherichia coli cells, and polypeptides are recovered from the cells (supernatant or cells after lysis). General methods for recombinant production of polypeptides (e.g., antibodies) are well known in the art and are reviewed in the following papers: Makrides, SC, Protein Expr. Purif. 17 (1999) 183-202; Geisse, S. et al., Protein Expr. Purif. 8 (1996) 271-282; Kaufman, RJ, Mol. Biotechnol 16 (2000) 151-161; Werner, RG, Drug Res. 48 (1998) 870-880.

[0129] The polypeptide produced by the host cell may be post-translationally cleaved at one or more, in particular one or two, amino acids from the C-terminus of the polypeptide chain comprising the CH3 domain at the C-terminus. Thus, the polypeptide produced by the host cell by expressing a specific nucleic acid molecule encoding such a polypeptide chain may include a full-length polypeptide chain, which includes a full-length CH3 domain, or the polypeptide may include a cleaved variant of the full-length polypeptide chain (also referred to herein as a "cleaved variant polypeptide chain"). This may be the case where the last two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447).

[0130] "Polynucleotide" or "nucleic acid" used interchangeably herein refers to a polymer of nucleotides of any length, and includes DNA and RNA. The nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or analogs thereof, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase or by a synthetic reaction. A polynucleotide can contain modified nucleotides, such as methylated nucleotides and their analogs. The sequence of nucleotides can be interrupted by non-nucleotide components. A polynucleotide can contain modifications made after synthesis, such as conjugation to a label. Other types of modifications include, for example, "capping", replacing one or more naturally occurring nucleotides with similar internucleotide modifications, such as, for example, those with uncharged bonds (e.g., methylphosphonates, phosphotriesters, phosphoramidates, carbamates) and with charged bonds (e.g., phosphorothioates, phosphorodithioates, etc.), those containing side groups, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, ply-L-lysine, etc.), those containing intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylating agents, those with modified bonds (e.g., α-anomeric nucleic acids, etc.), and unmodified forms of polynucleotides. In addition, any hydroxyl groups normally present in sugars can be replaced (e.g., phosphonate groups, phosphate groups), protected by standard protecting groups, or activated to prepare additional linkages with additional nucleotides, or can be conjugated to a solid or semi-solid support. The OH at 5' and 3' ends can be phosphorylated or partially replaced by the amine or organic end-capping group of 1-20 carbon atoms. Other hydroxyls can also be derived as standard protecting groups. Polynucleotides can also include similar forms of ribose or deoxyribose commonly known in the art, including for example 2'-O-methyl-, 2'-O-allyl, 2'-fluoro- or 2'-azido-ribose, carbocyclic sugar analogs, α-anomeric sugars, epimeric sugars (such as arabinose, xylose or lyxose, pyranose, furanose, sedoheptulose), acyclic analogs and alkaline nucleoside analogs such as methyl riboside. One or more phosphodiester bonds can be replaced by alternative linking groups. These alternative linker groups include, but are not limited to, embodiments in which the phosphate is replaced by P(O)S ("thioester"), P(S)S ("dithioester"), (O)NR2 ("amide ester"), P(O)R, P(O)OR', CO or CH2 ("methylal"), wherein each R or R' is independently H or substituted or unsubstituted alkyl (1-20 C) optionally containing an ether (-O-) bond, aryl, alkenyl, cycloalkyl, cycloalkenyl or aryl substitution. Not all linkages in a polynucleotide need be identical. The previous description applies to all polynucleotides referred to herein, including RNA and DNA.

[0131] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in a cell that normally contains the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

[0132] "Isolated nucleic acid encoding a heterodimeric polypeptide" refers to one or more nucleic acid molecules encoding one or more polypeptide chains (or fragments thereof) of the heterodimeric polypeptide, including such nucleic acid molecules in a single vector or different vectors, and such nucleic acid molecules present in one or more locations in a host cell.

[0133] As used herein, the term "vector" refers to a nucleic acid molecule capable of carrying another nucleic acid linked thereto. The term includes vectors that are self-replicating nucleic acid structures, and vectors that are incorporated into the genome of a host cell into which it has been introduced. The term includes vectors that are primarily used to insert DNA or RNA into cells (e.g., chromosomal integration), replication vectors that are primarily used for DNA or RNA replication, and expression vectors that are used for DNA or RNA transcription and / or translation. Also included are vectors that provide one or more of the functions described above.

[0134] An "expression vector" is a vector capable of directing the expression of a nucleic acid to which it is operably linked. When an expression vector is introduced into a suitable host cell, it can be transcribed and translated into a polypeptide. When a host cell is transformed in the method according to the present invention, an "expression vector" is used; therefore, as described herein, the term "vector" related to host cell transformation refers to an "expression vector". An "expression system" generally refers to a suitable host cell consisting of an expression vector that is capable of producing a desired expression product.

[0135] As used herein, "expression" refers to the process by which a nucleic acid is transcribed into mRNA and / or the process by which a transcribed mRNA (also referred to as a transcript) is subsequently translated into a peptide or polypeptide. Transcripts and encoded polypeptides are referred to individually or collectively as gene products. If the nucleic acid is derived from genomic DNA, expression in eukaryotic cells may include splicing of the corresponding mRNA.

[0136] As used herein, the term "transformation" refers to the process of transferring a vector or nucleic acid into a host cell. If cells without a strong cell wall barrier are used as host cells, transfection is performed, for example, by calcium phosphate precipitation transfection as described by Graham and Van der Eh, Virology 52 (1978) 546ff. However, other methods for introducing DNA into cells, such as by nuclear injection or by protoplast fusion, may also be used. If prokaryotic cells or cells containing a large amount of cell wall structure are used, for example, one transfection method is calcium treatment using calcium chloride, as described by Cohen, FN et al., PNAS 69 (1972) 7110 et seq.

[0137] As used in this application, the term "host cell" refers to any kind of cellular system that can be engineered to produce the polypeptides provided by the present invention.

[0138] As used herein, the expressions "cell", "cell line" and "cell culture" are used interchangeably, and all such names include progeny. Thus, the words "transformants" and "transformed cells" include the primary subject cell and cultures derived from the cell, regardless of the number of transformations. It should also be understood that all progeny may not be exactly identical in DNA content due to intentional or unintentional mutations. Variant progeny having the same function or biological activity as screened in the original transformed cell are included. If a different name is intended, it will be clear from the context.

[0139] Transient expression is described, for example, in Durocher, Y. et al., Nucl. Acids. Res. 30 (2002) E9. Cloning of variable domains is described in Orlandi, R. et al., Proc. Natl. Acad. Sci. USA 86 (1989) 3833-3837; Carter, P. et al., Proc. Natl. Acad. Sci. USA 89 (1992) 4285-4289; and Norderhaug, L. et al., J. Immunol. Methods 204 (1997) 77-87. A preferred transient expression system (HEK 293) is described in Schlaeger, E.-J. and Christensen, K., Cytotechnology 30 (1999) 71-83; and Schlaeger, E.-J., J. Immunol. Methods 194 (1996) 191-199.

[0140] The term "pharmaceutical composition" refers to a preparation that is in a form that allows the biological activity of the active ingredients contained therein to be effective and that does not contain additional components that are unacceptably toxic to the subject to which the composition will be administered. The pharmaceutical compositions of the present invention can be administered by a variety of methods known in the art. As will be appreciated by those skilled in the art, the route and / or mode of administration will vary depending on the desired results. In order to administer an antibody according to the present invention by certain routes of administration, it may be necessary to coat the antibody with a material or to co-administer the antibody with a material to prevent its inactivation. For example, a heterodimeric polypeptide can be administered to a subject in a suitable carrier such as a liposome or a diluent. Pharmaceutical diluents include saline and buffered aqueous solutions.

[0141] The pharmaceutical composition comprises an effective amount of the heterodimeric polypeptide provided by the present invention. A "therapeutically effective amount" of a medicament (e.g., a heterodimeric polypeptide) refers to an amount that effectively achieves the desired treatment or prevention result at the necessary dosage and time period. In particular, an "effective amount" is an amount representing a heterodimeric polypeptide of the present invention that, when administered to a subject, (i) treats or prevents a specific disease, disorder or illness, (ii) weakens, improves or eliminates one or more symptoms of a specific disease, disorder or illness, or (iii) prevents or delays the onset of one or more symptoms of a specific disease, disorder or illness described herein. A "therapeutically effective amount" will vary depending on the heterodimeric polypeptide molecule used, the disease state being treated, the severity of the disease being treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending physician or veterinary practitioner, and other factors.

[0142] "Pharmaceutically acceptable carrier" refers to ingredients in a pharmaceutical formulation other than the active ingredient that are non-toxic to the subject. Pharmaceutically acceptable carriers include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc. that are physiologically compatible. In a preferred embodiment, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion).

[0143] Pharmaceutical compositions according to the present invention may also include adjuvants, such as preservatives, wetting agents, emulsifiers and dispersants. Can be sterilized by the above-mentioned sterilization procedure and by adding various antibacterial and antifungal agents (such as parabens, chlorobutanol, phenol, sorbic acid, etc.) to ensure that there is no microorganism. It may also be desirable to include isotonic agents, such as sugar, sodium chloride, etc. in the composition. In addition, the extended absorption of injectable drug forms can be achieved by comprising a medicament (such as aluminum monostearate and gelatin) that delays absorption.

[0144] As used herein, the phrases "parenteral administration" and "administered parenterally" mean modes of administration other than enteral and topical administration, which are usually administered by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion.

[0145] Regardless of the route of administration selected, the compounds of the present invention, which can be used in a suitable hydrated form, and / or the pharmaceutical compositions of the present invention, can be formulated into pharmaceutical dosage forms by conventional methods known to those skilled in the art.

[0146] Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration without being toxic to the patient. The selected dosage level will depend on a variety of pharmacokinetic factors, including the activity of the particular composition of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound employed, the duration of the treatment, other drugs, compounds, and / or materials used in combination with the particular composition employed, the age, sex, weight, condition, general health, and previous medical history of the patient being treated, and similar factors well known in the medical field.

[0147] The composition must be sterile and fluid to the extent that the composition is deliverable by syringe. In addition to water, in one embodiment, the carrier is an isotonic buffered saline solution.

[0148] Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol or sorbitol, and sodium chloride in the composition.

[0149] As used herein, "treatment" (and grammatical variations such as "treat" or "treating") refers to clinical intervention that attempts to alter the natural course of the individual being treated, and can be performed for prevention or during the course of clinical pathology. Desired effects of treatment include, but are not limited to, preventing the occurrence or recurrence of disease, alleviating symptoms, attenuating any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, ameliorating or alleviating the disease state, and alleviating or improving prognosis. In some embodiments, the antibodies of the invention are used to delay the development of a disease or slow the progression of a disease.

[0150] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human. 2. DETAILED DESCRIPTION

[0152] The present invention provides useful precursor polypeptides, for example, for producing product polypeptides in vitro by polypeptide chain exchange. Each precursor polypeptide comprises a pair of CH3 domains, which are arranged on two separate polypeptide chains associated with each other through the CH3 domains. The CH3 domains comprise several amino acid substitutions. Thus, the two polypeptide chains comprising the CH3 domains within the precursor polypeptide form a heterodimer. The CH3 domains of the precursor polypeptides provided by the present invention comprise at least two mutation patterns with different functions. The first mutation pattern is a mutation that supports heterodimerization of the two polypeptide chains comprising the CH3 domains, i.e., a knob-into-hole mutation. Thus, one CH3 domain of the precursor polypeptide comprises a knob mutation, and another CH3 domain of the precursor polypeptide comprises a hole mutation. The second mutation pattern is one or more mutations provided only in one of the CH3 domains involved in the precursor polypeptide heterodimer, wherein the mutation destabilizes the interaction of the two polypeptides comprising the CH3 domains. Thus, each precursor polypeptide comprises a CH3 domain with a destabilizing mutation, which is selected and arranged so that they support the correct assembly of the product polypeptide after polypeptide chain exchange between the precursor polypeptides.

[0153] Precursor polypeptide

[0154] In one aspect, the present invention provides a set of heterodimeric precursor polypeptides comprising:

[0155] a) a first heterodimeric precursor polypeptide comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising a CH3 domain associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation,

[0156] wherein the first heterodimeric precursor polypeptide comprises a first antigen binding portion, wherein at least a portion of the first antigen binding portion is disposed on one of the two polypeptide chains comprising a CH3 domain, and

[0157] b) a second heterodimeric precursor polypeptide comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising a CH3 domain associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation,

[0158] wherein the second heterodimeric precursor polypeptide comprises a second antigen binding portion, wherein at least a portion of the second antigen binding portion is disposed on one of the two polypeptide chains comprising a CH3 domain,

[0159] in

[0160] A) either i) within the first heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain comprising the knob mutation comprises at least a portion of the first antigen binding portion, and within the second heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain having the hole mutation comprises at least a portion of the second antigen binding portion, or ii) within the first heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain comprising the hole mutation comprises at least a portion of the first antigen binding portion, and within the second heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain having the knob mutation comprises at least a portion of the second antigen binding portion; and wherein

[0161] B) or

[0162] i) a CH3 domain of a first heterodimeric precursor polypeptide comprising a knob mutation and a CH3 domain of a second heterodimeric precursor polypeptide comprising a hole mutation, or

[0163] ii) a CH3 domain of a first heterodimeric precursor polypeptide comprising a hole mutation and a CH3 domain of a second heterodimeric precursor polypeptide comprising a knob mutation

[0164] Comprising amino acid substitutions that destabilize the CH3 / CH3 interface, wherein the amino acid substitutions are arranged such that the substituted amino acids interact in the CH3 / CH3 interface within a pair of said CH3 domains.

[0165] In one aspect, the present invention provides a set of heterodimeric precursor polypeptides comprising:

[0166] a) a first heterodimeric precursor polypeptide comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising a CH3 domain associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation,

[0167] wherein the first heterodimeric precursor polypeptide comprises a first antigen binding portion, wherein at least a portion of the first antigen binding portion is disposed on one of the two polypeptide chains comprising a CH3 domain, and

[0168] b) a second heterodimeric precursor polypeptide comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising a CH3 domain associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation,

[0169] wherein the second heterodimeric precursor polypeptide comprises a second antigen binding portion, wherein at least a portion of the second antigen binding portion is disposed on one of the two polypeptide chains comprising a CH3 domain,

[0170] in

[0171] A) either i) within the first heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain comprising the knob mutation comprises at least a portion of the first antigen binding portion, and within the second heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain having the hole mutation comprises at least a portion of the second antigen binding portion, or ii) within the first heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain comprising the hole mutation comprises at least a portion of the first antigen binding portion, and within the second heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain having the knob mutation comprises at least a portion of the second antigen binding portion; and wherein

[0172] B) or

[0173] i) a CH3 domain of a first heterodimeric precursor polypeptide comprising a knob mutation and a CH3 domain of a second heterodimeric precursor polypeptide comprising a hole mutation, or

[0174] ii) a CH3 domain of a first heterodimeric precursor polypeptide comprising a hole mutation and a CH3 domain of a second heterodimeric precursor polypeptide comprising a knob mutation

[0175] The following amino acid substitutions (also referred to herein as "destabilizing mutations") are included, where numbering is according to the Kabat numbering system:

[0176] - the CH3 domain with hole mutation comprises at least one amino acid substitution selected from the group consisting of:

[0177] o Replacement of S354 with a hydrophobic amino acid;

[0178] o Replacement of D356 with a positively charged amino acid;

[0179] o replacing E357 with a positively charged amino acid or with a hydrophobic amino acid;

[0180] o replacement of D356 with a positively charged amino acid and replacement of E357 with a positively charged amino acid or with a hydrophobic amino acid;

[0181] o replacing S364 with a hydrophobic amino acid;

[0182] o replacing A368 with a hydrophobic amino acid;

[0183] ο Replacement of E392 with a negatively charged amino acid;

[0184] o Replacement of T394 with a hydrophobic amino acid;

[0185] o Replacement of D399 with a hydrophobic amino acid and replacement of S400 with a positively charged amino acid;

[0186] o replacement of D399 with a hydrophobic amino acid and replacement of F405 with a positively charged amino acid;

[0187] o replacing V407 with a hydrophobic amino acid; and

[0188] o replacing K409 with a negatively charged amino acid; and

[0189] ο Replacement of K439 with a negatively charged amino acid;

[0190] - the CH3 domain with the knob mutation comprises at least one amino acid substitution selected from the group consisting of:

[0191] o replacement of Q347 with a positively charged amino acid and replacement of K360 with a negatively charged amino acid;

[0192] o Replacement of Y349 with a negatively charged amino acid;

[0193] o replacing L351 with a hydrophobic amino acid and replacing E357 with a hydrophobic amino acid;

[0194] o replacing S364 with a hydrophobic amino acid;

[0195] o Replacement of W366 with a hydrophobic amino acid and replacement of K409 with a negatively charged amino acid;

[0196] o replacing L368 with a hydrophobic amino acid;

[0197] ο Replacement of K370 with a negatively charged amino acid;

[0198] o replacement of K370 with a negatively charged amino acid and replacement of K439 with a negatively charged amino acid;

[0199] ο Replacement of K392 with a negatively charged amino acid;

[0200] o Replacement of T394 with a hydrophobic amino acid;

[0201] o Replacement of V397 with a hydrophobic amino acid;

[0202] o replacing D399 with a positively charged amino acid and replacing K409 with a negatively charged amino acid;

[0203] ο Replacement of S400 with a positively charged amino acid;

[0204] οF405W;

[0205] οY407W; and

[0206] o Replacement of K439 with a negatively charged amino acid.

[0207] In another aspect, the present invention provides a first heterodimeric precursor polypeptide comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising a CH3 domain associate with each other through the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation, wherein the first heterodimeric precursor polypeptide comprises a first antigen binding portion, wherein at least a portion of the first antigen binding portion is disposed on one of the two polypeptide chains comprising a CH3 domain; and wherein one of the CH3 domains (but not the other CH3 domain) comprises the following amino acid substitutions (i.e., destabilizing mutations), wherein the numbering is according to the Kabat numbering system:

[0208] or the CH3 domain with the hole mutation comprises at least one amino acid substitution, i.e. a destabilizing mutation, selected from the group consisting of: replacement of S354 with a hydrophobic amino acid; replacement of D356 with a positively charged amino acid; replacement of E357 with a positively charged amino acid or with a hydrophobic amino acid; replacement of D356 with a positively charged amino acid and E357 with a positively charged amino acid or with a hydrophobic amino acid; replacement of S364 with a hydrophobic amino acid; replacement of A368 with a hydrophobic amino acid; replacement of E392 with a negatively charged amino acid; replacement of T394 with a hydrophobic amino acid; replacement of D399 with a hydrophobic amino acid and replacement of S400 with a positively charged amino acid; replacement of D399 with a hydrophobic amino acid and replacement of F405 with a positively charged amino acid; replacement of V407 with a hydrophobic amino acid; replacement of K409 with a negatively charged amino acid; replacement of K439 with a negatively charged amino acid; or

[0209] the CH3 domain with the knob mutation comprises at least one amino acid substitution, i.e. a destabilizing mutation, selected from the group consisting of: replacement of Q347 with a positively charged amino acid and replacement of K360 with a negatively charged amino acid; replacement of Y349 with a negatively charged amino acid; replacement of L351 with a hydrophobic amino acid and replacement of E357 with a hydrophobic amino acid; replacement of S364 with a hydrophobic amino acid; replacement of W366 with a hydrophobic amino acid and replacement of K409 with a negatively charged amino acid; replacement of L36 with a hydrophobic amino acid 8; replace K370 with a negatively charged amino acid; replace K370 with a negatively charged amino acid and replace K439 with a negatively charged amino acid; replace K392 with a negatively charged amino acid; replace T394 with a hydrophobic amino acid; replace V397 with a hydrophobic amino acid; replace D399 with a positively charged amino acid and replace K409 with a negatively charged amino acid; replace S400 with a positively charged amino acid; F405W; Y407W; and replace K439 with a negatively charged amino acid.

[0210] In another aspect, the present invention provides a second heterodimeric precursor polypeptide comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising a CH3 domain associate with each other through the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation, wherein the second heterodimeric precursor polypeptide comprises a second antigen binding portion, wherein at least a portion of the second antigen binding portion is disposed on one of the two polypeptide chains comprising a CH3 domain; and wherein one of the CH3 domains (but not the other CH3 domain) comprises the following amino acid substitutions (i.e., destabilizing mutations), wherein the numbering is according to the Kabat numbering system:

[0211] or the CH3 domain with the hole mutation comprises at least one amino acid substitution, i.e. a destabilizing mutation, selected from the group consisting of: replacement of S354 with a hydrophobic amino acid; replacement of D356 with a positively charged amino acid; replacement of E357 with a positively charged amino acid or with a hydrophobic amino acid; replacement of D356 with a positively charged amino acid and E357 with a positively charged amino acid or with a hydrophobic amino acid; replacement of S364 with a hydrophobic amino acid; replacement of A368 with a hydrophobic amino acid; replacement of E392 with a negatively charged amino acid; replacement of T394 with a hydrophobic amino acid; replacement of D399 with a hydrophobic amino acid and replacement of S400 with a positively charged amino acid; replacement of D399 with a hydrophobic amino acid and replacement of F405 with a positively charged amino acid; replacement of V407 with a hydrophobic amino acid; replacement of K409 with a negatively charged amino acid; replacement of K439 with a negatively charged amino acid; or

[0212] the CH3 domain with the knob mutation comprises at least one amino acid substitution, i.e. a destabilizing mutation, selected from the group consisting of: replacement of Q347 with a positively charged amino acid and replacement of K360 with a negatively charged amino acid; replacement of Y349 with a negatively charged amino acid; replacement of L351 with a hydrophobic amino acid and replacement of E357 with a hydrophobic amino acid; replacement of S364 with a hydrophobic amino acid; replacement of W366 with a hydrophobic amino acid and replacement of K409 with a negatively charged amino acid; replacement of L36 with a hydrophobic amino acid 8; replace K370 with a negatively charged amino acid; replace K370 with a negatively charged amino acid and replace K439 with a negatively charged amino acid; replace K392 with a negatively charged amino acid; replace T394 with a hydrophobic amino acid; replace V397 with a hydrophobic amino acid; replace D399 with a positively charged amino acid and replace K409 with a negatively charged amino acid; replace S400 with a positively charged amino acid; F405W; Y407W; and replace K439 with a negatively charged amino acid.

[0213] On the other hand, the present invention provides the use of the first heterodimer precursor polypeptide according to the present invention in combination with the second heterodimer polypeptide according to the present invention for forming a heterodimer product polypeptide. In one embodiment, the first heterodimer precursor polypeptide according to the present invention is used in combination with the second heterodimer polypeptide according to the present invention for forming a heterodimer product polypeptide by polypeptide chain exchange.

[0214] On the other hand, the present invention provides the use of a second heterodimer precursor polypeptide according to the present invention in combination with a first heterodimer polypeptide according to the present invention for forming a heterodimer product polypeptide. In one embodiment, the second heterodimer precursor polypeptide according to the present invention is used in combination with a first heterodimer polypeptide according to the present invention for forming a heterodimer product polypeptide by polypeptide chain exchange.

[0215] In another aspect of the present invention, there is provided the use of a first heterodimer precursor polypeptide according to the present invention in a group of heterodimer precursor polypeptides according to the present invention. In another aspect of the present invention, there is provided the use of a second heterodimer precursor polypeptide according to the present invention in a group of heterodimer precursor polypeptides according to the present invention.

[0216] Another aspect of the present invention is the use of a first heterodimer precursor polypeptide according to the present invention in a method for producing a heterodimer polypeptide according to the present invention. Another aspect of the present invention is the use of a second heterodimer precursor polypeptide according to the present invention in a method for producing a heterodimer polypeptide according to the present invention.

[0217] Another aspect of the present invention is the use of a first heterodimer precursor polypeptide according to the present invention in a method for identifying a multispecific heterodimer polypeptide according to the present invention. Another aspect of the present invention is the use of a second heterodimer precursor polypeptide according to the present invention in a method for identifying a multispecific heterodimer polypeptide according to the present invention.

[0218] Another aspect of the present invention is the use of said set of heterodimeric precursor polypeptides according to the present invention in a method for producing a heterodimeric polypeptide according to the present invention. Another aspect of the present invention is the use of said set of heterodimeric precursor polypeptides according to the present invention in a method for identifying a multispecific heterodimeric polypeptide according to the present invention.

[0219] In one embodiment, the following applies to the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide:

[0220] - in case the CH3 domain with the knob mutation comprises the mutation E357K, the CH3 domain with the hole mutation does not comprise the mutation K370E; and

[0221] - In case the CH3 domain with the knob mutation comprises the mutation D356K, the CH3 domain with the hole mutation does not comprise the mutation K439E.

[0222] In other words, according to one embodiment of the present invention, the following applies to the precursor polypeptide provided by the present invention:

[0223] - in case the CH3 domain with the knob mutation comprises the amino acid substitution E357K, the CH3 domain with the hole mutation comprises a K at position 370; and

[0224] - In case the CH3 domain with the knob mutation comprises the amino acid substitution D356K, the CH3 domain with the hole mutation comprises a K at position 439.

[0225] In one embodiment, the first heterodimeric precursor polypeptide comprises at least two (in one embodiment, exactly two) polypeptide chains comprising a CH3 domain, wherein one of the two polypeptide chains comprising the CH3 domain comprises at least a portion of the (first) antigen binding portion that specifically binds to an antigen; and the other of the two polypeptide chains comprising the CH3 domain does not comprise an antigen binding portion that specifically binds to an antigen. In one embodiment, the second heterodimeric precursor polypeptide comprises at least two (in one embodiment, exactly two) polypeptide chains comprising a CH3 domain, wherein one of the two polypeptide chains comprising the CH3 domain comprises at least a portion of the (first) antigen binding portion that specifically binds to an antigen; and the other of the two polypeptide chains comprising the CH3 domain does not comprise an antigen binding portion that specifically binds to an antigen. In one embodiment, the first heterodimeric precursor polypeptide comprises at least two (in one embodiment, exactly two) polypeptide chains comprising a CH3 domain, wherein one of the two polypeptide chains comprising a CH3 domain comprises at least a portion of a (first) antigen binding portion that specifically binds to an antigen; and wherein the other of the two polypeptide chains comprising a CH3 domain does not comprise an antigen binding portion that specifically binds to an antigen; and the second heterodimeric precursor polypeptide comprises at least two (in one embodiment, exactly two) polypeptide chains comprising a CH3 domain, wherein one of the two polypeptide chains comprising a CH3 domain comprises at least a portion of a (first) antigen binding portion that specifically binds to an antigen; and wherein the other of the two polypeptide chains comprising a CH3 domain does not comprise an antigen binding portion that specifically binds to an antigen. In other words, according to this embodiment of the invention, one or more functional antigen binding portions are disposed only on one of the two polypeptide chains comprising a CH3 domain, and no functional antigen binding portion is disposed on the other polypeptide chain comprising a CH3 domain. This polypeptide chain is also referred to herein as a "mimetic polypeptide". In one embodiment, the mimetic polypeptide associates only with another polypeptide chain comprising a CH3 domain, i.e., in a heterodimer, but not with another (e.g., a third) polypeptide chain. The mimetic polypeptide may comprise a portion of an antigen binding moiety, such as an antibody variable domain, which is not contained in a functional antigen binding site within the heterodimeric precursor polypeptide. One advantage of this arrangement, for example, combining a mimetic polypeptide comprising a CH3 domain with a polypeptide chain comprising a CH3 domain that participates in the formation of one or more functional antigen binding sites, is that the product polypeptide formed after polypeptide chain exchange is of a different size than the heterodimeric precursor molecule, which allows for improved product polypeptides from unreacted precursor polypeptides.

[0226] As indicated, within each heterodimeric precursor polypeptide, one of the polypeptide chains comprising the CH3 domain comprises a CH3 domain having a knob mutation, and the other polypeptide chain comprising the CH3 domain comprises a CH3 domain having a hole mutation. After polypeptide chain exchange, the polypeptide chain comprising the CH3 domain having a knob mutation from the first precursor polypeptide forms a heterodimer with the polypeptide chain comprising the CH3 domain having a hole from the second precursor polypeptide (i.e., the first heterodimeric product polypeptide), and the polypeptide chain comprising the CH3 domain having a hole mutation from the first precursor polypeptide forms a heterodimer with the polypeptide chain comprising the CH3 domain having a knob from the second precursor polypeptide (i.e., the second heterodimeric product polypeptide).

[0227] As indicated, one CH3 domain contained within the first heterodimeric precursor polypeptide comprises one or more destabilizing mutations, as indicated above, while another CH3 domain contained within the first heterodimeric precursor polypeptide does not comprise a destabilizing mutation; and one CH3 domain contained within the second heterodimeric polypeptide comprises one or more destabilizing mutations, as indicated above, while another CH3 domain contained within the second heterodimeric precursor polypeptide does not comprise a destabilizing mutation. The destabilizing mutations present within the precursor polypeptides are arranged so that they are present within the same product polypeptide after polypeptide chain exchange. Thus, in one of the precursor polypeptides, one or more destabilizing mutations are arranged in a CH3 domain comprising a knob mutation, while in the other precursor polypeptide, one or more destabilizing mutations are arranged in a CH3 domain comprising a hole mutation.

[0228] In one embodiment, within the first heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain containing the knob mutation comprises at least a portion of the first antigen binding portion, and within the second heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain having the hole mutation comprises at least a portion of the second antigen binding portion.

[0229] In one embodiment, within the first heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain containing the hole mutation comprises at least a portion of the first antigen binding portion, and within the second heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain having the knob mutation comprises at least a portion of the second antigen binding portion.

[0230] In one embodiment, the heterodimeric precursor polypeptide comprises exactly two polypeptide chains comprising a CH3 domain.

[0231] In one embodiment, the CH3 domain comprising a destabilizing mutation comprises one, two or three destabilizing mutations. In one embodiment, the CH3 domain comprising a destabilizing mutation comprises one or two destabilizing mutations.

[0232] The present invention includes heterodimeric precursor polypeptides, wherein in a CH3 domain having a knob mutation, the knob mutation is replaced by a destabilizing mutation. For example, a destabilizing mutation can be arranged at position 366 in a CH3 domain having a knob mutation, e.g., T366W. Thus, the heterodimeric precursor polypeptide comprises a destabilizing mutation, i.e., a hydrophobic amino acid, at position 366 of the CH3 domain (but not tryptophan (W)). However, heterodimeric precursor polypeptides having such substitutions are considered to be included in the present invention.

[0233] The present invention also includes heterodimer precursor polypeptides, wherein in the CH3 domain with a hole mutation, one or more mutations are replaced by destabilizing mutations. For example, a destabilizing mutation can be arranged at position 368 in the CH3 domain with a hole mutation, for example, T366S L368A Y407V. Therefore, the heterodimer precursor polypeptide comprises a destabilizing mutation, i.e., another hydrophobic amino acid, at position 368 of the CH3 domain (but not alanine (A)). In another example, a destabilizing mutation can be arranged at position 407 in the CH3 domain with a hole mutation, for example, T366S L368A Y407V. Therefore, the heterodimer precursor polypeptide comprises a destabilizing mutation, i.e., another hydrophobic amino acid, at position 407 of the CH3 domain (but not valine (V)). However, it is believed that such heterodimer precursor polypeptides with such one or more substitutions are included in the present invention.

[0234] In one embodiment of the present invention, no interchain disulfide bonds are formed between the two polypeptide chains comprising the CH3 domain of the first heterodimeric polypeptide. In one embodiment of the present invention, no interchain disulfide bonds are formed between the two polypeptide chains comprising the CH3 domain of the second heterodimeric polypeptide. In one embodiment of the present invention, no interchain disulfide bonds are formed between the two polypeptide chains comprising the CH3 domain of the first heterodimeric polypeptide and the second heterodimeric polypeptide. A heterodimeric precursor polypeptide having no interchain disulfide bonds between the two polypeptide chains comprising the CH3 domain is capable of polypeptide chain exchange in the absence of a reducing agent. Therefore, a heterodimeric precursor polypeptide in which no interchain disulfide bonds are present between the polypeptide chains comprising the CH3 domain is particularly suitable for applications in which the presence of a reducing agent is not possible or desirable; for example, for use in therapy.

[0235] A) Amino acid substitutions in the CH3 domain

[0236] The precursor polypeptide provided by the present invention comprises an amino acid substitution in its CH3 domain.

[0237] Knob-in-hole mutation

[0238] In one embodiment, the knob mutation contained within the first heterodimeric precursor polypeptide is the same as the knob mutation contained within the second heterodimeric precursor polypeptide.

[0239] In one embodiment, the knob mutation is T366W. In one embodiment, the hole mutation is T366S L368AY407V.

[0240] Destabilizing mutation

[0241] As noted above, only one CH3 domain of each precursor polypeptide contains one or more destabilizing mutations.

[0242] According to the present invention, either i) the CH3 domain of the first heterodimeric precursor polypeptide comprising a knob mutation and the CH3 domain of the second heterodimeric precursor polypeptide comprising a hole mutation, or ii) the CH3 domain of the first heterodimeric precursor polypeptide comprising a hole mutation and the CH3 domain of the second heterodimeric precursor polypeptide comprising a knob mutation comprise one or more destabilizing mutations. The one or more destabilizing mutations within the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide are selected so that they interact in the CH3 / CH3 interface of the product polypeptide formed by the polypeptide chain exchange between the precursor polypeptides.

[0243] In the case where the CH3 domain comprising a knob mutation of the heterodimer precursor polypeptide comprises a destabilizing mutation, the CH3 domain comprising a hole mutation of the heterodimer precursor polypeptide does not comprise a destabilizing mutation. When the CH3 domain "does not comprise a destabilizing mutation", it comprises a wild-type amino acid residue at a position in a wild-type immunoglobulin CH3 domain of the same class that interacts with an amino acid residue at the position of a destabilizing mutation comprised in the corresponding CH3 domain.

[0244] In one embodiment of the present invention, the CH3 domain with the hole mutation comprises at least one amino acid substitution, i.e., a destabilizing mutation, selected from the group consisting of: replacement of S354 with a hydrophobic amino acid; replacement of D356 with a positively charged amino acid; replacement of E357 with a positively charged amino acid or with a hydrophobic amino acid; replacement of D356 with a positively charged amino acid and replacement of E357 with a positively charged amino acid or with a hydrophobic amino acid; replacement of S364 with a hydrophobic amino acid; replacement of A368 with a hydrophobic amino acid; replacement of E392 with a negatively charged amino acid; replacement of T394 with a hydrophobic amino acid; replacement of D399 with a hydrophobic amino acid and replacement of S400 with a positively charged amino acid; replacement of D399 with a hydrophobic amino acid and replacement of F405 with a positively charged amino acid; replacement of V407 with a hydrophobic amino acid; replacement of K409 with a negatively charged amino acid; replacement of K439 with a negatively charged amino acid; and the CH3 domain with the knob mutation comprises at least one Amino acid substitutions, i.e., destabilizing mutations, are selected from the group consisting of: replacement of Q347 with a positively charged amino acid and replacement of K360 with a negatively charged amino acid; replacement of Y349 with a negatively charged amino acid; replacement of L351 with a hydrophobic amino acid and replacement of E357 with a hydrophobic amino acid; replacement of S364 with a hydrophobic amino acid; replacement of W366 with a hydrophobic amino acid and replacement of K409 with a negatively charged amino acid; replacement of L368 with a hydrophobic amino acid; replacement of replacing K370 with a negatively charged amino acid, and replacing K439 with a negatively charged amino acid; replacing K392 with a negatively charged amino acid; replacing T394 with a hydrophobic amino acid; replacing V397 with a hydrophobic amino acid; replacing D399 with a positively charged amino acid, and replacing K409 with a negatively charged amino acid; replacing S400 with a positively charged amino acid; F405W; Y407W; and replacing K439 with a negatively charged amino acid.

[0245] In one embodiment, the hydrophobic amino acid is selected from norleucine, Met, Ala, Val, Leu, Ile, Trp, Tyr and Phe. In one embodiment, the hydrophobic amino acid is selected from Ala, Val, Leu, Ile and Tyr. In one embodiment, the hydrophobic amino acid is Val, Leu or Ile. In one embodiment, the hydrophobic amino acid is Leu. In one embodiment, the hydrophobic amino acid is Tyr. In one embodiment, the hydrophobic amino acid is Phe.

[0246] In one embodiment, the positively charged amino acid is His, Lys or Arg. In one embodiment, the positively charged amino acid is Lys or Arg. In one embodiment, the positively charged amino acid is Lys.

[0247] In one embodiment, the negatively charged amino acid is Asp or Glu. In one embodiment, the negatively charged amino acid is Asp. In one embodiment, the negatively charged amino acid is Glu.

[0248] It was found that substitution of amino acids at designated amino acid positions in the CH3 domain with amino acids having respective side chain properties supports polypeptide chain exchange from two precursor polypeptides and formation of product polypeptides.

[0249] In one embodiment of the present invention, the CH3 domain with a hole mutation comprises at least one amino acid substitution selected from the group consisting of S354V, S354I, S354L, D356K, D356R, E357K, E357R, E357F, S364L, S364I, A368F, K392D, K392E, T394L, T394I, V407Y, K409E, K409D, K439D, K439E, and the double mutations D399A S400K, D399A S400R, D399A and the CH3 domain with the knob mutation comprises at least one amino acid substitution selected from the group consisting of Y349E, Y349D, S364V, S364I, S364L, L368F, K370E, K370D, K392E, K392D, T394L, T394I, V397Y, S400K, S400R, F405W, Y407W, K349E, K439D and the double mutations Q347K K360E, Q347R K360E, Q347K K360D, Q347R K360D, L351F E357F, W366I K409E, W366L K409E, W366K K409D, W366L K409D, D399K K409E, D399R K409E, D399K K409D and D399K K409E.

[0250] In one embodiment of the present invention, the CH3 domain with the hole mutation comprises at least one amino acid substitution selected from the group consisting of S354V, D356K, E357K, E357F, S364L, A368F, K392E, T394I, V407Y, K409E, K439E and the double mutation D399A S400K; and the CH3 domain with the knob mutation comprises at least one amino acid substitution selected from the group consisting of Y349E, S364V, L368F, K370E, K392D, T394I, V397Y, S400K, F405W, Y407W, K349E and the double mutations Q347K K360E, L351F E357F, W366I K409E and D399K K409E.

[0251] In one embodiment of the present invention, the CH3 domain with the hole mutation comprises at least one amino acid substitution selected from the group consisting of D356K, D356R, E357K, E357R, E357F, S364L, S364I, V407Y, K409E, K409D and the double mutation D399A S400K, D399A S400R; and the CH3 domain with the knob mutation comprises at least one amino acid substitution selected from the group consisting of Y349E, Y349D, K370E, K370D, K392E, K392D, T394L, T394I, V397Y, F405W, Y407W, K349E, K439D and the double mutation Q347K K360E, Q347R K360E, Q347K K360D, Q347R K360D, W366I K409E, W366L K409E, W366K K409D, W366L K409D, D399K K409E, D399R K409E, D399K K409D and D399K K409E.

[0252] In one embodiment of the present invention, the CH3 domain with the hole mutation comprises at least one amino acid substitution selected from the group consisting of D356K, E357K, E357F, S364L, V407Y, K409E and the double mutation D399A S400K; and the CH3 domain with the knob mutation comprises at least one amino acid substitution selected from the group consisting of Y349E, K370E, K392D, T394I, V397Y, F405W, Y407W, K349E and the double mutations Q347K K360E, W366I K409E and D399K K409E.

[0253] In one embodiment of the present invention, the CH3 domain with a hole mutation and the CH3 domain with a knob mutation comprising a destabilizing mutation comprise one of the amino acid substitutions selected from the group shown in the following table:

[0254]

[0255]

[0256]

[0257] For clarity, the table should be read as CH3 domains comprising hole mutations comprising the destabilizing mutations as shown in the first column of the table above, and CH3 domains comprising knob mutations comprising the destabilizing mutations listed in the right column of the table above, shown on the same row.

[0258] In one embodiment of the present invention, the CH3 domain with a hole mutation and the CH3 domain with a knob mutation comprising a destabilizing mutation comprise one of the amino acid substitutions selected from the group shown in the following table:

[0259] CH3 domain containing hole mutation CH3 domain containing knob mutation V407Y K370E V407Y K370E K439E V407Y V397Y S364L K439E S364L W366I K409E S364L K370E K439E S364L D399K K409E S364L T394I S364L W366I K409E S364L K370E K439E S364L D399K K409E S364L T394I

[0260] In one embodiment of the present invention, the CH3 domain with a hole mutation and the CH3 domain with a knob mutation comprising a destabilizing mutation comprise one of the amino acid substitutions selected from the group shown in the following table:

[0261] CH3 domain containing hole mutation CH3 domain containing knob mutation T394I E357F Y349E Y407W S364L E357F Y349E Y407W E357K T394I Y349E K439E E357K T394I Y349E W366I K409E D356K V407Y W366I K409E F405W S364L E357F W366I K409E K439E T394I E357F W366I K409E K439E S364L D356K W366I K409E K439E D356K V407Y T394I F405W S364L D356K T394I F405W

[0262] In one embodiment of the present invention, the CH3 domain with a hole mutation and the CH3 domain with a knob mutation comprising a destabilizing mutation comprise one of the amino acid substitutions selected from the group shown in the following table:

[0263] CH3 domain containing hole mutation CH3 domain containing knob mutation E357F S364L K370E K439E E357F S364L Y349E W366I K409D E357F S364L Y349E K439E D356K V407Y K370E K439E E357F S364L Y407W D356K V407Y Y349E W366I K409D E357F S364L Y349E Y407W D356K V407Y Y349E K439E E357F S364L W366I F405W K409D E357F S364L D399K K409E D356K V407Y W366I K409D K439E S364I Y349E K439E D356K V407Y D399K K409E D356K V407Y W366I K409D D356K V407Y T394I F405W V407Y D399K K409E E357K T394I D399K K409E E357K T394I W366I K409D

[0264] For clarity, the table should be read as CH3 domains comprising hole mutations comprising destabilizing mutations as shown in the first column of the table above, and CH3 domains comprising knob mutations comprising destabilizing mutations listed in the right column of the table above, shown in the same row. Precursor molecules with this combination of destabilizing mutations exhibit particularly beneficial polypeptide chain exchange.

[0265] In one embodiment of the present invention, the CH3 domain with a hole mutation and the CH3 domain with a knob mutation comprising a destabilizing mutation comprise one of the amino acid substitutions selected from the group shown in the following table:

[0266] CH3 domain containing hole mutation CH3 domain containing knob mutation E357F S364L Y349D S364A Y349D E357F S364L Y407W E357F S364L Y349E S364A Y349E E357F S364L W336I F405W K409D S364A W336I F405W K409D E357F S364L D399K K409E S364A D399K K409E S364I Y349D S364I Y407W S364I Y349E S364I W336I F405W K409D S364L Y349D S364I D399K K409E S364L Y407W K409E Y349D S364L Y349E S364L W336I F405W K409D K409E Y407W K409E Y349E S364L D399K K409E K409E W336I F405W K409D K409E D399K K409E

[0267] For clarity, the table should be understood as CH3 domains comprising hole mutations comprising destabilizing mutations as shown in the first column of the table above, and CH3 domains comprising knob mutations comprising destabilizing mutations listed in the right column of the table above, shown in the same row. Precursor molecules with this combination of destabilizing mutations exhibit particularly beneficial polypeptide chain exchange while being produced at high yields.

[0268] Cysteine ​​mutation

[0269] In one embodiment of the present invention, the CH3 domain of the heterodimeric precursor polypeptide comprises a third mutation pattern, i.e., different amino acids in the CH3 / CH3 interface are substituted by cysteine ​​to allow formation of an interchain disulfide bond between the two CH3 domains having cysteine ​​substitutions at the interaction positions.

[0270] Therefore, in one embodiment of the present invention, either i) the CH3 domain comprising the knob mutation of the first heterodimer precursor polypeptide comprises a cysteine ​​mutation, and the CH3 domain comprising the hole mutation of the second heterodimer precursor polypeptide comprises a cysteine ​​mutation, or ii) the CH3 domain comprising the hole mutation of the first heterodimer precursor polypeptide comprises a cysteine ​​mutation, and the CH3 domain comprising the knob mutation of the second heterodimer precursor polypeptide comprises a cysteine ​​mutation. In other words, in one embodiment, either i) within the first heterodimeric polypeptide, the CH3 domain comprising a knob mutation comprises a cysteine ​​mutation, and the CH3 domain comprising a hole mutation does not comprise a cysteine ​​mutation, and within the second heterodimeric polypeptide, the CH3 domain comprising a knob mutation does not comprise a cysteine ​​mutation, and the CH3 domain comprising a hole mutation comprises a cysteine ​​mutation, or ii) within the first heterodimeric polypeptide, the CH3 domain comprising a knob mutation does not comprise a cysteine ​​mutation, and the CH3 domain comprising a hole mutation comprises a cysteine ​​mutation, and within the second heterodimeric polypeptide, the CH3 domain comprising a knob mutation comprises a cysteine ​​mutation, and the CH3 domain comprising a hole mutation does not comprise a cysteine ​​mutation.

[0271] In one embodiment, either i) the CH3 domain comprising the knob mutation of the first heterodimer precursor polypeptide comprises a first cysteine ​​mutation, and the CH3 domain comprising the hole mutation of the second heterodimer precursor polypeptide comprises a second cysteine ​​mutation, or ii) the CH3 domain comprising the hole mutation of the first heterodimer precursor polypeptide comprises a first cysteine ​​mutation, and the CH3 domain comprising the knob mutation of the second heterodimer precursor polypeptide comprises a second cysteine ​​mutation, wherein the first cysteine ​​mutation and the second cysteine ​​mutation are selected from the following pair:

[0272] First cysteine ​​mutation Second cysteine ​​mutation D399C K392C Y349C S354C Y349C E356C Y349C E357C L351C S354C T394C V397C

[0273] In one embodiment, the first cysteine ​​mutation is Y349C and the second cysteine ​​mutation is S354C.

[0274] In one embodiment of the present invention, i) the CH3 domain comprising the knob mutation of the first heterodimer precursor polypeptide comprises the substitution S354C, and the CH3 domain comprising the hole mutation of the second heterodimer precursor polypeptide comprises the substitution Y349C, or ii) the CH3 domain comprising the hole mutation of the first heterodimer precursor polypeptide comprises the substitution Y349C, and the CH3 domain comprising the knob mutation of the second heterodimer precursor polypeptide comprises the substitution S354C.

[0275] In one embodiment of the present invention, within the first heterodimeric precursor polypeptide, the CH3 domain comprising the knob mutation comprises the substitution S354C, and the CH3 domain comprising the hole mutation comprises Y at position 349; and wherein within the second heterodimeric precursor polypeptide, the CH3 domain comprising the hole mutation comprises the substitution Y349C, and the CH3 domain comprising the knob mutation comprises S at position 354.

[0276] In one embodiment of the present invention, i) the CH3 domain comprising the knob mutation of the first heterodimer precursor polypeptide comprises the substitution T366W S354C, and the CH3 domain comprising the hole mutation of the second heterodimer precursor polypeptide comprises the substitution T366S L368A Y407V Y349C, or ii) the CH3 domain comprising the hole mutation of the first heterodimer precursor polypeptide comprises the substitution T366S L368A Y407V Y349C, and the CH3 domain comprising the knob mutation of the second heterodimer precursor polypeptide comprises the substitution T366W S354C.

[0277] In one embodiment of the present invention, within the first heterodimeric precursor polypeptide, the CH3 domain comprising the knob mutation comprises the substitution T366W S354C, and the CH3 domain comprising the hole mutation comprises Y and the substitution T366SL368A Y407V at position 349; and wherein in the second heterodimeric precursor polypeptide, the CH3 domain comprising the hole mutation comprises the substitution T366S L368A Y407V Y349C, and the CH3 domain comprising the knob mutation comprises S and the substitution T366W at position 354.

[0278] In one embodiment of the invention, the CH3 domain of the heterodimeric precursor polypeptide does not contain an interchain disulfide bond.

[0279] B) Antigen Binding Moiety

[0280] In one embodiment of the present invention, the antigen binding moiety is a polypeptide that specifically binds to an antigen. In one embodiment, the antigen binding moiety is selected from an antibody, a receptor, a ligand, and a DARPin that can specifically bind to an antigen.

[0281] In one embodiment of the invention, the antigen binding portion comprised in the (precursor) polypeptide according to the invention is an antibody fragment.

[0282] In one embodiment of the present invention, the antigen binding portion comprises a pair of VH domain and VL domain, which form an antigen binding site that specifically binds to the target antigen.

[0283] In one embodiment of the present invention, the antibody fragment contained in the (precursor) polypeptide according to the present invention is an antibody fragment selected from the following groups: Fv, Fab, Fab', Fab'-SH, F(ab')2, diabody, scFv and scFab. In one embodiment, the antibody fragment contained in the (precursor) polypeptide according to the present invention is Fv or Fab.

[0284] In one embodiment of the invention, the antigen binding portion is a Fab fragment.

[0285] In one embodiment of the invention, the first antigen binding moiety is a first Fab fragment, and the second antigen binding moiety is a second Fab fragment. In one embodiment of the invention, the first Fab fragment, the second Fab fragment, or both, the first Fab fragment and the second Fab fragment are altered by domain swapping such that:

[0286] a) Only the CH1 domain and CL domain are replaced with each other;

[0287] b) only the VH domain and the VL domain are replaced with each other; or

[0288] c) The CH1 domain and the CL domain are replaced with each other, and the VH domain and the VL domain are replaced with each other.

[0289] In one embodiment of the invention, the antigen binding moiety is a Fv fragment.In one embodiment of the invention, the first antigen binding moiety is a first Fv fragment and the second antigen binding moiety is a second Fv fragment.

[0290] In one embodiment of the invention, the antigen binding portion of the first heterodimer precursor polypeptide and the antigen binding portion of the second heterodimer precursor polypeptide bind to the same antigen. In one embodiment of the invention, the antigen binding portion of the first heterodimer precursor polypeptide and the antigen binding portion of the second heterodimer precursor polypeptide are the same antigen binding portion.

[0291] In one embodiment of the invention, the antigen binding portion of the first heterodimer precursor polypeptide and the antigen binding portion of the second heterodimer precursor polypeptide bind to different antigens. In this case, after the polypeptide chain exchange between the two heterodimer precursor polypeptides, a multispecific product polypeptide is formed, which comprises an antigen binding portion derived from the first heterodimer precursor polypeptide and an antigen binding portion derived from the second heterodimer precursor polypeptide.

[0292] Additional antigen binding moieties may be present in the heterodimeric precursor polypeptides and may be fused to the N-terminus or C-terminus of the polypeptide chains contained in the heterodimeric precursor polypeptides to provide a higher valency product polypeptide.

[0293] This additional antigen binding moiety is fused to the polypeptide chain via a suitable peptide linker. In one embodiment, the peptide linker is a glycine serine linker.

[0294] In one embodiment of the present invention, in the heterodimeric precursor polypeptide, only one polypeptide chain comprising the CH3 domain comprises at least a portion of the antigen binding portion. In one embodiment of the present invention, in the heterodimeric precursor polypeptide, one polypeptide chain comprising the CH3 domain of the antigen binding site specifically binds to the target antigen. In one embodiment of the present invention, in the heterodimeric precursor polypeptide, one polypeptide chain comprising the CH3 domain comprises the hinge region, the antibody variable domain, and the CH3 domain from the N-terminal to the C-terminal direction, and the polypeptide chain is not part of the antigen binding site that specifically binds to the target antigen. In one embodiment of the present invention, in the heterodimeric precursor polypeptide, one polypeptide chain comprising the CH3 domain comprises the hinge region, the antibody variable domain, the CH2 domain, and the CH3 domain from the N-terminal to the C-terminal direction, and the polypeptide chain is not part of the antigen binding site that specifically binds to the target antigen.

[0295] C) Domain arrangement of precursor polypeptide

[0296] Precursor polypeptides according to the present invention are suitable for producing various forms and product polypeptides with various domain arrangements. Depending on the selection of the domains provided in the heterodimeric precursor molecule and the number of antigen binding moieties, product polypeptides with different antigen binding characteristics (e.g., specificity, valency) and different effector functions can be produced.

[0297] In one embodiment, the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide contain exactly two polypeptide chains containing a CH3 domain. Therefore, another polypeptide chain without a CH3 domain may be contained in the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide.

[0298] Precursor polypeptides comprising antibody fragments

[0299] In one embodiment of the present invention, the antigen binding portion comprises a pair of VH domains and VL domains, which form an antigen binding site that specifically binds to the target antigen; and

[0300] a) the first heterodimeric precursor polypeptide comprises:

[0301] - a first heavy chain polypeptide comprising a CH3 domain and a first antibody variable domain,

[0302] - a second heavy chain polypeptide comprising a CH3 domain, wherein the first heavy chain polypeptide and the second heavy chain polypeptide associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0303] - a light chain polypeptide comprising a second antibody variable domain, wherein the first antibody variable domain and the second antibody variable domain together form a first antigen binding site that specifically binds to a target antigen; and wherein

[0304] b) the second heterodimeric precursor polypeptide comprises:

[0305] - a third heavy chain polypeptide comprising a CH3 domain and a third antibody variable domain,

[0306] - a fourth heavy chain polypeptide comprising a CH3 domain, wherein the third heavy chain polypeptide and the fourth heavy chain polypeptide associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0307] - a light chain polypeptide comprising a fourth antibody variable domain, wherein the third antibody variable domain and the fourth antibody variable domain together form a second antigen binding site that specifically binds to a target antigen; and wherein

[0308] c) either i) the first heavy chain polypeptide comprises a CH3 domain comprising a knob mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a hole mutation; or ii) the first heavy chain polypeptide comprises a CH3 domain comprising a hole mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a knob mutation.

[0309] In one embodiment of the present invention, the antigen binding portion comprises a pair of VH domains and VL domains, which form an antigen binding site that specifically binds to the target antigen; and

[0310] a) the first heterodimeric precursor polypeptide comprises:

[0311] - a first heavy chain polypeptide comprising, from N-terminal to C-terminal direction, a first VH domain and the constant antibody domains CH1, CH2 and CH3.

[0312] - a second heavy chain polypeptide, which comprises, from the N-terminal to the C-terminal direction, constant antibody domains CH2 and CH3 domains, wherein the first heavy chain polypeptide and the second heavy chain polypeptide associate with each other via the CH3 domains and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0313] - a light chain polypeptide comprising, from the N-terminal to the C-terminal direction, a first VL domain and a CL domain, wherein the first VH domain and the first VL domain associate with each other and form an antigen binding site that specifically binds to a target antigen; and wherein

[0314] b) the second heterodimeric precursor polypeptide comprises:

[0315] - a third heavy chain polypeptide comprising, from N-terminal to C-terminal direction, a second VH domain and the constant antibody domains CH1 , CH2 and CH3.

[0316] - a fourth heavy chain polypeptide, which comprises, from the N-terminal to the C-terminal direction, constant antibody domains CH2 and CH3 domains, wherein the third heavy chain polypeptide and the fourth heavy chain polypeptide associate with each other via the CH3 domains and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0317] - a light chain polypeptide comprising, from the N-terminal to the C-terminal direction, a second VL domain and a CL domain, wherein the second VH domain and the second VL domain associate with each other and form an antigen binding site that specifically binds to a target antigen; and wherein either i) the first heavy chain polypeptide comprises a CH3 domain comprising a knob mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a hole mutation; or ii) the first heavy chain polypeptide comprises a CH3 domain comprising a hole mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a knob mutation.

[0318] In one embodiment of the present invention, the antigen binding portion comprises a pair of VH domains and VL domains, which form an antigen binding site that specifically binds to the target antigen; and

[0319] a) the first heterodimeric precursor polypeptide comprises:

[0320] - a first heavy chain polypeptide comprising, from the N-terminus to the C-terminus, a CH2 domain, a CH3 domain, a peptide connector, a first VH domain and a CH1 domain,

[0321] - a second heavy chain polypeptide, which comprises, from the N-terminal to the C-terminal direction, constant antibody domains CH2 and CH3 domains, wherein the first heavy chain polypeptide and the second heavy chain polypeptide associate with each other via the CH3 domains and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0322] - a light chain polypeptide comprising, from the N-terminal to the C-terminal direction, a first VL domain and a CL domain, wherein the first VH domain and the first VL domain associate with each other and form an antigen binding site that specifically binds to a target antigen; and wherein

[0323] b) the second heterodimeric precursor polypeptide comprises:

[0324] - a third heavy chain polypeptide, which comprises, from the N-terminal to the C-terminal direction, a CH2 domain, a CH3 domain, a peptide connector, a first VH domain and a CH1 domain,

[0325] - a fourth heavy chain polypeptide, which comprises, from the N-terminal to the C-terminal direction, constant antibody domains CH2 and CH3 domains, wherein the third heavy chain polypeptide and the fourth heavy chain polypeptide associate with each other via the CH3 domains and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0326] - a light chain polypeptide comprising, from the N-terminal to the C-terminal direction, a second VL domain and a CL domain, wherein the second VH domain and the second VL domain associate with each other and form an antigen binding site that specifically binds to a target antigen; and wherein either i) the first heavy chain polypeptide comprises a CH3 domain comprising a knob mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a hole mutation; or ii) the first heavy chain polypeptide comprises a CH3 domain comprising a hole mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a knob mutation.

[0327] In one embodiment of the present invention, the antigen binding portion comprises a pair of VH domains and VL domains, which form an antigen binding site that specifically binds to the target antigen; and

[0328] a) the first heterodimeric precursor polypeptide comprises:

[0329] - a first heavy chain polypeptide which comprises, from N-terminal to C-terminal direction, a first VH domain and constant antibody domains CH1, CH2, CH3, a peptide connector, the first VH domain and the CH1 domain,

[0330] - a second heavy chain polypeptide, which comprises, from the N-terminal to the C-terminal direction, constant antibody domains CH2 and CH3 domains, wherein the first heavy chain polypeptide and the second heavy chain polypeptide associate with each other via the CH3 domains and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0331] - a light chain polypeptide comprising, from the N-terminal to the C-terminal direction, a first VL domain and a CL domain, wherein the first VH domain and the first VL domain associate with each other and form an antigen binding site that specifically binds to a target antigen; and wherein

[0332] b) the second heterodimeric precursor polypeptide comprises:

[0333] - a third heavy chain polypeptide comprising, from N-terminal to C-terminal direction, a second VH domain and the constant antibody domains CH1, CH2 and CH3, a peptide linker, a first VH domain and a CH1 domain.

[0334] - a fourth heavy chain polypeptide, which comprises, from the N-terminal to the C-terminal direction, constant antibody domains CH2 and CH3 domains, wherein the third heavy chain polypeptide and the fourth heavy chain polypeptide associate with each other via the CH3 domains and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0335] - a light chain polypeptide comprising, from the N-terminal to the C-terminal direction, a second VL domain and a CL domain, wherein the second VH domain and the second VL domain associate with each other and form an antigen binding site that specifically binds to a target antigen; and wherein either i) the first heavy chain polypeptide comprises a CH3 domain comprising a knob mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a hole mutation; or ii) the first heavy chain polypeptide comprises a CH3 domain comprising a hole mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a knob mutation.

[0336] Precursor polypeptide containing a CH2 domain

[0337] In one embodiment of the present invention, the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide comprise at least two polypeptide chains comprising a CH2 domain and a CH3 domain. The heterodimer precursor polypeptide comprising a CH2 domain and a CH3 domain exhibits advantageous properties, such as long half-life in circulation and mediation of Fc-mediated effector functions.

[0338] In one embodiment of the present invention, the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide comprise at least two polypeptide chains comprising a CH2 domain and a CH3 domain from the N-terminus to the C-terminus.

[0339] In one embodiment of the present invention, either i) the first heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain, a CH2 domain and a CH3 domain, and wherein the second heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VH domain, a CH2 domain and a CH3 domain, wherein when associated with a pair of VH domain and VL domain, the VL domain and the VH domain specifically bind to an antigen; or ii) the first heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VH domain, a CH2 domain and a CH3 domain, and wherein the second heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain, a CH2 domain and a CH3 domain, wherein when associated with a pair of VH domain and VL domain, the VL domain and the VH domain specifically bind to an antigen.

[0340] In one embodiment of the present invention, the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide do not have a CH2 domain. Heterodimeric precursor polypeptides without a CH2 domain can exhibit advantageous properties, such as rapid clearance from the circulation.

[0341] Precursor polypeptide comprising an activatable antigen binding site

[0342] In one embodiment, each precursor polypeptide comprises a portion of an antigen binding moiety, wherein the antigen binding moiety is non-functional in the precursor polypeptide, and wherein in the product polypeptide formed by the exchange of polypeptide chains between the precursor polypeptides, the antigen binding moiety is functional and specifically binds to the target antigen. An exemplary structure of such a precursor polypeptide is shown in Figure 2 and Figure 3 .

[0343] In one embodiment of the present invention, the antigen binding portion is an antigen binding site comprising a pair of antibody variable domains.

[0344] In one embodiment of the present invention, the first heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain and a CH3 domain, and wherein the second heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VH domain and a CH3 domain, wherein when associated with a pair of VH domain and VL domain, the VL domain and the VH domain specifically bind to an antigen.

[0345] In one embodiment, an activatable antigen binding site, such as a pair of antibody variable domains, is stabilized by an interchain disulfide bond. In one embodiment, a first heterodimer precursor polypeptide and a second heterodimer precursor polypeptide comprise a hinge region, wherein the hinge region does not comprise an interchain disulfide bond, and wherein the activatable antigen binding site is stabilized by an interchain disulfide bond.

[0346] In one embodiment, the first heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain and a CH3 domain and a polypeptide chain comprising a VH domain and a CH3 domain, wherein the CH3 domains are associated with each other, and wherein the VH domain and the VL domain are associated with each other, and wherein a disulfide bond is formed between the VH domain and the VL domain by a cysteine ​​residue introduced at an amino acid position, wherein the amino acid position is selected from the following pairs: VH position 44 and VL position 100, VH position 105 and VL position 43, VH position 101 and VL position 100; in one embodiment, VH position 44 and VL position 100.

[0347] In one embodiment, the second heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain and a CH3 domain and a polypeptide chain comprising a VH domain and a CH3 domain, wherein the CH3 domains are associated with each other, and wherein the VH domain and the VL domain are associated with each other, and wherein a disulfide bond is formed between the VH domain and the VL domain by a cysteine ​​residue introduced at an amino acid position, wherein the amino acid position is selected from the following pairs: VH position 44 and VL position 100, VH position 105 and VL position 43, VH position 101 and VL position 100; in one embodiment, VH position 44 and VL position 100.

[0348] In one embodiment, the first heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain and a CH3 domain and a polypeptide chain comprising a VH domain and a CH3 domain, wherein the CH3 domains are associated with each other, and wherein the VH domain and the VL domain are associated with each other, and wherein a disulfide bond is formed between the VH domain and the VL domain by a cysteine ​​residue introduced at an amino acid position selected from the following pairs: VH position 44 and VL position 100, VH position 105 and VL position 43, VH position 101 and VL position 100; and the second heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain and a CH3 domain and a polypeptide chain comprising a VH domain and a CH3 domain. Peptide chain, wherein CH3 domains are associated with each other, and wherein the VH domain and the VL domain are associated with each other, and wherein a disulfide bond is formed between the VH domain and the VL domain by a cysteine ​​residue introduced at an amino acid position, wherein the amino acid position is selected from the following pairs: VH position 44 and VL position 100, VH position 105 and VL position 43, VH position 101 and VL position 100; wherein the amino acid substituted by cysteine ​​in the VH domain of the first heterodimeric precursor polypeptide is at the same position as in the VH domain of the second heterodimeric precursor polypeptide, and wherein the amino acid substituted by cysteine ​​in the VL domain of the first heterodimeric precursor polypeptide is at the same position as in the VL domain of the second heterodimeric precursor polypeptide.

[0349] In one embodiment, the first heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain and a CH3 domain and a polypeptide chain comprising a VH domain and a CH3 domain, wherein the CH3 domains are associated with each other, and wherein the VH domain and the VL domain are associated with each other, and wherein a disulfide bond is formed between the VH domain and the VL domain by a cysteine ​​residue introduced at an amino acid position selected from the following pairs: VH position 44 and VL position 100, VH position 105 and VL position 43, VH position 101 and VL position 100; and the second heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain and a CH3 domain and a polypeptide chain comprising a VH domain and a CH3 domain. Peptide chain, wherein CH3 domains are associated with each other, and wherein the VH domain and the VL domain are associated with each other, and wherein a disulfide bond is formed between the VH domain and the VL domain by a cysteine ​​residue introduced at an amino acid position, wherein the amino acid position is selected from the following pairs: VH position 44 and VL position 100, VH position 105 and VL position 43, VH position 101 and VL position 100; wherein the amino acid substituted by cysteine ​​in the VH domain of the first heterodimeric precursor polypeptide is at the same position as in the VH domain of the second heterodimeric precursor polypeptide, and wherein the amino acid substituted by cysteine ​​in the VL domain of the first heterodimeric precursor polypeptide is at the same position as in the VL domain of the second heterodimeric precursor polypeptide.

[0350] In one embodiment of the present invention, the first heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain and a CH3 domain from the N-terminus to the C-terminus, and wherein the second heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VH domain and a CH3 domain from the N-terminus to the C-terminus, wherein when associated with a pair of VH domain and VL domain, the VL domain and the VH domain specifically bind to an antigen.

[0351] In one embodiment of the present invention,

[0352] a) the first heterodimeric precursor polypeptide comprises:

[0353] - a first heavy chain polypeptide comprising, from N-terminal to C-terminal direction, a first VH domain, a CH1 domain, a second antibody variable domain selected from a VH domain and a VL domain, and a CH3 domain,

[0354] - a second heavy chain polypeptide which comprises, from the N-terminal to the C-terminal direction, an antibody variable domain capable of associating with a second antibody variable domain of a first heavy chain polypeptide and a CH3 domain, wherein the first heavy chain polypeptide and the second heavy chain polypeptide associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0355] - a light chain polypeptide comprising, from the N-terminal to the C-terminal direction, a first VL domain and a CL domain, wherein the first VH domain and the first VL domain associate with each other and form an antigen binding site that specifically binds to a target antigen; and wherein

[0356] b) the second heterodimeric precursor polypeptide comprises:

[0357] a third heavy chain polypeptide which comprises, from the N-terminal to the C-terminal direction, a second VH domain, a CH1 domain, a third antibody variable domain selected from a VH domain and a VL domain, and a CH3 domain,

[0358] - a fourth heavy chain polypeptide which comprises, from the N-terminal to the C-terminal direction, an antibody variable domain capable of associating with a third antibody variable domain of a third heavy chain polypeptide and a CH3 domain, wherein the third heavy chain polypeptide and the fourth heavy chain polypeptide associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0359] - a light chain polypeptide comprising, from the N-terminal to the C-terminal direction, a second VL domain and a CL domain, wherein the second VH domain and the second VL domain associate with each other and form an antigen binding site that specifically binds to a target antigen; and wherein

[0360] c) either i) the first heavy chain polypeptide comprises a CH3 domain comprising a knob mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a hole mutation; or ii) the first heavy chain polypeptide comprises a CH3 domain comprising a hole mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a knob mutation; and wherein

[0361] d) The variable domains of the first heavy chain polypeptide and the third heavy chain polypeptide are capable of forming an antigen binding site that specifically binds to the target antigen.

[0362] In one embodiment, the first heavy chain polypeptide comprises, from the N-terminal to the C-terminal direction, a first VH domain, a CH1 domain, a second antibody variable domain selected from a VH domain and a VL domain, a peptide connector, and a CH3 domain, and the second heavy chain polypeptide comprises, from the N-terminal to the C-terminal direction, an antibody variable domain capable of associating with the second antibody variable domain of the first heavy chain polypeptide, a peptide connector, and a CH3 domain, wherein the first heavy chain polypeptide and the second heavy chain polypeptide associate with each other through the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation, and the other CH3 domain comprises Hole mutation; the third heavy chain polypeptide comprises a second VH domain, a CH1 domain, a third antibody variable domain selected from a VH domain and a VL domain, a peptide connector and a CH3 domain from the N-terminal to the C-terminal direction, and the fourth heavy chain polypeptide comprises an antibody variable domain capable of associating with the third antibody variable domain of the third heavy chain polypeptide, a peptide connector and a CH3 domain from the N-terminal to the C-terminal direction, wherein the third heavy chain polypeptide and the fourth heavy chain polypeptide associate with each other through the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation, and the other CH3 domain comprises a hole mutation. In one embodiment, the peptide connectors contained in the first heavy chain polypeptide, the second heavy chain polypeptide, the third heavy chain polypeptide and the fourth heavy chain polypeptide are the same.

[0363] In one embodiment, in the first heterodimer precursor polypeptide, the second antibody variable domain contained in the first heavy chain polypeptide is derived from an antibody that specifically binds to the first target antigen, and the antibody variable domain contained in the second heavy chain polypeptide specifically binds to the second target antigen. Both variable domains can associate with each other. Therefore, one heavy chain polypeptide comprises a VH domain and the other heavy chain polypeptide comprises a VL domain. The VH domain and the VL domain can associate with each other. However, a non-functional antigen binding site is formed. Therefore, the term "variable domains that can associate with each other" in the context of the present invention refers to providing a pair of VH and VL domains. In this embodiment, in the second heterodimer precursor polypeptide, the third antibody variable domain contained in the third heavy chain polypeptide is derived from an antibody that specifically binds to the first target antigen (i.e., it can form a functional VH / VL pair with the second variable domain contained in the first heavy chain polypeptide of the first heterodimer precursor polypeptide), and the antibody variable domain contained in the fourth heavy chain polypeptide specifically binds to another (e.g., second) target antigen. The variable domains contained in the first heavy chain polypeptide and the third heavy chain polypeptide are capable of associating with each other, that is, one variable domain is a VH domain and the other is a VL domain; and the variable domains contained in the first heavy chain polypeptide and the third heavy chain polypeptide are capable of forming an antigen binding site that specifically binds to a target antigen, that is, both variable domains are derived from the same antibody that specifically binds to a target antigen.

[0364] In one embodiment of the present invention, the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide comprise at least two polypeptide chains comprising a CH2 domain and a CH3 domain from the N-to-C-terminal direction, wherein the first heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain, a CH2 domain and a CH3 domain from the N-to-C-terminal direction, and wherein the second heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VH domain, a CH2 domain and a CH3 domain from the N-terminal to the C-terminal direction, wherein the VL domain and the VH domain are capable of forming an antigen binding site that specifically binds to a target antigen.

[0365] In one embodiment of the present invention,

[0366] a) the first heterodimeric precursor polypeptide comprises:

[0367] - a first heavy chain polypeptide which comprises, from the N-terminal to the C-terminal direction, a first VH domain, a CH1 domain, a second antibody variable domain selected from a VH domain and a VL domain, a CH2 domain and a CH3 domain,

[0368] - a second heavy chain polypeptide which comprises, from the N-terminal to the C-terminal direction, an antibody variable domain capable of associating with a second antibody variable domain of a first heavy chain polypeptide, a CH2 domain, and a CH3 domain, wherein the first heavy chain polypeptide and the second heavy chain polypeptide associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0369] - a light chain polypeptide comprising, from the N-terminal to the C-terminal direction, a first VL domain and a CL domain, wherein the first VH domain and the first VL domain associate with each other and form an antigen binding site that specifically binds to a target antigen; and wherein

[0370] b) the second heterodimeric precursor polypeptide comprises:

[0371] - a third heavy chain polypeptide which comprises, from the N-terminal to the C-terminal direction, a second VH domain, a CH1 domain, a third antibody variable domain selected from a VH domain and a VL domain, a CH2 domain and a CH3 domain,

[0372] - a fourth heavy chain polypeptide which comprises, from the N-terminal to the C-terminal direction, an antibody variable domain capable of associating with a third antibody variable domain of a third heavy chain polypeptide, a CH2 domain, and a CH3 domain, wherein the third heavy chain polypeptide and the fourth heavy chain polypeptide associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0373] - a light chain polypeptide comprising, from the N-terminal to the C-terminal direction, a second VL domain and a CL domain, wherein the second VH domain and the second VL domain associate with each other and form an antigen binding site that specifically binds to a target antigen; and wherein

[0374] c) either i) the first heavy chain polypeptide comprises a CH3 domain comprising a knob mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a hole mutation; or ii) the first heavy chain polypeptide comprises a CH3 domain comprising a hole mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a knob mutation; and wherein

[0375] d) The variable domains of the first heavy chain polypeptide and the third heavy chain polypeptide are capable of forming an antigen binding site that specifically binds to the target antigen.

[0376] In one embodiment, the first heavy chain polypeptide comprises, from the N-terminal to the C-terminal direction, a first VH domain, a CH1 domain, a second antibody variable domain selected from a VH domain and a VL domain, a peptide connector, a CH2 domain, and a CH3 domain, and the second heavy chain polypeptide comprises, from the N-terminal to the C-terminal direction, an antibody variable domain capable of associating with the second antibody variable domain of the first heavy chain polypeptide, a peptide connector, a CH2 domain, and a CH3 domain, wherein the first heavy chain polypeptide and the second heavy chain polypeptide associate with each other through the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation, and the other CH3 domain comprises Hole mutation; the third heavy chain polypeptide comprises a second VH domain, a CH1 domain, a third antibody variable domain selected from a VH domain and a VL domain, a peptide connector, a CH2 domain and a CH3 domain from the N-terminal to the C-terminal direction, and the fourth heavy chain polypeptide comprises an antibody variable domain capable of associating with the third antibody variable domain of the third heavy chain polypeptide, a peptide connector, a CH2 domain and a CH3 domain from the N-terminal to the C-terminal direction, wherein the third heavy chain polypeptide and the fourth heavy chain polypeptide associate with each other through the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation, and the other CH3 domain comprises a hole mutation. In one embodiment, the peptide connectors contained in the first heavy chain polypeptide, the second heavy chain polypeptide, the third heavy chain polypeptide and the fourth heavy chain polypeptide are the same.

[0377] Precursor polypeptide containing hinge region

[0378] In one embodiment of the present invention, the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide comprise at least two polypeptide chains comprising a hinge region and a CH3 domain from the N-terminus to the C-terminus.

[0379] In one embodiment of the present invention, the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide comprise at least two polypeptide chains comprising a hinge region, a CH2 domain and a CH3 domain from the N-terminus to the C-terminus.

[0380] In one embodiment of the invention, the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide comprise an interchain disulfide bond in the hinge region. The heterodimer precursor polypeptide having a hinge region comprising at least one interchain disulfide bond undergoes polypeptide chain exchange in the presence of a reducing agent. Therefore, those heterodimer precursor polypeptides are suitable for applications in which a reducing agent may be present, such as for in vitro generation of product polypeptides or for screening purposes.

[0381] In one embodiment of the invention, the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide do not contain an interchain disulfide bond in the hinge region. Heterodimer precursor polypeptides having a hinge region without an interchain disulfide bond are capable of polypeptide chain exchange in the absence of a reducing agent. Therefore, heterodimer precursor polypeptides having a hinge region without an interchain disulfide bond are particularly suitable for applications in which it is impossible or undesirable to have a reducing agent. Therefore, those heterodimer precursor polypeptides can be advantageously used in treatment.

[0382] In one embodiment of the present invention, the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide comprise a native hinge region that does not form interchain disulfides in the hinge region. An example is a hinge region peptide derived from an IgG4 isotype antibody.

[0383] Instead of a hinge region without an interchain disulfide bond, the heterodimeric precursor polypeptide may comprise a peptide connector that connects (a portion of) the antigen binding portion to the constant antibody domain (i.e., CH2 or CH3). In one embodiment of the invention, no interchain disulfide bond is formed between the peptide connectors comprised in the two polypeptide chains comprising the CH3 domain of the precursor polypeptide. In one embodiment of the invention, the peptide connectors comprised in the two polypeptide chains comprising the CH3 domain are identical to each other.

[0384] In one embodiment of the present invention, the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide comprise at least two polypeptide chains comprising a peptide connector and a CH3 domain from the N-terminus to the C-terminus.

[0385] In one embodiment of the present invention, the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide comprise at least two polypeptide chains comprising a peptide connector, a CH2 domain and a CH3 domain from the N-terminus to the C-terminus.

[0386] In one embodiment of the present invention, the first heterodimeric precursor polypeptide comprises a first polypeptide chain comprising a first peptide connector, an antibody variable domain, optionally a CH2 domain and a CH3 domain, and a second polypeptide chain comprising a first peptide connector, an antibody variable domain capable of associating with the antibody variable domain from the first polypeptide chain, optionally a CH2 domain and a CH3 domain; and the second heterodimeric precursor polypeptide comprises a first polypeptide chain comprising a first peptide connector, an antibody variable domain, optionally a CH2 domain and a CH3 domain, and a second polypeptide chain comprising a first peptide connector, an antibody variable domain capable of associating with the antibody variable domain from the first polypeptide chain, optionally a CH2 domain and a CH3 domain.

[0387] In one embodiment of the invention, the peptide connector is a peptide of at least 15 amino acids. In another embodiment of the invention, the peptide connector is a peptide of 15-70 amino acids. In another embodiment of the invention, the peptide connector is a peptide of 20-50 amino acids. In another embodiment of the invention, the peptide connector is a peptide of 10-50 amino acids. Depending on, for example, the type of antigen to be bound by the activatable binding site, shorter (or even longer) peptide connectors may also be suitable for use in heterodimeric precursor polypeptides according to the present invention.

[0388] In another embodiment of the present invention, the length of the first and second peptide connectors is about the length of the native hinge region (for the native hinge region, the antibody molecule of the IgG1 isotype is about 15 amino acids, and the antibody molecule of the IgG3 isotype is about 62 amino acids). Therefore, in one embodiment, wherein the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide are IgG1 isotypes, the peptide connector is a peptide of 10-20 amino acids, and in a preferred embodiment, 12-17 amino acids. In another embodiment, wherein the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide are IgG3 isotypes, the peptide connector is a peptide of 55-70 amino acids, and in a preferred embodiment, 60-65 amino acids.

[0389] In one embodiment of the invention, the peptide linker is a glycine-serine linker. In one embodiment of the invention, the peptide linker is a peptide consisting of glycine and serine residues. In one embodiment of the invention, the glycine-serine linker has the following structure

[0390] (GxS)n or (GxS)nGm

[0391] wherein G=glycine, S=serine, x=3 or 4, n=2, 3, 4, 5 or 6, and m=0, 1, 2 or 3.

[0392] In one embodiment, in the above defined glycine-serine linker, x=3, n=3, 4, 5 or 6, and m=0, 1, 2 or 3; or x=4, n=2, 3, 4 or 5, and m=0, 1, 2 or 3. In a preferred embodiment, x=4 and n=2 or 3, and m=0. In another preferred embodiment, x=4 and n=2. In one embodiment, the peptide linker is (G4S)4 or (G4S)6.

[0393] In one embodiment of the present invention, either i) the first heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain, a peptide connector and a CH3 domain, and wherein the second heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VH domain, a peptide connector and a CH3 domain, wherein when associated with a pair of VH domain and VL domain, the VL domain and the VH domain specifically bind to an antigen; or ii) the first heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VH domain, a peptide connector and a CH3 domain, and wherein the second heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain, a peptide connector and a CH3 domain, wherein when associated with a pair of VH domain and VL domain, the VL domain and the VH domain specifically bind to an antigen.

[0394] In one embodiment of the present invention, either i) the first heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain, a peptide connector, a CH2 domain and a CH3 domain, and wherein the second heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VH domain, a peptide connector, a CH2 domain and a CH3 domain, wherein when associated with a pair of VH domain and VL domain, the VL domain and the VH domain specifically bind to an antigen; or ii) the first heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VH domain, a peptide connector, a CH2 domain and a CH3 domain, and wherein the second heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain, a peptide connector, a CH2 domain and a CH3 domain, wherein when associated with a pair of VH domain and VL domain, the VL domain and the VH domain specifically bind to an antigen.

[0395] D) Antibody isotype and titer

[0396] In one embodiment of the invention, the precursor polypeptide comprises the immunoglobulin constant region of one or more immunoglobulin classes. Immunoglobulin classes include IgG, IgM, IgA, IgD and IgE isotypes, and in the case of IgG and IgA, also include their subtypes. In one embodiment of the invention, the precursor polypeptide has the constant domain structure of an IgG type antibody.

[0397] In one embodiment of the present invention, the CH3 domain contained in the precursor polypeptide belongs to the mammalian IgG class. In one embodiment of the present invention, the CH3 domain contained in the precursor polypeptide belongs to the mammalian IgG1 subclass. In one embodiment of the present invention, the CH3 domain contained in the precursor polypeptide belongs to the mammalian IgG4 subclass.

[0398] In one embodiment of the present invention, the CH3 domain contained in the precursor polypeptide belongs to the human IgG class. In one embodiment of the present invention, the CH3 domain contained in the precursor polypeptide belongs to the human IgG1 subclass. In one embodiment of the present invention, the CH3 domain contained in the precursor polypeptide belongs to the human IgG4 subclass.

[0399] In one embodiment, the constant domain of the precursor polypeptide according to the present invention belongs to the human IgG class. In one embodiment, the constant domain of the precursor polypeptide according to the present invention belongs to the human IgG1 subclass. In one embodiment, the constant domain of the precursor polypeptide according to the present invention belongs to the human IgG4 subclass.

[0400] In one embodiment, the precursor polypeptide lacks a CH4 domain.

[0401] In one embodiment of the invention, the constant domains of the precursor polypeptide according to the invention belong to the same immunoglobulin subclass. In one embodiment of the invention, the variable domains and the constant domains of the precursor polypeptide according to the invention belong to the same immunoglobulin subclass.

[0402] In one embodiment of the invention, the precursor polypeptide is an isolated precursor polypeptide. In one embodiment of the invention, the product polypeptide is an isolated product polypeptide.

[0403] In one embodiment, the heterodimeric precursor polypeptide or heterodimeric product polypeptide comprising a polypeptide chain including a CH3 domain comprises a full-length CH3 domain or a CH3 domain in which one or both C-terminal amino acid residues, ie, G446 and / or K447, are absent.

[0404] In one embodiment, the first heterodimer precursor polypeptide is monospecific. In one embodiment, the second heterodimer precursor polypeptide is monospecific. In one embodiment, the heterodimer product polypeptide is bispecific.

[0405] In one embodiment, the first heterodimer precursor polypeptide is monospecific and comprises a portion of the second antigen binding site; the second heterodimer precursor polypeptide is monospecific and comprises another portion of the second antigen binding site. In the embodiment, the heterodimer product polypeptide is trispecific.

[0406] In one embodiment, the first heterodimer precursor polypeptide is bispecific. In one embodiment, the second heterodimer precursor polypeptide is monospecific. In one embodiment, the heterodimer product polypeptide is trispecific.

[0407] In one embodiment, the first heterodimer precursor polypeptide is bispecific. In one embodiment, the second heterodimer precursor polypeptide is bispecific. In one embodiment, the heterodimer product polypeptide is tetraspecific.

[0408] In one embodiment, the first heterodimeric precursor polypeptide is monovalent.In one embodiment, the second heterodimeric precursor polypeptide is monovalent.

[0409] In one embodiment, the first heterodimeric precursor polypeptide is divalent.In one embodiment, the second heterodimeric precursor polypeptide is divalent.

[0410] In one embodiment, the first heterodimeric precursor polypeptide is trivalent.In one embodiment, the second heterodimeric precursor polypeptide is trivalent.

[0411] In one embodiment, the heterodimer product polypeptide is divalent. In one embodiment, the heterodimer product polypeptide is trivalent. In one embodiment, the heterodimer product polypeptide is tetravalent.

[0412] E) Other components of the precursor polypeptide

[0413] In one embodiment of the present invention, or

[0414] i) comprising a polypeptide chain having a CH3 domain with a knob mutation in the first heterodimer precursor polypeptide, and comprising a polypeptide chain having a CH3 domain with a hole mutation in the second heterodimer precursor polypeptide; or

[0415] ii) a polypeptide chain comprising a CH3 domain having a hole mutation in the first heterodimer precursor polypeptide, and a polypeptide chain comprising a CH3 domain having a knob mutation in the second heterodimer precursor polypeptide

[0416] In one embodiment, the tag portion is fused to the C-terminus of the CH3 domain. In one embodiment, the tag portion is an affinity tag. In one embodiment, the tag portion is a poly(his) tag, a C tag, or a Strep tag. In one embodiment, the tag portion is a poly(his) tag or a C tag.

[0417] F) Method for producing product polypeptide

[0418] In one aspect, the invention provides a method for producing a heterodimeric product polypeptide, the method comprising the steps of:

[0419] a) contacting a first heterodimeric precursor polypeptide and a second heterodimeric precursor polypeptide according to the present invention to form a third heterodimeric polypeptide comprising at least one polypeptide chain comprising the CH3 domain from the first heterodimeric precursor polypeptide, and at least one polypeptide chain comprising the CH3 domain from the second heterodimeric precursor polypeptide, and

[0420] b) recovering the third heterodimeric polypeptide.

[0421] In one embodiment, the first heterodimer precursor polypeptide according to the present invention is contacted with the second heterodimer precursor polypeptide to form a third heterodimer polypeptide, which comprises at least one polypeptide chain comprising the CH3 domain from the first heterodimer precursor polypeptide and at least one polypeptide chain comprising the CH3 domain from the second heterodimer polypeptide, and a fourth heterodimer polypeptide, which comprises another polypeptide containing the CH3 domain from the first heterodimer precursor polypeptide and another polypeptide containing the CH3 domain from the second heterodimer precursor polypeptide. In one embodiment, the method includes the step of recovering the fourth heterodimer product polypeptide.

[0422] In one embodiment of the present invention, the method includes forming a third heterodimeric product polypeptide and a fourth heterodimeric product polypeptide, wherein one of the product polypeptides does not comprise an antigen binding site that specifically binds to an antigen.

[0423] In one embodiment of the present invention, the first heterodimeric precursor polypeptide comprises an antigen binding portion that specifically binds to a first antigen, wherein the second heterodimeric precursor polypeptide comprises an antigen binding portion that specifically binds to a second antigen, and wherein the third heterodimeric polypeptide comprises an antigen binding portion that specifically binds to the first antigen, and an antigen binding portion that specifically binds to the second antigen.

[0424] In one embodiment, the contacting step is performed in a liquid solution. In one embodiment, the contacting step is performed in a buffered solution.

[0425] In one embodiment, the recovering step is performed by chromatography.

[0426] Reduction of hinge disulfides

[0427] In one embodiment of the present invention, the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide comprise a hinge region containing an interchain disulfide bond, and the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide are contacted in the presence of a reducing agent. In the case where the precursor polypeptide comprises a hinge region having an interchain disulfide bond, polypeptide chain exchange occurs only after the interchain disulfide bond is reduced by a reducing agent.

[0428] In one embodiment of the invention, the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide include a hinge region that does not include an interchain disulfide bond. In this case, polypeptide chain exchange can occur in the absence of a reducing agent. Therefore, in one embodiment, the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide include a hinge region that does not include an interchain disulfide bond, and the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide contact in the absence of a reducing agent.

[0429] purification

[0430] In one embodiment, either i) a polypeptide chain comprising a CH3 domain with a knob mutation in the first heterodimer precursor polypeptide, and a polypeptide chain comprising a CH3 domain with a hole mutation in the second heterodimer precursor polypeptide; or ii) a polypeptide chain comprising a CH3 domain with a hole mutation in the first heterodimer precursor polypeptide, and a polypeptide chain comprising a CH3 domain with a knob mutation in the second heterodimer precursor polypeptide comprise a tag portion as defined above, and the method comprises a step of recovering the third heterodimer polypeptide by tag-specific affinity chromatography. In an alternative embodiment, the method comprises a step of recovering a fourth heterodimer polypeptide by tag-specific affinity chromatography.

[0431] In one embodiment, the tag moiety is a poly(his) tag and the method comprises the step of purifying the polypeptide by metal chelate affinity chromatography. In one embodiment, the tag moiety is a poly(his) tag and the method comprises the step of purifying the polypeptide by nickel chelate affinity chromatography.

[0432] In one embodiment, the tag moiety is a C tag and the method comprises the step of purifying the polypeptide by C tag affinity chromatography.

[0433] In one embodiment of the present invention, no interchain disulfide bond is formed between the two polypeptide chains comprising the CH3 domains of the first heterodimeric polypeptide and the second heterodimeric polypeptide, and the contacting is performed in the absence of a reducing agent.

[0434] G) Heterodimer product polypeptide

[0435] One aspect of the invention is a heterodimeric product polypeptide obtained by a method of producing a heterodimeric product polypeptide of the invention.

[0436] One aspect of the present invention is a heterodimeric polypeptide, in one embodiment a heterodimeric product polypeptide, comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising a CH3 domain associate with each other through the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; wherein the heterodimeric polypeptide comprises a first antigen binding portion, wherein at least a portion of the first antigen binding portion is disposed on one of the two polypeptide chains comprising a CH3 domain; and wherein the heterodimeric polypeptide comprises a second antigen binding portion, wherein at least a portion of the second antigen binding portion is disposed on the other of the two polypeptide chains comprising a CH3 domain; and

[0437] The CH3 domain having a hole mutation comprises at least one amino acid substitution selected from the group consisting of:

[0438] - Replace S354 with a hydrophobic amino acid;

[0439] - Replacement of D356 with a positively charged amino acid;

[0440] - Replacement of E357 with a positively charged amino acid or with a hydrophobic amino acid;

[0441] - Replacement of D356 with a positively charged amino acid and replacement of E357 with a positively charged amino acid or with a hydrophobic amino acid;

[0442] - Replace S364 with a hydrophobic amino acid;

[0443] - Replacement of A368 with a hydrophobic amino acid;

[0444] - Replacement of E392 with a negatively charged amino acid;

[0445] - Replacement of T394 with a hydrophobic amino acid;

[0446] - Replacement of D399 with a hydrophobic amino acid and replacement of S400 with a positively charged amino acid;

[0447] - Replacement of D399 with a hydrophobic amino acid and replacement of F405 with a positively charged amino acid;

[0448] - replacing V407 with a hydrophobic amino acid; and

[0449] - Replacement of K409 with a negatively charged amino acid; and

[0450] - replacing K439 with a negatively charged amino acid; and wherein

[0451] The CH3 domain with a knob mutation comprises at least one amino acid substitution selected from the group consisting of:

[0452] - Replace Q347 with a positively charged amino acid and replace K360 with a negatively charged amino acid;

[0453] - Replacement of Y349 with a negatively charged amino acid;

[0454] - Replacement of L351 with a hydrophobic amino acid and replacement of E357 with a hydrophobic amino acid;

[0455] - Replace S364 with a hydrophobic amino acid;

[0456] - Replacement of W366 with a hydrophobic amino acid and replacement of K409 with a negatively charged amino acid;

[0457] - Replacement of L368 with a hydrophobic amino acid;

[0458] - Replace K370 with a negatively charged amino acid;

[0459] - Replacement of K370 with a negatively charged amino acid and replacement of K439 with a negatively charged amino acid;

[0460] - Replacement of K392 with a negatively charged amino acid;

[0461] - Replacement of T394 with a hydrophobic amino acid;

[0462] - Replacement of V397 with a hydrophobic amino acid;

[0463] - Replacement of D399 with a positively charged amino acid and replacement of K409 with a negatively charged amino acid;

[0464] - Replacement of S400 with a positively charged amino acid;

[0465] -F405W;

[0466] -Y407W; and

[0467] - Replace K439 with a negatively charged amino acid.

[0468] The heterodimer (product) polypeptide according to the present invention comprises two polypeptide chains comprising a CH3 domain, wherein both CH3 domains comprise a destabilizing mutation as defined above. All embodiments listed above for destabilizing mutations in the heterodimer precursor polypeptide of the present invention are applicable to the heterodimer product polypeptide, except that the heterodimer product polypeptide comprises a destabilizing mutation in both CH3 domains.

[0469] Another product of the method for producing a heterodimeric product polypeptide, and therefore another aspect of the invention, is a heterodimeric product polypeptide preferably obtained by the method of the invention, which comprises two polypeptide chains comprising a CH3 domain, wherein neither CH3 domain comprises a destabilizing mutation.

[0470] In one embodiment of the invention, the heterodimeric product polypeptide comprises two polypeptide chains comprising a CH3 domain, wherein both CH3 domains comprise a cysteine ​​mutation as defined above. In one embodiment of the invention, the heterodimeric product polypeptide comprises two polypeptide chains comprising a CH3 domain, wherein neither CH3 domain comprises a cysteine ​​mutation as defined above.

[0471] H) Methods for producing multispecific polypeptides

[0472] In one aspect, the invention provides a method for identifying a multispecific heterodimeric polypeptide comprising the steps of:

[0473] a) producing a plurality of multispecific heterodimeric polypeptides by performing the method of producing a heterodimeric polypeptide of the present invention on each of the following combinations:

[0474] - a first heterodimeric precursor polypeptide from the plurality of first heterodimeric precursor polypeptides, comprising an antigen binding portion that specifically binds to a first antigen, and

[0475] - a second heterodimeric precursor polypeptide from the plurality of second heterodimeric precursor polypeptides, comprising an antigen binding portion that specifically binds to a second antigen;

[0476] as well as

[0477] b) individually testing each multispecific heterodimeric polypeptide from the plurality of multispecific heterodimeric polypeptides produced in step a) for a desired characteristic, and

[0478] c) Selecting a multispecific heterodimeric polypeptide.

[0479] In one embodiment of the invention, the multispecific heterodimeric polypeptide specifically binds to a first antigen and specifically binds to a second antigen.

[0480] In one embodiment, the multispecific heterodimeric polypeptide is selected based on the desired characteristics detected in step b).

[0481] In one embodiment, the desired characteristic detected in step b) is the binding affinity of the multispecific heterodimeric polypeptide to the first antigen. In one embodiment, the desired characteristic detected in step b) is the binding affinity of the multispecific heterodimeric polypeptide to the second antigen. In one embodiment, the desired characteristic detected in step b) is the thermal stability of the multispecific heterodimeric polypeptide.

[0482] Another aspect of the present invention is a multispecific heterodimeric polypeptide obtained by the method of identifying a multispecific heterodimeric polypeptide of the present invention.

[0483] I) Recombination method

[0484] The precursor polypeptide according to the invention is prepared by recombinant methods. Therefore, the present invention also relates to a method for preparing a heterodimeric precursor polypeptide according to the invention, comprising culturing a host cell comprising a nucleic acid encoding a heterodimeric precursor polypeptide under conditions suitable for expression of the precursor polypeptide.

[0485] On the one hand, a method for preparing a heterodimeric precursor polypeptide of the present invention is provided, wherein the method comprises culturing a host cell containing a nucleic acid encoding a heterodimeric precursor polypeptide as provided above under conditions suitable for expression of the heterodimeric precursor polypeptide, and optionally recovering the heterodimeric precursor polypeptide from the host cell (or host cell culture medium).

[0486] In one embodiment, the method comprises the steps of transforming a host cell with an expression vector comprising a nucleic acid encoding a heterodimer precursor polypeptide, culturing the host cell under conditions that allow synthesis of the heterodimer precursor polypeptide, and recovering the heterodimer precursor polypeptide from the host cell culture.

[0487] For the recombinant production of heterodimer precursor polypeptides, nucleic acids encoding heterodimer precursor polypeptides (e.g., as described above) are isolated and inserted into one or more vectors for further cloning and / or expression in a host cell. Such nucleic acids can be easily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that specifically bind to genes encoding polypeptide chains of heterodimer precursor polypeptides), or produced by recombinant methods or obtained by chemical synthesis.

[0488] Suitable host cells for cloning or expressing vectors encoding antibodies include prokaryotes or eukaryotic cells as described herein. For example, heterodimer precursor polypeptides can be produced in bacteria. Regarding expressing polypeptides in bacteria, see, for example, US 5,648,237, US 5,789,199, and US 5,840,523, (see also Charlton, KA, in: Methods in Molecular Biology, Vol. 248, Lo, BKC (ed.), Humana Press, Totowa, NJ (2003), pp. 245-254, describing the expression of antibody fragments in Escherichia coli.) Heterodimer precursor polypeptides can be separated from bacterial cell paste in a soluble fraction after expression, and can be further purified.

[0489] In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are also suitable cloning or expression hosts for vectors encoding heterodimeric precursor polypeptides of the present invention, including fungi and yeast strains whose glycosylation pathways have been "humanized", resulting in the production of polypeptides with partial or complete human glycosylation patterns. See Gerngross, TU, Nat. Biotech. 22 (2004) 1409-1414; and Li, H. et al., Nat. Biotech. 24 (2006) 210-215.

[0490] Suitable host cells for expressing (glycosylated) heterodimeric precursor polypeptides are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant cells and insect cells. Many baculovirus strains have been identified that can be used in conjunction with insect cells, particularly for transfecting Spodoptera frugiperda cells.

[0491] Plant cell cultures can also be used as hosts. See, for example, US 5,959,177, US 6,040,498, US 6,420,548, US 7,125,978, and US 6,417,429 (describing PLANTIBODIES™ technology for producing antibodies in transgenic plants).

[0492] Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 lines (COS-7) transformed by SV40; human embryonic kidney cell lines (such as 293 or 293T cells described in, for example, Graham, FL et al., J. Gen Virol. 36 (1977) 59-74); small hamster kidney cells (BHK); mouse Sertoli cells (such as TM4 cells described in Mather, JP, Biol. Reprod. 23 (1980) 243-252); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK); Buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells (as described, for example, in Mather, JP et al., Annals N.Y. Acad. Sci. 383 (1982) 44-68; MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells (Urlaub, G. et al., Proc. Natl. Acad. Sci. USA 77 (1980) 4216-4220); and myeloma cell lines, such as Y0, NS0 and Sp2 / 0. For a review of certain mammalian host cell lines suitable for antibody production, see, for example, Yazaki, P. and Wu, AM, Methods in Molecular Biology, Vol. 248, Lo, BKC (ed.), Humana Press, Totowa, NJ (2004), pp. 255-268.

[0493] In one aspect, the host cell is a eukaryotic cell, such as a Chinese hamster ovary (CHO) cell or a lymphocyte (eg, a Y0, NS0, Sp20 cell).

[0494] In one aspect, the invention provides an isolated nucleic acid encoding a heterodimer precursor polypeptide of the invention. In one aspect, the invention provides an expression vector comprising a nucleic acid according to the invention. In another aspect, the invention provides a host cell comprising a nucleic acid according to the invention.

[0495] J) Therapeutic applications

[0496] The set of heterodimer precursor polypeptides of the present invention can be used for treatment. Therefore, one aspect of the present invention is the set of heterodimer precursor polypeptides according to the present invention used as a medicament. Another aspect of the present invention is a pharmaceutical composition comprising the set of heterodimer precursor polypeptides of the present invention and a pharmaceutically acceptable carrier. Another aspect of the present invention is a method for treating an individual suffering from a disease, comprising administering to the individual an effective amount of the first heterodimer precursor polypeptide of the present invention and the second heterodimer precursor polypeptide or the pharmaceutical composition of the present invention.

[0497] In one embodiment, the heterodimer precursor polypeptide for treatment comprises a hinge region as defined above, wherein the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide do not comprise an interchain disulfide bond in the hinge region. When there is no interchain disulfide bond in the hinge region, polypeptide chain exchange occurs in the absence of a reducing agent, and therefore can occur spontaneously; for example, when both heterodimer precursor polypeptides are bound to a target antigen or a target cell.

[0498] In one embodiment, the heterodimeric precursor polypeptide for use in therapy comprises an activatable antigen binding site as defined above.

[0499] Thus, in one embodiment, a heterodimeric precursor polypeptide for use in therapy comprises a hinge region that does not comprise an interchain disulfide bond; and an activatable antigen binding site as defined above.

[0500] 3. Specific embodiments of the present invention

[0501] Specific embodiments of the present invention are listed below.

[0502] 1. A set of heterodimeric precursor polypeptides comprising:

[0503] a) a first heterodimeric precursor polypeptide comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising a CH3 domain associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation,

[0504] wherein the first heterodimeric precursor polypeptide comprises a first antigen binding portion, wherein at least a portion of the first antigen binding portion is disposed on one of the two polypeptide chains comprising a CH3 domain, and

[0505] b) a second heterodimeric precursor polypeptide comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising a CH3 domain associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation,

[0506] wherein the second heterodimeric precursor polypeptide comprises a second antigen binding portion, wherein at least a portion of the second antigen binding portion is disposed on one of the two polypeptide chains comprising a CH3 domain;

[0507] in

[0508] A) either i) within the first heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain comprising the knob mutation comprises at least a portion of the first antigen binding portion, and within the second heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain having the hole mutation comprises at least a portion of the second antigen binding portion, or ii) within the first heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain comprising the hole mutation comprises at least a portion of the first antigen binding portion, and within the second heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain having the knob mutation comprises at least a portion of the second antigen binding portion; and wherein

[0509] B) or

[0510] i) a CH3 domain of a first heterodimeric precursor polypeptide comprising a knob mutation and a CH3 domain of a second heterodimeric precursor polypeptide comprising a hole mutation, or

[0511] ii) a CH3 domain of a first heterodimeric precursor polypeptide comprising a hole mutation and a CH3 domain of a second heterodimeric precursor polypeptide comprising a knob mutation

[0512] The following amino acid substitutions are included, where numbering is according to the Kabat numbering system:

[0513] - the CH3 domain with hole mutation comprises at least one amino acid substitution selected from the group consisting of:

[0514] o Replacement of S354 with a hydrophobic amino acid;

[0515] o Replacement of D356 with a positively charged amino acid;

[0516] o replacing E357 with a positively charged amino acid or with a hydrophobic amino acid;

[0517] o replacement of D356 with a positively charged amino acid and replacement of E357 with a positively charged amino acid or with a hydrophobic amino acid;

[0518] o replacing S364 with a hydrophobic amino acid;

[0519] o replacing A368 with a hydrophobic amino acid;

[0520] ο Replacement of E392 with a negatively charged amino acid;

[0521] o Replacement of T394 with a hydrophobic amino acid;

[0522] o Replacement of D399 with a hydrophobic amino acid and replacement of S400 with a positively charged amino acid;

[0523] o replacement of D399 with a hydrophobic amino acid and replacement of F405 with a positively charged amino acid;

[0524] o replacing V407 with a hydrophobic amino acid; and

[0525] o replacing K409 with a negatively charged amino acid; and

[0526] ο Replacement of K439 with a negatively charged amino acid;

[0527] - the CH3 domain with the knob mutation comprises at least one amino acid substitution selected from the group consisting of:

[0528] o replacement of Q347 with a positively charged amino acid and replacement of K360 with a negatively charged amino acid;

[0529] o Replacement of Y349 with a negatively charged amino acid;

[0530] o replacing L351 with a hydrophobic amino acid and replacing E357 with a hydrophobic amino acid;

[0531] o replacing S364 with a hydrophobic amino acid;

[0532] o replacement of W366 with a hydrophobic amino acid and replacement of K409 with a negatively charged amino acid;

[0533] o replacing L368 with a hydrophobic amino acid;

[0534] ο Replacement of K370 with a negatively charged amino acid;

[0535] o replacement of K370 with a negatively charged amino acid and replacement of K439 with a negatively charged amino acid;

[0536] ο Replacement of K392 with a negatively charged amino acid;

[0537] o Replacement of T394 with a hydrophobic amino acid;

[0538] o Replacement of V397 with a hydrophobic amino acid;

[0539] o replacing D399 with a positively charged amino acid and replacing K409 with a negatively charged amino acid;

[0540] ο Replacement of S400 with a positively charged amino acid;

[0541] οF405W;

[0542] οY407W; and

[0543] o Replacement of K439 with a negatively charged amino acid.

[0544] 2. A set of heterodimeric polypeptides according to embodiment 1, wherein the CH3 domain indicated in B) comprises the following amino acid substitutions:

[0545] - the CH3 domain with hole mutation comprises at least one amino acid substitution selected from the group consisting of S354V, S354I, S354L, D356K, D356R, E357K, E357R, E357F, S364L, S364I, A368F, K392D, K392E, T394L, T394I, V407Y, K409E, K409D, K439D, K439E and the double mutations D399A S400K, D399A S400R, D399AF405W; and

[0546] - the CH3 domain with a knob mutation comprises at least one amino acid substitution selected from the group consisting of Y349E, Y349D, S364V, S364I, S364L, L368F, K370E, K370D, K392E, K392D, T394L, T394I, V397Y, S400K, S400R, F405W, Y407W, K349E, K439D and the double mutations Q347K K360E, Q347R K360E, Q347K K360D, Q347R K360D, L351F E357F, W366I K409E, W366L K409E, W366K K409D, W366L K409D, D399KK409E, D399R K409E, D399K K409D and D399K K409E.

[0547] 3. A set of heterodimeric polypeptides according to embodiment 1 or 2, wherein the CH3 domain indicated in B) comprises the following amino acid substitutions:

[0548] - the CH3 domain with hole mutation comprises at least one amino acid substitution selected from the group consisting of S354V, D356K, E357K, E357F, S364L, A368F, K392E, T394I, V407Y, K409E, K439E and the double mutation D399A S400K; and

[0549] - the CH3 domain with a knob mutation comprises at least one amino acid substitution selected from the group consisting of Y349E, S364V, L368F, K370E, K392D, T394I, V397Y, S400K, F405W, Y407W, K349E and the double mutations Q347K K360E, L351F E357F, W366I K409E and D399K K409E.

[0550] 4. A set of heterodimeric polypeptides according to one of embodiments 1 to 3, wherein the CH3 domain indicated in B) comprises the following amino acid substitutions:

[0551] - the CH3 domain with hole mutation comprises at least one amino acid substitution selected from the group consisting of D356K, D356R, E357K, E357R, E357F, S364L, S364I, V407Y, K409E, K409D and double mutations D399A S400K, D399A S400R; and

[0552] - the CH3 domain with a knob mutation comprises at least one amino acid substitution selected from the group consisting of Y349E, Y349D, K370E, K370D, K392E, K392D, T394L, T394I, V397Y, F405W, Y407W, K349E, K439D and the double mutations Q347K K360E, Q347R K360E, Q347K K360D, Q347R K360D, W366I K409E, W366L K409E, W366K K409D, W366L K409D, D399K K409E, D399R K409E, D399K K409D and D399K K409E.

[0553] 5. A set of heterodimeric polypeptides according to one of embodiments 1 to 4, wherein the CH3 domain indicated in B) comprises the following amino acid substitutions:

[0554] - the CH3 domain with hole mutation comprises at least one amino acid substitution selected from the group consisting of D356K, E357K, E357F, S364L, V407Y, K409E and the double mutation D399A S400K; and

[0555] - the CH3 domain with the knob mutation comprises at least one amino acid substitution selected from the group consisting of Y349E, K370E, K392D, T394I, V397Y, F405W, Y407W, K349E and the double mutations Q347K K360E, W366I K409E and D399K K409E.

[0556] 6. A set of heterodimeric polypeptides according to one of the preceding embodiments, wherein the CH3 domain comprising a knob mutation and the CH3 domain comprising a hole mutation indicated in B) comprise one of the amino acid substitutions selected from the group indicated in the following table:

[0557]

[0558]

[0559] 7. A set of heterodimeric polypeptides according to one of the preceding embodiments, wherein the CH3 domain comprising a knob mutation and the CH3 domain comprising a hole mutation indicated in B) comprise one of the amino acid substitutions selected from the group indicated in the following table:

[0560] mortar pestle V407Y K370E V407Y K370E K439E V407Y V397Y S364L K439E S364L W366I K409E S364L K370E K439E S364L D399K K409E S364L T394I S364L W366I K409E S364L K370E K439E S364L D399K K409E S364L T394I

[0561] 8. A set of heterodimeric polypeptides according to one of the preceding embodiments, wherein in case the CH3 domain with the knob mutation indicated in B) comprises the mutation E357K, the CH3 domain with the hole mutation indicated in B) does not comprise the mutation K370E.

[0562] 9. A set of heterodimeric polypeptides according to one of the preceding embodiments, wherein in case the CH3 domain with the knob mutation indicated in B) comprises the mutation D356K, the CH3 domain with the hole mutation indicated in B) does not comprise the mutation K439E.

[0563] 10. A group of heterodimeric polypeptides according to one of the preceding embodiments, wherein either i) the CH3 domain comprising the knob mutation of the first heterodimeric precursor polypeptide comprises a cysteine ​​mutation, and the CH3 domain comprising the hole mutation of the second heterodimeric precursor polypeptide comprises a cysteine ​​mutation, or ii) the CH3 domain comprising the hole mutation of the first heterodimeric precursor polypeptide comprises a cysteine ​​mutation, and the CH3 domain comprising the knob mutation of the second heterodimeric precursor polypeptide comprises a cysteine ​​mutation.

[0564] 11. A group of heterodimeric polypeptides according to Example 10, wherein i) the CH3 domain comprising the knob mutation of the first heterodimeric precursor polypeptide comprises the substitution S354C, and the CH3 domain comprising the hole mutation of the second heterodimeric precursor polypeptide comprises the substitution Y349C, or ii) the CH3 domain comprising the hole mutation of the first heterodimeric precursor polypeptide comprises the substitution Y349C, and the CH3 domain comprising the knob mutation of the second heterodimeric precursor polypeptide comprises the substitution S354C.

[0565] 12. A group of heterodimeric polypeptides according to embodiment 10 or 11, wherein in the first heterodimeric precursor polypeptide, the CH3 domain comprising the knob mutation comprises the substitution S354C, and the CH3 domain comprising the hole mutation comprises Y at position 349; and wherein in the second heterodimeric precursor polypeptide, the CH3 domain comprising the hole mutation comprises the substitution Y349C, and the CH3 domain comprising the knob mutation comprises S at position 354.

[0566] 13. A group of heterodimeric polypeptides according to one of the preceding embodiments, wherein the first antigen binding portion and / or the second antigen binding portion comprises a pair of VH domains and VL domains, which form an antigen binding site that specifically binds to a target antigen.

[0567] 14. A set of heterodimeric polypeptides according to one of the preceding embodiments, wherein the first antigen binding moiety and / or the second antigen binding moiety is an antibody fragment.

[0568] 15. A group of heterodimeric polypeptides according to one of the embodiments, wherein

[0569] a) the first heterodimeric precursor polypeptide comprises:

[0570] - a first heavy chain polypeptide comprising a CH3 domain and a first antibody variable domain,

[0571] - a second heavy chain polypeptide comprising a CH3 domain, wherein the first heavy chain polypeptide and the second heavy chain polypeptide associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0572] - a light chain polypeptide comprising a second antibody variable domain, wherein the first antibody variable domain and the second antibody variable domain together form a first antigen binding site that specifically binds to a target antigen; and wherein

[0573] b) the second heterodimeric precursor polypeptide comprises:

[0574] - a third heavy chain polypeptide comprising a CH3 domain and a third antibody variable domain,

[0575] - a fourth heavy chain polypeptide comprising a CH3 domain, wherein the third heavy chain polypeptide and the fourth heavy chain polypeptide associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0576] - a light chain polypeptide comprising a fourth antibody variable domain, wherein the third antibody variable domain and the fourth antibody variable domain together form a second antigen binding site that specifically binds to a target antigen; and wherein

[0577] c) either i) the first heavy chain polypeptide comprises a CH3 domain comprising a knob mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a hole mutation; or ii) the first heavy chain polypeptide comprises a CH3 domain comprising a hole mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a knob mutation.

[0578] 16. A group of heterodimeric polypeptides according to one of the preceding embodiments, wherein the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide comprise at least two polypeptide chains comprising a CH2 domain and a CH3 domain.

[0579] 17. A group of heterodimeric polypeptides according to one of the preceding embodiments, wherein the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide comprise at least two polypeptide chains, which comprise a CH2 domain and a CH3 domain from the N-terminal to the C-terminal direction.

[0580] 18. A group of heterodimeric polypeptides according to one of the preceding embodiments, wherein the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide comprise at least two polypeptide chains, which comprise a hinge region, a CH2 domain and a CH3 domain from the N-terminus to the C-terminus.

[0581] 19. A set of heterodimeric polypeptides according to any one of embodiments 15 to 18, wherein:

[0582] a) the first heterodimeric precursor polypeptide comprises:

[0583] - a first heavy chain polypeptide comprising, from N-terminal to C-terminal direction, a first VH domain and the constant antibody domains CH1, CH2 and CH3.

[0584] - a second heavy chain polypeptide, which comprises, from the N-terminal to the C-terminal direction, constant antibody domains CH2 and CH3 domains, wherein the first heavy chain polypeptide and the second heavy chain polypeptide associate with each other via the CH3 domains and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0585] - a light chain polypeptide comprising, from the N-terminal to the C-terminal direction, a first VL domain and a CL domain, wherein the first VH domain and the first VL domain associate with each other and form an antigen binding site that specifically binds to a target antigen; and wherein

[0586] b) the second heterodimeric precursor polypeptide comprises:

[0587] - a third heavy chain polypeptide comprising, from N-terminal to C-terminal direction, a second VH domain and the constant antibody domains CH1 , CH2 and CH3.

[0588] - a fourth heavy chain polypeptide, which comprises, from the N-terminal to the C-terminal direction, constant antibody domains CH2 and CH3 domains, wherein the third heavy chain polypeptide and the fourth heavy chain polypeptide associate with each other via the CH3 domains and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0589] - a light chain polypeptide comprising, from the N-terminal to the C-terminal direction, a second VL domain and a CL domain, wherein the second VH domain and the second VL domain associate with each other and form an antigen binding site that specifically binds to a target antigen; and wherein

[0590] Either i) the first heavy chain polypeptide comprises a CH3 domain comprising a knob mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a hole mutation; or ii) the first heavy chain polypeptide comprises a CH3 domain comprising a hole mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a knob mutation.

[0591] 20. A group of heterodimeric polypeptides according to Example 19, wherein the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide comprise an interchain disulfide bond in the hinge region.

[0592] 21. A set of heterodimeric polypeptides according to one of the preceding embodiments, wherein the antigen binding site is an antibody fragment.

[0593] 22. A group of heterodimeric polypeptides according to one of the embodiments, wherein or

[0594] i) comprising a polypeptide chain having a CH3 domain with a knob mutation in the first heterodimer precursor polypeptide, and comprising a polypeptide chain having a CH3 domain with a hole mutation in the second heterodimer precursor polypeptide; or

[0595] ii) a polypeptide chain comprising a CH3 domain having a hole mutation in the first heterodimer precursor polypeptide, and a polypeptide chain comprising a CH3 domain having a knob mutation in the second heterodimer precursor polypeptide

[0596] Contains the marked section.

[0597] 23. A set of heterodimeric polypeptides according to Example 22, wherein the tag portion is fused to the C-terminus of the CH3 domain.

[0598] 24. A set of heterodimeric polypeptides according to embodiment 22 or 23, wherein the tag portion is a histidine tag or a C tag.

[0599] 25. A group of heterodimeric polypeptides according to one of the preceding embodiments, wherein the first heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain and a CH3 domain, and wherein the second heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VH domain and a CH3 domain, wherein when associated with a pair of VH domain and VL domain, the VL domain and the VH domain specifically bind to an antigen.

[0600] 26. A group of heterodimeric polypeptides according to one of the embodiments, wherein

[0601] a) the first heterodimeric precursor polypeptide comprises:

[0602] - a first heavy chain polypeptide comprising, from N-terminal to C-terminal direction, a first VH domain, a CH1 domain, a second antibody variable domain selected from a VH domain and a VL domain, and a CH3 domain,

[0603] - a second heavy chain polypeptide which comprises, from the N-terminal to the C-terminal direction, an antibody variable domain capable of associating with a second antibody variable domain of a first heavy chain polypeptide and a CH3 domain, wherein the first heavy chain polypeptide and the second heavy chain polypeptide associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0604] - a light chain polypeptide comprising, from the N-terminal to the C-terminal direction, a first VL domain and a CL domain, wherein the first VH domain and the first VL domain associate with each other and form an antigen binding site that specifically binds to a target antigen; and wherein

[0605] b) the second heterodimeric precursor polypeptide comprises:

[0606] a third heavy chain polypeptide which comprises, from the N-terminal to the C-terminal direction, a second VH domain, a CH1 domain, a third antibody variable domain selected from a VH domain and a VL domain, and a CH3 domain,

[0607] - a fourth heavy chain polypeptide which comprises, from the N-terminal to the C-terminal direction, an antibody variable domain capable of associating with a third antibody variable domain of a third heavy chain polypeptide and a CH3 domain, wherein the third heavy chain polypeptide and the fourth heavy chain polypeptide associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0608] - a light chain polypeptide comprising, from the N-terminal to the C-terminal direction, a second VL domain and a CL domain, wherein the second VH domain and the second VL domain associate with each other and form an antigen binding site that specifically binds to a target antigen; and wherein

[0609] c) either i) the first heavy chain polypeptide comprises a CH3 domain comprising a knob mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a hole mutation; or ii) the first heavy chain polypeptide comprises a CH3 domain comprising a hole mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a knob mutation; and wherein

[0610] d) The variable domains of the first heavy chain polypeptide and the third heavy chain polypeptide are capable of forming an antigen binding site that specifically binds to the target antigen.

[0611] 27. A group of heterodimeric polypeptides according to one of the embodiments,

[0612] The first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide comprise at least two polypeptide chains comprising a CH2 domain and a CH3 domain from the N-terminus to the C-terminus,

[0613] The first heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain, a CH2 domain and a CH3 domain from the N-terminus to the C-terminus, and the second heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VH domain, a CH2 domain and a CH3 domain from the N-terminus to the C-terminus, wherein the VL domain and the VH domain can form an antigen binding site that specifically binds to the target antigen.

[0614] 28. A group of heterodimeric polypeptides according to one of the embodiments, wherein

[0615] a) the first heterodimeric precursor polypeptide comprises:

[0616] - a first heavy chain polypeptide which comprises, from the N-terminal to the C-terminal direction, a first VH domain, a CH1 domain, a second antibody variable domain selected from a VH domain and a VL domain, a CH2 domain and a CH3 domain,

[0617] - a second heavy chain polypeptide which comprises, from the N-terminal to the C-terminal direction, an antibody variable domain capable of associating with a second antibody variable domain of a first heavy chain polypeptide, a CH2 domain, and a CH3 domain, wherein the first heavy chain polypeptide and the second heavy chain polypeptide associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0618] - a light chain polypeptide comprising, from the N-terminal to the C-terminal direction, a first VL domain and a CL domain, wherein the first VH domain and the first VL domain associate with each other and form an antigen binding site that specifically binds to a target antigen; and wherein

[0619] b) the second heterodimeric precursor polypeptide comprises:

[0620] - a third heavy chain polypeptide which comprises, from the N-terminal to the C-terminal direction, a second VH domain, a CH1 domain, a third antibody variable domain selected from a VH domain and a VL domain, a CH2 domain and a CH3 domain,

[0621] - a fourth heavy chain polypeptide which comprises, from the N-terminal to the C-terminal direction, an antibody variable domain capable of associating with a third antibody variable domain of a third heavy chain polypeptide, a CH2 domain, and a CH3 domain, wherein the third heavy chain polypeptide and the fourth heavy chain polypeptide associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and

[0622] - a light chain polypeptide comprising, from the N-terminal to the C-terminal direction, a second VL domain and a CL domain, wherein the second VH domain and the second VL domain associate with each other and form an antigen binding site that specifically binds to a target antigen; and wherein

[0623] c) either i) the first heavy chain polypeptide comprises a CH3 domain comprising a knob mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a hole mutation; or ii) the first heavy chain polypeptide comprises a CH3 domain comprising a hole mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a knob mutation; and wherein

[0624] d) The variable domains of the first heavy chain polypeptide and the third heavy chain polypeptide are capable of forming an antigen binding site that specifically binds to the target antigen.

[0625] 29. A set of heterodimeric polypeptides according to one of the preceding embodiments, wherein the antigen binding portion of the first heterodimeric precursor polypeptide and the antigen binding portion of the second heterodimeric precursor polypeptide bind to the same antigen.

[0626] 30. A set of heterodimeric polypeptides according to one of the preceding embodiments, wherein the antigen binding portion of the first heterodimeric precursor polypeptide and the antigen binding portion of the second heterodimeric precursor polypeptide bind to different antigens.

[0627] 31. A heterodimeric polypeptide comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising a CH3 domain associate with each other through the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; wherein the heterodimeric polypeptide comprises a first antigen binding portion, wherein at least a portion of the first antigen binding portion is disposed on one of the two polypeptide chains comprising a CH3 domain; and wherein the heterodimeric polypeptide comprises a second antigen binding portion, wherein at least a portion of the second antigen binding portion is disposed on the other of the two polypeptide chains comprising a CH3 domain; and

[0628] The CH3 domain having a hole mutation comprises at least one amino acid substitution selected from the group consisting of:

[0629] - Replace S354 with a hydrophobic amino acid;

[0630] - Replacement of D356 with a positively charged amino acid;

[0631] - Replacement of E357 with a positively charged amino acid or with a hydrophobic amino acid;

[0632] - Replacement of D356 with a positively charged amino acid and replacement of E357 with a positively charged amino acid or with a hydrophobic amino acid;

[0633] - Replace S364 with a hydrophobic amino acid;

[0634] - Replacement of A368 with a hydrophobic amino acid;

[0635] - Replacement of E392 with a negatively charged amino acid;

[0636] - Replacement of T394 with a hydrophobic amino acid;

[0637] - Replacement of D399 with a hydrophobic amino acid and replacement of S400 with a positively charged amino acid;

[0638] - Replacement of D399 with a hydrophobic amino acid and replacement of F405 with a positively charged amino acid;

[0639] - replacing V407 with a hydrophobic amino acid; and

[0640] - Replacement of K409 with a negatively charged amino acid; and

[0641] - replacing K439 with a negatively charged amino acid; and wherein

[0642] The CH3 domain with a knob mutation comprises at least one amino acid substitution selected from the group consisting of:

[0643] - Replace Q347 with a positively charged amino acid and replace K360 with a negatively charged amino acid;

[0644] - Replacement of Y349 with a negatively charged amino acid;

[0645] - Replacement of L351 with a hydrophobic amino acid and replacement of E357 with a hydrophobic amino acid;

[0646] - Replace S364 with a hydrophobic amino acid;

[0647] - Replacement of W366 with a hydrophobic amino acid and replacement of K409 with a negatively charged amino acid;

[0648] - Replacement of L368 with a hydrophobic amino acid;

[0649] - Replace K370 with a negatively charged amino acid;

[0650] - Replacement of K370 with a negatively charged amino acid and replacement of K439 with a negatively charged amino acid;

[0651] - Replacement of K392 with a negatively charged amino acid;

[0652] - Replacement of T394 with a hydrophobic amino acid;

[0653] - Replacement of V397 with a hydrophobic amino acid;

[0654] - Replacement of D399 with a positively charged amino acid and replacement of K409 with a negatively charged amino acid;

[0655] - Replacement of S400 with a positively charged amino acid;

[0656] -F405W;

[0657] -Y407W; and

[0658] - Replace K439 with a negatively charged amino acid.

[0659] 32. A method for producing a heterodimeric polypeptide comprising the steps of:

[0660] a) contacting a first heterodimeric precursor polypeptide and a second heterodimeric precursor polypeptide as defined in one of embodiments 1 to 30 to form a third heterodimeric polypeptide comprising at least one polypeptide chain comprising the CH3 domain from the first heterodimeric precursor polypeptide, and at least one polypeptide chain comprising the CH3 domain from the second heterodimeric polypeptide, and

[0661] b) recovering the third heterodimeric polypeptide.

[0662] 33. A method according to embodiment 32, wherein the first heterodimeric precursor polypeptide comprises an antigen binding portion that specifically binds to a first antigen, wherein the second heterodimeric precursor polypeptide comprises an antigen binding portion that specifically binds to a second antigen, and wherein the third heterodimeric polypeptide comprises an antigen binding portion that specifically binds to the first antigen, and an antigen binding portion that specifically binds to the second antigen.

[0663] 34. The method according to one of embodiments 32 or 33, wherein

[0664] i) comprising a polypeptide chain having a CH3 domain with a knob mutation in the first heterodimer precursor polypeptide, and comprising a polypeptide chain having a CH3 domain with a hole mutation in the second heterodimer precursor polypeptide; or

[0665] ii) a polypeptide chain comprising a CH3 domain having a hole mutation in the first heterodimer precursor polypeptide, and a polypeptide chain comprising a CH3 domain having a knob mutation in the second heterodimer precursor polypeptide

[0666] comprising a tag portion, and wherein the method comprises the step of recovering the third heterodimeric polypeptide by tag-specific affinity chromatography.

[0667] 35. A method according to one of embodiments 32 to 34, wherein the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide comprise an interchain disulfide bond in the hinge region, and the first heterodimer precursor polypeptide and the second heterodimer precursor polypeptide are contacted in the presence of a reducing agent.

[0668] 36. A heterodimeric polypeptide obtained by the method according to any one of embodiments 32 to 35.

[0669] 37. A method for identifying a multispecific heterodimeric polypeptide comprising the steps of:

[0670] a) producing a plurality of multispecific heterodimeric polypeptides by performing a method according to one of embodiments 32 to 35 for each of the following combinations:

[0671] - a first heterodimeric precursor polypeptide from the plurality of first heterodimeric precursor polypeptides, comprising an antigen binding portion that specifically binds to a first antigen, and

[0672] - a second heterodimeric precursor polypeptide from the plurality of second heterodimeric precursor polypeptides, comprising an antigen binding portion that specifically binds to a second antigen;

[0673] as well as

[0674] b) individually testing each multispecific heterodimeric polypeptide from the plurality of multispecific heterodimeric polypeptides produced in step a) for a desired characteristic, and

[0675] c) Selecting a multispecific heterodimeric polypeptide.

[0676] 38. The method of embodiment 37, wherein the desired characteristic is selected from affinity and thermal stability.

[0677] 39. A multispecific heterodimeric polypeptide obtained by the method according to any one of embodiments 37 to 38.

[0678] 40. A set of heterodimeric precursor polypeptides according to any one of embodiments 1 to 30 for use as a medicament.

[0679] 41. A set of heterodimeric precursor polypeptides according to any one of embodiments 26 to 30 for use as a medicament.

[0680] 42. A set of heterodimeric precursor polypeptides according to any one of embodiments 26 to 30 for use as a medicament, wherein the heterodimeric precursor polypeptides comprise a hinge region, wherein the hinge region does not comprise an interchain disulfide bond.

[0681] 43. A pharmaceutical composition comprising a set of heterodimeric precursor polypeptides according to one of embodiments 1 to 30 and a pharmaceutically acceptable carrier.

[0682] 44. A first heterodimeric precursor polypeptide as defined in any one of embodiments 1 to 30.

[0683] 45. A second heterodimeric precursor polypeptide as defined in any one of embodiments 1 to 30.

[0684] 46. ​​Use of the heterodimeric precursor polypeptide of one of embodiments 44 or 45 in a method of one of embodiments 32 to 36.

[0685] Description of amino acid sequence

[0686]

[0687]

[0688]

[0689]

[0690]

[0691]

[0692]

[0693]

[0694]

[0695] Examples

[0696] The following examples are provided to aid the understanding of the present invention, the true scope of the invention being set forth in the appended claims. It should be understood that modifications may be made to the procedures set forth without departing from the spirit of the present invention.

[0697] Example 1:

[0698] Generation of monospecific precursor polypeptides containing an entire Fc domain

[0699] To evaluate the formation of bispecific anti-biocytinamid / anti-fluorescein antibodies from monospecific precursor polypeptides, Figure 1 A first heterodimeric precursor polypeptide and a second heterodimeric precursor polypeptide are shown with the domain arrangements depicted.

[0700] The first heterodimeric precursor polypeptide (also referred to as "antibiological precursor") comprises a Fab fragment that specifically binds to biocytinamide ("bio"), a biotin derivative, having a VL domain of SEQ ID NO:01 and a VH domain of SEQ ID NO:02 (described in Dengl S et al. Hapten-directed spontaneous disulfide shuffling: universal technology for site-directed covalent coupling of payloads to antibodies. FASEB J 2015; 29: 1763–1779). The first precursor polypeptide comprises a light chain polypeptide of SEQ ID NO:03 (also referred to as "bio LC"), a first heavy chain polypeptide of SEQ ID NO:04 (also referred to as "bio HC"), and a second heavy chain polypeptide based on SEQ ID NO:05 (which represents a basic amino acid sequence without a destabilizing mutation), having a destabilizing mutation and a histidine tag as shown below. The second heavy chain polypeptide (also referred to as a "mimetic hole" polypeptide) comprises a hinge region, a CH2 domain, and a CH3 domain from the N-terminal to the C-terminal direction.

[0701] The second heterodimeric precursor polypeptide (also referred to as "anti-fluorescein precursor") comprises a Fab fragment that specifically binds to fluorescein ("fluo"), having a VL domain of SEQ ID NO:06 and a VH domain of SEQ ID NO:07. The second precursor polypeptide comprises a light chain polypeptide of SEQ ID NO:08 (also referred to as "fluo LC"), a first heavy chain polypeptide of SEQ ID NO:09 (also referred to as "fluo HC"), and a second heavy chain polypeptide based on SEQ ID NO:10 (which represents a basic amino acid sequence without a destabilizing mutation), having a destabilizing mutation and a histidine tag as shown below. The second heavy chain polypeptide (also referred to as a "mock knob" polypeptide) comprises a hinge region, a CH2 domain, and a CH3 domain from the N-terminal to the C-terminal direction.

[0702] The CH3 domain of the indicated polypeptide chain comprises the following mutations:

[0703] Table 1: Amino acid substitutions in the CH3 domain of the precursor polypeptides

[0704]

[0705] Antibiotic precursors were generated that comprised a mimetic hole polypeptide having an amino acid sequence of SEQ ID NO: 05, wherein one of the following amino acid substitutions was made: E357K, D356K, C349Y, C349A, C349W, E357F, A368F, F405W, V407Y, D399A F405W, L441Y, K409E, T394I, D356K E357K, L351Y, Q347K, S354V, K370E, S364L, K392E, K439E, or D399A S400K.

[0706] An anti-fluorescein precursor comprising a knob-mimicking polypeptide having the amino acid sequence of SEQ ID NO: 10 was generated, wherein one of the following amino acid substitutions was made: K370E, K439E, C354S, C354S N297Q, S354E, S364L, Y407W, F405W, W366I K409E, K370E K439E, D399K K409E, Y349E, S364V, L368F, K392D, T394I, Q347K K360E, E357F, S400K or L351F E357F.

[0707] The expression plasmid for the precursor polypeptide was generated as follows:

[0708] For the expression of the anti-biotin and anti-fluorescein precursors as reported herein, a transcription unit comprising the following functional elements was used:

[0709] - the immediate early enhancer and promoter from human cytomegalovirus (P-CMV), including intron A,

[0710] - human heavy chain immunoglobulin 5'-untranslated region (5'UTR),

[0711] - mouse immunoglobulin heavy chain signal sequence,

[0712] - a nucleic acid encoding the corresponding precursor polypeptide, and

[0713] - Bovine growth hormone polyadenylation sequence (BGH pA).

[0714] - In addition to the expression unit / cassette including the desired gene to be expressed, the basic / standard mammalian expression plasmid also contains

[0715] - an origin of replication from the vector pUC18, which allows replication of this plasmid in E. coli, and

[0716] -β-lactamase gene, which confers ampicillin resistance in Escherichia coli.

[0717] Recombinant production of precursor peptides

[0718] This article reports the transient expression of anti-biotin and anti-fluorescein precursors using the transfection reagent mixture ExpiFectamine TM 293 transfection kit (A14524; Life Technologies TM ) in Expi293F TM Expression medium (A1435101; Life Technologies TM ) Expi293F TM Cells (A14527; Life Technologies TM ) is carried out in

[0719] Cells were passaged at least four times by dilution after thawing in 125 ml shake flasks (volume 30 ml) (incubated / shaken at 37°C, 7% CO2, 85% humidity, 135 rpm). Cells were expanded to 3x10 in 250 ml volume. 5 Three days later, the cells were split and concentrated at 1.3*10 6 The cells were freshly inoculated at a density of 10 cells / ml in a 250 ml volume in a 1 liter shake flask. After 24 hours, the density was approximately 2.2-2.8 x 10 6 The cells were transfected at a density of 10 cells / ml.

[0720] Prior to transfection, 30 μg of plasmid DNA was diluted to a final volume of 1.5 ml with pre-warmed (water bath; 37°C) Opti-MEM (Gibco). The solution was gently mixed and incubated at room temperature for no longer than 5 minutes. Then 1.5 ml of ExpiFectamine TM The pre-incubated solution of reagents in Opti-MEM is added to the DNA-OptiMEM solution. The resulting solution is gently mixed and incubated at room temperature for 20-30 minutes. The entire volume of the mixture is added to a 100 ml shake flask, a 50 ml centrifuge tube, or a deep well in a 48-well deep well plate containing 30 ml of Expi293F TM Culture.

[0721] The transfected cells were incubated for 7 days at 37°C, 7% CO2, 85% humidity and shaken at 110 rpm in shake flasks and 205 rpm in centrifuge tubes.

[0722] 16-24h after transfection, add 20μl ExpiFectamine TM Enhancer 1 and 200 μl ExpiFectamine TM Enhancer 2 was added to 30 ml of cell culture.

[0723] The supernatant was collected by centrifugation at 4,000 rpm for 20 minutes at 4° C. Thereafter, the cell-free supernatant was filtered through a 0.22 μm bottle-top filter and stored in a refrigerator (−20° C.).

[0724] Antibodies were purified from cell culture supernatants by affinity chromatography using MabSelectSure-Sepharose™ (GE Healthcare, Sweden).

[0725] Briefly, sterile filtered cell culture supernatant was captured on MabSelectSuRe resin equilibrated with PBS buffer (10 mM Na2HPO4, 1 mM KH2PO4, 137 mM NaCl and 2.7 mM KCl, pH 7.4), washed with equilibration buffer and eluted with 25 mM sodium citrate (pH 3.0). The eluted fractions of each precursor polypeptide were combined and neutralized with 2M Tris, pH 9.0.

[0726] Alternatively, the precursor polypeptide was purified from cell culture supernatant by affinity chromatography using ani-C kappa resin (KappaSelect, GE Healthcare, Sweden).

[0727] Briefly, sterile filtered cell culture supernatant was captured on KappaSelect resin equilibrated with PBS buffer (10 mM Na2HPO4, 1 mM KH2PO4, 137 mM NaCl and 2.7 mM KCl, pH 7.4), washed with equilibration buffer and eluted with 25 mM sodium citrate (pH 3.0). The eluted precursor polypeptide fractions were combined and neutralized with 2 M Tris, pH 9.0.

[0728] The identity of the precursor polypeptide is confirmed by mass spectrometry. For each individual sample, the conserved Fc N-glycosylation is enzymatically removed (using N-glycosidase F), the protein is denatured (guanidine hydrochloride) and the disulfide bonds are reduced (using DTT or TCEP). The sample is desalted by liquid chromatography (by size exclusion or reverse phase chromatography) and analyzed by mass spectrometry (Bruker Maxis Q-ToF). The identity of each molecule is confirmed by accurate mass measurement and comparison with the theoretical expected molecular mass.

[0729] The chromatographic analysis was performed on a BioSuite high-resolution SEC column ( Analytical size exclusion chromatography was performed using PCR (Waters, USA). The monomer content of all individual precursor polypeptides was assessed prior to reaction setup.

[0730] Table 2: Monomer content of anti-biological precursor polypeptides with mimetic holmium chains having the indicated destabilizing mutations in the CH3 domain (LMW... large molecular weight byproduct; monomer = desired heterodimeric precursor polypeptide; HMW... high molecular weight byproduct)

[0731]

[0732]

[0733] Table 3: Monomer content of anti-fluorescein precursor polypeptides with knob-mimicking chains having the indicated destabilizing mutations in the CH3 domain (LMW... large molecular weight byproduct; monomer = desired heterodimeric precursor polypeptide; HMW... high molecular weight byproduct)

[0734]

[0735]

[0736] Example 2:

[0737] Analysis of polypeptide chain exchange efficiency by direct detection of bispecific product peptide formation by ELISA

[0738] To evaluate the effects of different destabilizing mutations on polypeptide chain exchange, 460 exchange reactions were set up using the precursor polypeptide produced in Example 1. The structure of the expected product polypeptide is shown in Figure 1 The presence of the bispecific anti-biocytinamide / anti-fluorescein antibody product polypeptide was assessed by ELISA.

[0739] To initiate the exchange reaction, the anti-bioprecursor peptide and the anti-fluorescein precursor peptide were added in equimolar amounts (normalized to % monomer SEC values ​​to ensure the same number of intact molecules in a single reaction) in a 384-well plate. Plate (Brooks, #1800030) was mixed in a total volume of 48 μl 1xPBS + 0.05% Tween 20 + 0.25 mM TCEP, and the protein concentration was 2 μM. It is worth noting that the addition of the reducing agent TCEP reduces the hinge disulfide, thereby supporting the dissociation of the polypeptide chain. After centrifugation, the plate was sealed and incubated at 37°C for one hour. The resulting reaction mixture was analyzed by ELISA.

[0740] The bispecific antibodies were then quantified using a biotin-fluorescein bridging ELISA:

[0741] Therefore, white MaxiSorp TM 384-well plates were coated with 1 μg / ml albumin-fluorescein isothiocyanate conjugate (Sigma, #A9771) and incubated overnight at 4°C. After washing 3 times with 90 μl PBST-buffer (PBST, double distilled water, 10xPBS+0.05% Tween 20), blocking buffer (1xPBS, 2% gelatin, 0.1% Tween-20) was added to 90 μl / well and incubated for one hour at room temperature. After washing 3 times with 90 μl PBST-buffer, 25 μl of each reaction mixture diluted 1:4 was added to each well. After incubation at room temperature for one hour, the plate was washed again with 90 μl PBST-buffer 3 times. 25 μl / well biotin-Cy5 conjugate in 0.5% BSA, 0.025% Tween-20, 1xPBS was added to a final concentration of 0.1 μg / ml, and the plate was incubated for one hour at room temperature. After washing 6 times with 90 μl PBST-buffer, 25 μl 1xPBS were added to each well.Cy5 fluorescence was measured on a Tecan Safire 2 Reader at an emission wavelength of 670 nm (excitation at 649 nm).

[0742] Preformed anti-fluorescein / anti-biocytinamide bispecific reference antibodies (biocytin light chain of SEQ ID NO: 03, biocytin heavy chain of SEQ ID NO: 04, fluorescent light chain of SEQ ID NO: 08, and fluorescent heavy chain of SEQ ID NO: 09) were used as a 100% control for the reaction results.

[0743] As shown above, the preformed bispecific reference antibody was analyzed by analytical size exclusion chromatography:

[0744] Table 4: Monomer content of bispecific reference antibodies

[0745]

[0746] The absorbance signal of the reference antibody in the bridging ELISA setup is the average of 23 reactions. This average is used as the 100% bridging signal for normalization of all polypeptide chain exchange reactions. The assay variability of the reference antibody in the bridging ELISA is 100 + / - 15.2%. Polypeptide chain exchange reactions above 100% may belong to this variability. In addition, potential aggregates that may be present in the reaction mixture may result in an increased bridging signal.

[0747] The results are shown in Table 5. Relative absorbance values ​​from CH3 mutation pairs considered to support polypeptide chain exchange are underlined.

[0748] Table 5: Formation of bispecific product polypeptides by polypeptide chain reaction from anti-biological and anti-fluorescein photoprecursor polypeptides containing the indicated destabilizing mutations in the CH3 domain of the simulated chain. Columns represent destabilizing mutations in the simulated hole polypeptide of the anti-biological precursor; rows represent destabilizing mutations in the simulated knob polypeptide of the anti-fluorescein precursor. Relative absorbance detected by bridging ELISA is shown.

[0749]

[0750]

[0751]

[0752] Example 3:

[0753] Biochemical quantification of bispecific product formation to analyze polypeptide chain exchange efficiency

[0754] A subset of anti-biotin and anti-fluorescein photoprecursors were reacted to form 86 bispecific product polypeptides. For the reaction, equimolar amounts of the precursor polypeptides were combined as described in Example 1. Freshly prepared TCEP (60 eq 0.5 mM TCEP in 1x PBS pH 7.4, 0.05% Tween 20) was added to the reaction mixture as a reducing agent, and the mixture was incubated at 37° C. with gentle shaking at 300 rpm for 1 hour.

[0755] The bispecific product polypeptides were separated by flowing through a complete His-Tag column (Roche Diagnostics GmbH) balanced with a flow rate of 50 mM Na2HPO4, 300 mM NaCl, pH 8.0 and 1 ml / min. The remaining unreacted precursor polypeptides and the product polypeptides consisting of the simulated chain heterodimers were retained by their histidine tags and eluted with 50 mM Na2HPO4, 300 mM NaCl, 250 mM imidazole at pH 8.0 for analytical purposes. The samples were concentrated to a protein concentration of 0.2-1.5 mg / ml by Amicon Ultra centrifuge tubes (Millipore) and were separated by HPLC with BioSuite high resolution SEC columns ( 5μm, Waters, USA), using 200mM K2HPO4 / KH2PO4, 250mM KCl, pH 7.0 running buffer, and analyzed at a flow rate of 0.5ml / min to determine the purity of bispecific product formation. CE-SDS (LabChipGXII (Perkin Elmer)) was used to determine the quality of the bispecific product polypeptide under non-reducing (reformation of disulfide bridges) and reducing conditions (correct number and presence of protein chains). Samples for CE-SDS were prepared as follows: 5μl, c = 0.1–1mg / ml were mixed with 35μl sample buffer or sample denaturation solution in a 96-well PCR plate and incubated at 70°C for 10 minutes with gentle shaking. For reducing conditions, the reducing agent (NuPage) was diluted 10 times in HT Protein Express sample buffer (e.g. 100μl reducing agent + 900μl sample buffer). 70 μl of pure water was then added to the samples and the sample plate was placed in the LAbChip system for analysis.

[0756] The results of 86 chain exchange reactions are shown in Table 6. The results from the CH3 mutant pairs with particularly high yields are underlined and bold. Shown is the total yield of the bispecific product polypeptide after the polypeptide chain exchange and purification steps in mg. The product yield in % is calculated as the relative amount of the recombinant product corrected to the maximum expected product mass. For this calculation, the amount of the precursor polypeptide has been corrected for the monomer content as analyzed by analytical size exclusion chromatography, because only monomers are expected to be effective for recombination. In addition, it is taken into account that the maximum expected product mass is limited by the less abundant precursor polypeptide.

[0757] Table 6: Bispecific product polypeptide yields after polypeptide chain exchange and purification from anti-biotin and anti-fluorescein precursor polypeptides containing the indicated destabilizing mutations in the CH3 domain of the mock chain.

[0758]

[0759]

[0760]

[0761] Example 4:

[0762] Generation of monospecific precursor polypeptides for generating activatable binding sites following polypeptide chain exchange

[0763] To evaluate the formation of bispecific anti-LeY / anti-CD3 antibodies from monospecific precursor polypeptides, Figure 2 and Figure 3 A first heterodimeric precursor polypeptide and a second heterodimeric precursor polypeptide are shown with the domain arrangements depicted.

[0764] Precursor polypeptide without CH2 domain

[0765] In the first set of experiments, a Figure 2 Heterodimeric precursor polypeptide with the domain arrangement shown. The precursor polypeptide lacks a CH2 domain and comprises an antibody variable domain arranged N-terminally to a CH3 domain.

[0766] In a first alternative, the following precursor polypeptide is provided:

[0767] -The first heterodimeric precursor polypeptide (also referred to as "anti-LeY-CD3 (VH) -knob precursor") comprises a Fab fragment that specifically binds to LeY. The anti-LeY-CD3 (VH) -knob precursor comprises a light chain polypeptide of SEQ ID NO: 11 (also referred to as "LeY LC"), a first heavy chain polypeptide of SEQ ID NO: 12 (also referred to as "LeY-CD3 (VH) -knob HC"), which comprises a VH domain derived from an antibody that specifically binds to CD3 ("CD3 (VH)"), and a second heavy chain polypeptide based on SEQ ID NO: 13 (which represents a basic amino acid sequence without a destabilizing mutation), having a destabilizing mutation and a histidine tag as shown below. The second heavy chain polypeptide (also referred to as "mimetic-VL-hole" polypeptide) comprises, from the N-terminal to the C-terminal direction, a hinge region, a VL domain derived from an antibody that specifically binds to digoxigenin ("dig"), and a CH3 domain.

[0768] -The second heterodimeric precursor polypeptide (also referred to as "anti-LeY-CD3 (VL) -hole precursor") comprises a Fab fragment that specifically binds to LeY. The anti-LeY-CD3 (VL) -knob precursor comprises a light chain polypeptide of SEQ ID NO: 11 (i.e., LeY LC); a first heavy chain polypeptide of SEQ ID NO: 14 (also referred to as "LeY-CD3 (VL) -hole HC"), which comprises a VL domain derived from an antibody that specifically binds to CD3 ("CD3 (VL)"), and a second heavy chain polypeptide based on SEQ ID NO: 15 (which represents a basic amino acid sequence without a destabilizing mutation), having a destabilizing mutation and a histidine tag as shown below. The second heavy chain polypeptide (also referred to as a "mimetic-VH-knob" polypeptide) comprises, from the N-terminal to the C-terminal direction, a hinge region, a VH domain derived from a non-binding antibody, and a CH3 domain.

[0769] In a second alternative, the following precursor polypeptide is provided:

[0770] -The first heterodimeric precursor polypeptide (also referred to as "anti-LeY-CD3 (VL) -knob precursor") comprises a Fab fragment that specifically binds to LeY. The anti-LeY-CD3 (VL) -knob precursor comprises a light chain polypeptide of SEQ ID NO: 11 (i.e., LeY LC); a first heavy chain polypeptide of SEQ ID NO: 16 (also referred to as "LeY-CD3 (VL) -knob HC"), which comprises a CD3 (VL) domain, and a second heavy chain polypeptide based on SEQ ID NO: 17 (which represents a basic amino acid sequence without a destabilizing mutation), having a destabilizing mutation and a histidine tag as shown below. The second heavy chain polypeptide (also referred to as a "mimetic-VH-hole" polypeptide) comprises, from the N-terminal to the C-terminal direction, a hinge region, a VH domain derived from a non-binding antibody, and a CH3 domain.

[0771] -The second heterodimeric precursor polypeptide (also referred to as "anti-LeY-CD3 (VH) -hole precursor") comprises a Fab fragment that specifically binds to LeY. Anti-LeY-CD3 (VH) -hole precursor comprises a light chain polypeptide of SEQ ID NO: 11 (i.e., LeY LC); a first heavy chain polypeptide of SEQ ID NO: 18 (also referred to as "LeY-CD3 (VH) -hole HC"), which comprises a CD3 (VH) domain, and a second heavy chain polypeptide based on SEQ ID NO: 19 (which represents a basic amino acid sequence without a destabilizing mutation), having a destabilizing mutation and a histidine tag as shown below. The second heavy chain polypeptide (also referred to as a "mimetic-VL-knob" polypeptide) comprises a hinge region, a VL domain derived from an anti-dig antibody, and a CH3 domain from the N-terminal to the C-terminal direction.

[0772] The polypeptide chain shown contains the following mutations:

[0773] Table 7: Amino acid substitutions in the CH3 domain of the precursor polypeptide

[0774]

[0775] Precursor polypeptide with Fc domain

[0776] In the second set of experiments, a Figure 3 Heterodimeric precursor polypeptide with the domain arrangement shown. The precursor polypeptide comprises a complete Fc domain and comprises an antibody variable domain arranged at the N-terminus of the CH2 domain.

[0777] In a first alternative, the following precursor polypeptide is provided:

[0778] -The first heterodimeric precursor polypeptide (also referred to as "anti-LeY-CD3 (VH) -Fc (knob) precursor") comprises a Fab fragment that specifically binds to LeY. The anti-LeY-CD3 (VH) -Fc (knob) precursor comprises a light chain polypeptide of SEQ ID NO: 11 (i.e., LeY LC); a first heavy chain polypeptide of SEQ ID NO: 20 (also referred to as "LeY-CD3 (VH) -Fc (knob) HC"), which comprises a CD3 (VH) domain, and a second heavy chain polypeptide based on SEQ ID NO: 21 (which represents a basic amino acid sequence without a destabilizing mutation), having a destabilizing mutation and a histidine tag as shown below. The second heavy chain polypeptide (also referred to as "mimetic-VL-Fc (hole)" polypeptide) comprises, from the N-terminal to the C-terminal direction, a hinge region, a VL domain derived from an antibody that specifically binds to digoxigenin ("dig"), a CH2 domain, and a CH3 domain.

[0779] -The second heterodimeric precursor polypeptide (also referred to as "anti-LeY-CD3 (VL) -Fc (hole) precursor") comprises a Fab fragment that specifically binds to LeY. The anti-LeY-CD3 (VL) -Fc (hole) precursor comprises LeY LC; a first heavy chain polypeptide of SEQ ID NO: 22 (also referred to as "LeY-CD3 (VL) -Fc (hole) HC"), which comprises a CD3 (VL) domain, and a second heavy chain polypeptide based on SEQ ID NO: 23 (which represents a basic amino acid sequence without a destabilizing mutation), having a destabilizing mutation and a histidine tag as shown below. The second heavy chain polypeptide (also referred to as "mimetic-VH-Fc (knob)" polypeptide) comprises, from the N-terminal to the C-terminal direction, a hinge region, a VH domain derived from an anti-dig antibody, a CH2 domain, and a CH3 domain.

[0780] In a second alternative, the following precursor polypeptide is provided:

[0781] -The first heterodimeric precursor polypeptide (also referred to as "anti-LeY-CD3 (VL) -Fc (knob) precursor") comprises a Fab fragment that specifically binds to LeY. The anti-LeY-CD3 (VL) -Fc (knob) precursor comprises LeY LC; a first heavy chain polypeptide of SEQ ID NO: 24 (also referred to as "LeY-CD3 (VL) -Fc (knob) HC"), which comprises a CD3 (VL) domain, and a second heavy chain polypeptide based on SEQ ID NO: 25 (which represents a basic amino acid sequence without a destabilizing mutation), having a destabilizing mutation and a histidine tag as shown below. The second heavy chain polypeptide (also referred to as "mimetic-VH-Fc (hole)" polypeptide) comprises, from the N-terminal to the C-terminal direction, a hinge region, a VH domain derived from an anti-dig antibody, a CH2 domain, and a CH3 domain.

[0782] -The second heterodimeric precursor polypeptide (also referred to as "anti-LeY-CD3 (VH) -Fc (hole) precursor") comprises a Fab fragment that specifically binds to LeY. The anti-LeY-CD3 (VH) -Fc (hole) precursor comprises LeY LC; a first heavy chain polypeptide of SEQ ID NO: 26 (also referred to as "LeY-CD3 (VH) -Fc (hole) HC"), which comprises a CD3 (VH) domain, and a second heavy chain polypeptide based on SEQ ID NO: 27 (which represents a basic amino acid sequence without a destabilizing mutation), having a destabilizing mutation and a histidine tag as shown below. The second heavy chain polypeptide (also referred to as "mimetic-VL-Fc (knob)" polypeptide) comprises, from the N-terminal to the C-terminal direction, a hinge region, a VL domain derived from an anti-dig antibody, a CH2 domain, and a CH3 domain.

[0783] The polypeptide chain shown contains the following mutations:

[0784] Table 8: Amino acid substitutions in the CH3 domain of the precursor polypeptide

[0785]

[0786] A heterodimeric precursor polypeptide is produced, which comprises a simulated VL-hole polypeptide of SEQ ID NO: 13 as shown above and a simulated VH-hole polypeptide of SEQ ID NO: 17, having the amino acid sequence of the corresponding simulated polypeptide as shown above, wherein one of the following amino acid substitutions is made: E357K, A368F, D399A F405W, S364L, Y407W or S354V.

[0787] A heterodimeric precursor polypeptide is produced, which comprises a simulated VH-knob polypeptide of SEQ ID NO: 15 as shown above and a simulated VL-knob polypeptide of SEQ ID NO: 19, having the amino acid sequence of the corresponding simulated polypeptide as shown above, wherein one of the following amino acid substitutions is made: K370E, no destabilizing mutation, W366I K409D, V397Y or K392D.

[0788] A heterodimeric precursor polypeptide is produced, which comprises the mimetic VL-Fc (hole) polypeptide of SEQ ID NO: 21 as shown above and the mimetic -VH-Fc (hole) polypeptide of SEQ ID NO: 25, having the amino acid sequence of the corresponding mimetic polypeptide as shown above, wherein one of the following amino acid substitutions is made: E357K, A368F, D399A F405W, S364L, D356K or S354V.

[0789] A heterodimeric precursor polypeptide is produced, which comprises the mimetic-VH-Fc (knob) polypeptide of SEQ ID NO:23 as shown above and the mimetic-VL-Fc (knob) polypeptide of SEQ ID NO:27, having the amino acid sequence of the corresponding mimetic polypeptide as shown above, wherein one of the following amino acid substitutions is made: K370E, no destabilizing mutation, W366I K409D, V397Y, K392D or K370EK439E.

[0790] Recombinant production of precursor peptides

[0791] The plasmid and the three polypeptide chains of each precursor polypeptide are co-transfected into mammalian cells (such as HEK293 or Expi293F) by existing techniques. TM ) to express it.

[0792] To express the above-mentioned precursor polypeptide, a transcription unit comprising the following functional elements is used:

[0793] - the immediate early enhancer and promoter from human cytomegalovirus (P-CMV), including intron A,

[0794] - human heavy chain immunoglobulin 5'-untranslated region (5'UTR),

[0795] - mouse immunoglobulin heavy chain signal sequence,

[0796] - a nucleic acid encoding the corresponding precursor polypeptide, and

[0797] - 3'-untranslated region with a polyadenylation signal sequence.

[0798] In addition to the expression unit / cassette containing the desired gene to be expressed, the basic / standard mammalian expression plasmid also contains

[0799] - an origin of replication, which allows replication of the plasmid in E. coli, and

[0800] -β-lactamase gene, which confers ampicillin resistance in Escherichia coli.

[0801] An expression cassette encoding a precursor polypeptide chain is generated by PCR and / or gene synthesis, and the fusion gene is assembled by known recombination methods and techniques, for example, by connecting the corresponding nucleic acid segments using unique restriction sites in the corresponding plasmids. The subcloned nucleic acid sequence is verified by DNA sequencing. For transient transfection, a larger amount of plasmids (HiSpeed ​​Plasmid Maxi Kit, Qiagen) is prepared from the transformed E. coli culture by plasmid preparation.

[0802] Standard cell culture techniques as described in Current Protocols in Cell Biology (2000), Bonifacino, JS, Dasso, M., Harford, JB, Lippincott-Schwartz, J. and Yamada, KM (eds.), John Wiley & Sons, Inc, were used.

[0803] Precursor peptide derivatives were prepared by using the HEK293-F system (Invitrogen) or Expi293F TM (Live Technologies) were transiently transfected with the corresponding plasmids according to the manufacturer's instructions. Briefly, cells were suspended in serum-free FreeStyle TM 293 Expression Medium (Invitrogen) or Expi293F TM HEK293-F cells (Invitrogen) or Expi293F grown in expression medium (Life Technologies) TMCells (Live Technologies) were transfected with corresponding expression plasmids and 293fectin TM , fectin (Invitrogen) or PEIpro (Polyplus) or reagent mixture ExpiFectamine TM HEK293-F cells or Expi293F were transfected using the Expi293 transfection kit (Life Technologies). TM Cells were cultured in 250-600 mL at a rate of 1-1.3*10 6 The cells were inoculated at a density of 10 cells / mL and incubated at 120 rpm and 8% CO2. The day after transfection of the cells with the appropriate expression plasmid, HEK293-F cells were plated at a density of approximately 1.5*10 6 The cells were transfected at a cell density of 10 cells / mL with a volume of 42 mL of the following mixture: A) 20 mL Opti-MEM (Invitrogen) with 300 μg total plasmid DNA (0.5 μg / mL) and B) 20 ml Opti-MEM + 1.2 mL 293fectin or fectin (2 μL / mL) or 750 μl PEIpro (1.25 μL / mL). Expi293F TM The cells were approximately 2.2-2.8 x 10 6 The cells were transfected at a cell density of 10 cells / ml. Prior to transfection, 30 μg of plasmid DNA was diluted to a final volume of 1.5 ml with pre-warmed (water bath; 37°C) Opti-MEM (Gibco). The solution was gently mixed and incubated at room temperature for no more than 5 minutes. Then 1.5 ml of ExpiFectamine TM The pre-incubated solution of the reagent in Opti-MEM was added to the DNA-OptiMEM solution. The resulting solution was gently mixed and incubated at room temperature for 20-30 minutes. The entire volume of the mixture was added to a 30 ml Expi293F TM The culture was incubated at 37°C, 7% CO2, 85% humidity at 110 rpm for 7 days. TM Culture, 15-24h after transfection, 20μl ExpiFectamine TM Enhancer 1 and 200 μl ExpiFectamine TMEnhancer 2 is added to 30 ml of cell culture. Glucose solution is added during fermentation according to glucose consumption. Correctly assembled split cytokine molecules are secreted into the culture supernatant like standard IgG. Supernatant containing split cytokine molecules is harvested after 5-10 days and the split cytokine molecules are purified directly from the supernatant or the supernatant is frozen and stored at -20°C.

[0804] Precursor polypeptides with intact Fc regions (CH2-CH3) were conjugated to Protein A. These precursors were purified by Protein A chromatography and SEC.

[0805] The precursor polypeptides do not contain a CH2 domain but contain a kappa light chain. Therefore, these precursors are purified by applying standard kappa light chain affinity chromatography. Precursor polypeptides are purified from cell culture supernatants by affinity chromatography using KappaSelect (GE Healthcare, Sweden) and Superdex 200 size exclusion (GE Healthcare, Sweden) chromatography or ion exchange chromatography.

[0806] In brief, the sterile filtered cell culture supernatant was captured on a KappaSelect resin balanced with PBS buffer (10 mM Na2HPO4, 1 mM KH2PO4, 137 mM NaCl and 2.7 mM KCl, pH 7.4), washed with equilibrium buffer and eluted with 50 mM sodium citrate, 150 mM NaCl (pH 3.0). The eluted precursor polypeptide fractions were combined and neutralized with 2M Tris, pH 9.0. The precursor polypeptide pool was further purified by size exclusion chromatography or ion exchange chromatography. For size exclusion chromatography, a Superdex® balanced with 20 mM histidine, 140 mM NaCl, pH 6.0 was used. TM 200pg HiLoad TM 16 / 600 (GE Healthcare, Sweden) column. For ion exchange chromatography, protein samples obtained from KappaSelect purification were diluted 1:10 in 20 mM histidine, pH 6.0 and loaded onto a HiTrap HPLC column equilibrated with buffer A (20 mM histidine, pH 6.0). TM SPHP ion exchange (GE Healthcare, Sweden) column. A gradient of 0-100% buffer B (20 mM histidine, 1 M NaCl, pH 6.0) was applied to elute the different protein species.

[0807] Purity and integrity were analyzed after purification by SDS-PAGE. The protein solution (13 μl) was mixed with 5 μl 4x NuPAGE LDS sample buffer (Invitrogen) and 2 μl 10x NuPAGE sample reducing agent (Invitrogen) and heated to 95°C for 5 minutes. The samples were loaded onto NuPAGE 4-12% Bis-Tris gels (Invitrogen) and run using Novex Mini-Cell (Invitrogen) and NuPAGE MES SDS running buffer (Life Technologies) according to the manufacturer's instructions. The gel was run using InstantBlue TM Coomassie protein stain was used for staining. In addition, the integrity and homogeneity of the protein were analyzed using analytical size exclusion chromatography.

[0808] (CE-)SDS-PAGE showed that all expected polypeptide chains were present in the preparation; analytical size exclusion confirmed >90% purity of the preparation.For review of methods for assessing, e.g., antibody purity, see Flatman, S. et al., J. Chrom. B 848 (2007) 79-87.

[0809] Example 5:

[0810] Determination of polypeptide chain exchange by T cell activation assay

[0811] To evaluate the effects of different destabilizing mutations on polypeptide chain exchange, exchange reactions were set up using the precursor polypeptides produced in Example 4. The structure of the expected product polypeptide of the precursor polypeptide without the CH2 domain is shown in Figure 2 The structure of the expected product polypeptide of the precursor polypeptide containing the complete Fc domain is shown in Figure 3 Polypeptide chain exchange results in the formation of an antigen binding site that specifically binds to CD3. The presence of the bispecific anti-LeY / anti-CD3 product polypeptide is assessed by a cell-based assay.

[0812] According to the following principle, the effect of different CH3 interface mutations on the chain exchange reaction efficiency was evaluated in a cell-based reporter gene assay system consisting of MCF7 cells expressing LeY and Jurkat reporter gene cell lines (Promega J1621): the binding of the first heterodimeric polypeptide and the second heterodimeric polypeptide to MCF7 cells and polypeptide chain exchange resulted in the formation of an antigen binding site that specifically binds to CD3. Jurkat cells expressing CD3 bind to the antigen binding site that specifically binds to CD3, which results in Jurkat cells expressing luciferase. Luminescence was detected after adding BioGlo substrate.

[0813] Briefly, the cell-based assay was performed in 384-well plates as follows. RPMI1640 containing 10% FCS was used as assay medium. 4 Jurkat effector cells and 2x10 4 MCF7 cells were mixed in a total volume of 10 μl. Precursor peptides were applied alone or in combination at 200 nM and 2 nM in a final volume of 30 μl. Cells were incubated for 20 hours under cell culture conditions. 24 μl Bioglo was added to each well and incubated for 5 minutes. Luminescence was measured in a 200PRO reader (TECAN).

[0814] Table 9: Formation of bispecific product polypeptides by polypeptide chain reaction from a precursor polypeptide without a CH2 domain as defined in Example 4 above, comprising the indicated destabilizing mutations in the CH3 domain of the mock chain. The results show the exchange reaction at a precursor polypeptide concentration of 200 nM. The luminescence efficiency was assessed as follows: <10% ... "-", 10-29% ... "+", 30-50% ... "++", >50% ... "+++")

[0815]

[0816]

[0817] Table 10: Formation of bispecific product polypeptides by polypeptide chain reaction from a precursor polypeptide without a CH2 domain as defined in Example 4 above, comprising the indicated destabilizing mutations in the CH3 domain of the mock chain. The results show the exchange reaction at a precursor polypeptide concentration of 2 nM. The luminescence efficiency was assessed as follows: <2% ... "-", 2-4% ... "+", 5-10% ... "++", >10% ... "+++")

[0818]

[0819] Table 11: Formation of bispecific product polypeptides by polypeptide chain reaction from a precursor polypeptide with an Fc domain as defined in Example 4 above, comprising the indicated destabilizing mutations in the CH3 domain of the mock chain. The results show the exchange reaction at a precursor polypeptide concentration of 2 nM. The luminescence efficiency was assessed as follows: <10% ... "-", 10-19% ... "+", 20-50% ... "++", >50% ... "+++")

[0820]

[0821] Example 6:

[0822] Generation of other monospecific precursor polypeptides containing a complete Fc domain

[0823] To evaluate the formation of bispecific anti-biocytinamid / anti-fluorescein antibodies from monospecific precursor polypeptides, Figure 1 Monospecific precursor polypeptides with the depicted domain arrangements for the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide are shown. Note that in this experiment, the knob and hole mutations were arranged on opposite chains.

[0824] The first heterodimeric precursor polypeptide (also referred to as "anti-fluorescein precursor") comprises a Fab fragment that specifically binds to fluorescein ("fluo"), a biotin derivative, having a VL domain of SEQ ID NO:06 and a VH domain of SEQ ID NO:07. The first precursor polypeptide comprises a light chain polypeptide of SEQ ID NO:08 (also referred to as "fluo LC"), a first heavy chain polypeptide of SEQ ID NO:29 (also referred to as "fluo HC"), and a second heavy chain polypeptide based on SEQ ID NO:05 (which represents a basic amino acid sequence without a destabilizing mutation), having a destabilizing mutation and a C tag as shown below. The second heavy chain polypeptide (also referred to as a "mimetic hole" polypeptide) comprises a hinge region, a CH2 domain, and a CH3 domain from the N-terminal to the C-terminal direction.

[0825] The second heterodimeric precursor polypeptide (also referred to as "anti-bio precursor") comprises a Fab fragment that specifically binds to biocytinamide ("bio"), having a VL domain of SEQ ID NO:01 and a VH domain of SEQ ID NO:02. The second precursor polypeptide comprises a light chain polypeptide of SEQ ID NO:03 (also referred to as "bio LC"), a first heavy chain polypeptide of SEQ ID NO:28 (also referred to as "bio HC"), and a second heavy chain polypeptide based on SEQ ID NO:10 (which represents a basic amino acid sequence without a destabilizing mutation), having a destabilizing mutation and a C-tag as shown below. The second heavy chain polypeptide (also referred to as a "mock knob" polypeptide) comprises a hinge region, a CH2 domain, and a CH3 domain from the N-terminal to the C-terminal direction.

[0826] The first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide are produced according to the method disclosed in Example 1.

[0827] The CH3 domain of the indicated polypeptide chain comprises the following mutations:

[0828] Table 12: Purification yield and monomer content of anti-fluorescein precursor polypeptides with mimetic holmium chains having the indicated destabilizing mutations in the CH3 domain (purification yield [mg / ml] = amount of purified antibody per liter of expression volume, corrected by % monomer peak; monomer = desired heterodimeric precursor polypeptide)

[0829] Destabilizing mutation Purification yield [mg / L] %SEC Monomer E357F 45.6 96.6 V407Y 30.1 95.7 D356K 39.5 90.7 K409E 78.3 99.1 D356K-E357K 42.1 95.9 S364L 65.9 95.8 S364A 75.0 81.5 S364I 61.9 90.8 S364Q 34.3 98.5 E357F-T394I 43.2 98.9 E357F-S364L 56.1 81.2 D356K-V407Y 28.7 84.7 D356K-S364L 43.4 92.0 E357K-T394I 40.6 98.0

[0830] Table 13: Purification yield and monomer content of anti-biological precursor polypeptides with knob-mimicking chains having the indicated destabilizing mutations in the CH3 domain (Purification yield [mg / ml] = amount of purified antibody per liter of expression volume, corrected by % monomer peak; Monomer = desired heterodimeric precursor polypeptide)

[0831]

[0832]

[0833] Example 7:

[0834] Analysis of polypeptide chain exchange efficiency of the precursor polypeptide from Example 6

[0835] In order to evaluate the effect of different destabilizing mutations on polypeptide chain exchange, exchange reactions between the precursor polypeptides produced in Example 6 were performed. The experiment was performed according to the method described in Example 2. The structure of the expected product polypeptide is shown in Figure 1 shown.

[0836] Table 14: Formation of bispecific product polypeptides from anti-biological and anti-fluorescein photoprecursor polypeptides by polypeptide chain exchange reactions, the precursor polypeptides comprising the indicated destabilizing mutations in the CH3 domain of the simulated chain. Columns represent destabilizing mutations in the simulated hole polypeptide of the anti-fluorescein precursor; rows represent destabilizing mutations in the simulated knob polypeptide of the anti-biological precursor. Values ​​represent the exchange efficiency by product yield [%]. The experimentally obtained yields are related to the maximum possible yield of the bispecific antibody. The maximum possible yield of the bispecific antibody was corrected by the lowest % monomer peak SEC of the two corresponding input formats in each reaction, since only monomers are expected to be effective for recombination.

[0837]

[0838]

[0839] Example 8:

[0840] Generation of other monospecific precursor polypeptides comprising a complete Fc domain, wherein the CH3 domain of the precursor polypeptide comprises a knob-into-hole mutation but does not comprise a cysteine ​​mutation

[0841] To evaluate the formation of bispecific anti-biocytinamid / anti-fluorescein antibodies from monospecific precursor polypeptides, Figure 1Monospecific precursor polypeptides with the depicted domain arrangements for the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide are shown. Note that in this experiment, the knob and hole mutations were arranged on opposite chains.

[0842] A first heterodimeric precursor polypeptide and a second heterodimeric precursor polypeptide as described in Example 6 are produced according to the structures and methods disclosed therein.

[0843] Furthermore, unlike Example 1, bio HC is based on SEQ ID NO: 28 but has a serine residue at position 354, and fluo HC is based on SEQ ID NO: 29 but has a tyrosine residue at position 349. Therefore, the mutations of the CH3 domain are summarized as follows:

[0844] Table 15: Amino acid substitutions in the CH3 domain of the precursor polypeptide

[0845]

[0846] The CH3 domain of the indicated polypeptide chain comprises the following mutations:

[0847] Table 16: Purification yield and monomer content of anti-biological precursor polypeptides with knob-mimicking chains having the indicated destabilizing mutations in the CH3 domain (Purification yield [mg / ml] = amount of purified antibody per liter of expression volume, corrected by % monomer peak; Monomer = desired heterodimeric precursor polypeptide)

[0848]

[0849]

[0850] Table 17: Purification yield and monomer content of anti-fluorescein precursor polypeptides with mimetic holmium chains having the indicated destabilizing mutations in the CH3 domain (purification yield [mg / ml] = amount of purified antibody per liter of expression volume, corrected by % monomer peak; monomer = desired heterodimeric precursor polypeptide)

[0851]

[0852] Example 9:

[0853] Analysis of polypeptide chain exchange efficiency of the precursor polypeptide from Example 8

[0854] In order to evaluate the effect of different destabilizing mutations on polypeptide chain exchange, exchange reactions were performed between the precursor polypeptides produced in Example 8. The experiments were performed according to the method described in Example 2.

[0855] Table 18: Formation of bispecific product polypeptides from anti-biological and anti-fluorescein photoprecursor polypeptides by polypeptide chain exchange reactions, the precursor polypeptides comprising the indicated destabilizing mutations in the CH3 domain of the simulated chain. Columns represent destabilizing mutations in the simulated hole polypeptide of the anti-fluorescein precursor; rows represent destabilizing mutations in the simulated knob polypeptide of the anti-biological precursor. Values ​​represent the exchange efficiency by product yield [%]. The experimentally obtained yields are related to the maximum possible yield of the bispecific antibody. The maximum possible yield of the bispecific antibody was corrected by the lowest % monomer peak SEC of the two corresponding input formats in each reaction, since only monomers are expected to be effective for recombination.

[0856]

[0857]

[0858] The results show that polypeptide chain exchange is detectable for heterodimeric precursor polypeptides in which the knob-into-hole mutation is not stabilized by additional cysteine ​​mutations.

[0859] Example 10:

[0860] Generation of other monospecific precursor polypeptides comprising a complete Fc domain having different mutations in the CH3 domain of the precursor polypeptide

[0861] To evaluate the formation of bispecific anti-biocytinamid / anti-fluorescein antibodies from monospecific precursor polypeptides, Figure 1 Monospecific precursor polypeptides with the depicted domain arrangements for the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide are shown. Note that in this experiment, the knob and hole mutations were arranged on opposite chains.

[0862] The first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide as described in Example 6 are produced according to the structures and methods disclosed therein, but with the following differences:

[0863] Different from Example 6, three precursor polypeptides that specifically bind to fluorescein were generated, wherein the fluo HC was based on SEQ ID NO: 29, and the mimetic polypeptide was based on SEQ ID NO: 05 with the following CH3 mutations:

[0864]

[0865]

[0866] - Different from Example 1, three precursor polypeptides that specifically bind to biocytinamide were generated, wherein the bio HC is based on SEQ ID NO: 28 and the mimetic knob polypeptide is based on SEQ ID NO: 10 with the following CH3 mutations:

[0867]

[0868] Table 19: Purification yield and monomer content of the indicated precursor polypeptides (Purification yield [mg / ml] = amount of purified antibody per liter of expression volume, corrected by % monomer peak; Monomer = desired heterodimeric precursor polypeptide)

[0869] Mutation simulation Purification yield [mg / L] %SEC Monomer #01 70.0 97.4 #02 17.1 92.1 #03 67.4 99.6 #04 114.3 96.1 #05 44.7 96.1 #06 142.6 98.8

[0870] Example 11:

[0871] Analysis of polypeptide chain exchange efficiency of the precursor polypeptide from Example 10

[0872] In order to evaluate the effect of different destabilizing mutations on polypeptide chain exchange, exchange reactions between the precursor polypeptides produced in Example 10 were performed. The experiments were performed according to the method described in Example 2.

[0873] Table 20: Formation of bispecific product polypeptides from the indicated anti-biological and anti-fluorescein photoprecursor polypeptides by polypeptide chain exchange reactions. Values ​​represent exchange efficiency by product yield [%]. The experimentally obtained yields are related to the maximum possible yield of the bispecific antibody. The maximum possible yield of the bispecific antibody was corrected by the lowest % monomer peak SEC of the two corresponding input formats in each reaction, since only monomers are expected to be effective for recombination.

[0874]

[0875] The results indicate that the appearance of the polypeptide chain is independent of the placement of cysteine ​​mutations on either the mimicking chain polypeptide or the polypeptide chain comprising the antigen binding portion.

Claims

1. A heterodimeric precursor polypeptide comprising: a) a first heterodimeric precursor polypeptide comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising a CH3 domain associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation, wherein the first heterodimeric precursor polypeptide comprises a first antigen binding portion, wherein at least a portion of the first antigen binding portion is disposed on one of the two polypeptide chains comprising a CH3 domain, and b) a second heterodimeric precursor polypeptide comprising at least two polypeptide chains comprising a CH3 domain, wherein the two polypeptide chains comprising a CH3 domain associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation, wherein the second heterodimeric precursor polypeptide comprises a second antigen binding portion, wherein at least a portion of the second antigen binding portion is disposed on one of the two polypeptide chains comprising a CH3 domain; The CH3 domain contained in the precursor polypeptide belongs to the human IgG1 subclass; in A) either i) within the first heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain comprising the knob mutation comprises at least a portion of the first antigen binding portion, and within the second heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain having the hole mutation comprises at least a portion of the second antigen binding portion, or ii) within the first heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain comprising the hole mutation comprises at least a portion of the first antigen binding portion, and within the second heterodimeric precursor polypeptide, the polypeptide chain comprising the CH3 domain having the knob mutation comprises at least a portion of the second antigen binding portion; and wherein B) or i) a CH3 domain of a first heterodimeric precursor polypeptide comprising a knob mutation and a CH3 domain of a second heterodimeric precursor polypeptide comprising a hole mutation, or ii) a CH3 domain of a first heterodimeric precursor polypeptide comprising a hole mutation and a CH3 domain of a second heterodimeric precursor polypeptide comprising a knob mutation The following amino acid substitutions are included, where numbering is according to the Kabat numbering system: Wherein the CH3 domain comprising a knob mutation and the CH3 domain comprising a hole mutation shown in B) comprise one of the amino acid substitutions selected from the group shown in the following table: wherein the first antigen binding moiety and / or the second antigen binding moiety is an antibody fragment; and wherein a) the first heterodimeric precursor polypeptide comprises: - a first heavy chain polypeptide comprising a CH3 domain and a first antibody variable domain, - a second heavy chain polypeptide comprising a CH3 domain, wherein the first heavy chain polypeptide and the second heavy chain polypeptide associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and - a light chain polypeptide comprising a second antibody variable domain, wherein the first antibody variable domain and the second antibody variable domain together form a first antigen binding site that specifically binds to a target antigen; and wherein b) the second heterodimeric precursor polypeptide comprises: - a third heavy chain polypeptide comprising a CH3 domain and a third antibody variable domain, - a fourth heavy chain polypeptide comprising a CH3 domain, wherein the third heavy chain polypeptide and the fourth heavy chain polypeptide associate with each other via the CH3 domain and form a heterodimer, wherein one of the CH3 domains comprises a knob mutation and the other CH3 domain comprises a hole mutation; and - a light chain polypeptide comprising a fourth antibody variable domain, wherein the third antibody variable domain and the fourth antibody variable domain together form a second antigen binding site that specifically binds to a target antigen; and wherein c) either i) the first heavy chain polypeptide comprises a CH3 domain comprising a knob mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a hole mutation; or ii) the first heavy chain polypeptide comprises a CH3 domain comprising a hole mutation, and the third heavy chain polypeptide comprises a CH3 domain comprising a knob mutation.

2. A heterodimeric polypeptide according to claim 1, wherein either i) the CH3 domain comprising the knob mutation of the first heterodimeric precursor polypeptide comprises a cysteine ​​mutation, and the CH3 domain comprising the hole mutation of the second heterodimeric precursor polypeptide comprises a cysteine ​​mutation, or ii) the CH3 domain comprising the hole mutation of the first heterodimeric precursor polypeptide comprises a cysteine ​​mutation, and the CH3 domain comprising the knob mutation of the second heterodimeric precursor polypeptide comprises a cysteine ​​mutation.

3. A heterodimeric polypeptide according to claim 2, wherein within the first heterodimeric precursor polypeptide, the CH3 domain comprising the knob mutation comprises the substitution S354C, and the CH3 domain comprising the hole mutation comprises Y at position 349; and wherein within the second heterodimeric precursor polypeptide, the CH3 domain comprising the hole mutation comprises the substitution Y349C, and the CH3 domain comprising the knob mutation comprises S at position 354.

4. A heterodimeric polypeptide according to claim 1, wherein the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide comprise at least two polypeptide chains, which comprise a hinge region, a CH2 domain and a CH3 domain from the N-terminus to the C-terminus.

5. The heterodimeric polypeptide according to claim 4, wherein the first heterodimeric precursor polypeptide and the second heterodimeric precursor polypeptide comprise an interchain disulfide bond in the hinge region.

6. A heterodimeric polypeptide according to claim 1, wherein the first heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VL domain and a CH3 domain, and wherein the second heterodimeric precursor polypeptide comprises a polypeptide chain comprising a VH domain and a CH3 domain, wherein when associated with a pair of VH domains and VL domains, the VL domains and the VH domains specifically bind to an antigen.